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Abstract 
Dense deposit disease (DDD) is a rare, progressive and incurable kidney disease 
characterized by complement C3 accumulation along the glomerular basement membrane 
(GBM). It is the prototypical form of C3 glomerulopathy, which comprises renal disorders due 
to excessive C3 activation via the alternative pathway (AP). Human and murine studies 
indicate that renal inflammation in DDD is initiated by the specific C3 activation product iC3b. 
I have assessed the role of iC3b in DDD using the uniquely informative experimental model 
of C3 glomerulopathy in factor H (FH)-deficient mice. I demonstrate that coexisting 
deficiency of CD11b, the specific leukocyte receptor for iC3b, exacerbates the spontaneous 
renal phenotype in FH-deficient mice. This suggests that the iC3b-CD11b interaction may 
mediate partial renal protection in DDD. I also show that CD11b deficiency produces 
hypersensitivity to experimentally triggered glomerular injury in both FH-deficient and FH-
sufficient mice. My second experimental approach in vivo and in vitro was to assess whether 
C3 activation in the circulation or on the GBM surface is the predominant cause of iC3b 
accumulation in DDD. This included experiments in which administration of a novel 
engineered human FH protein fragment reduced glomerular C3 staining in FH-deficient 
mice. 
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1.1 Overview of my thesis 
Dense deposit disease (DDD), sometimes called membranoproliferative glomerulonephritis 
(MPGN) type 2, is a rare glomerular disorder that typically progresses to end-stage kidney 
disease (ESKD) and recurs after transplantation [Appel et al. 2005, Smith et al. 2007, Smith 
et al. 2011]. Its name derives from the original pathological description identifying electron-
dense deposits in the glomerular basement membrane (GBM) and other renal structures 
[Berger & Galle 1962]. Several lines of evidence suggest causation of DDD due to abnormal 
regulation of the alternative pathway (AP) of complement. These include: (1) glomerular 
accumulation of complement C3 metabolites, with little or no accumulation of 
immunoglobulin (Ig) or early classical pathway (CP) complement components, in patients 
with DDD; (2) evidence of excessive AP activation in patients with DDD, including low 
plasma levels of C3 and AP components due to secondary depletion; (3) presence of 
circulating C3 nephritic factors (C3NeFs) or other autoantibodies against AP-associated 
proteins in many patients with DDD; (4) a small number of family studies showing co-
segregation of DDD or similar renal phenotypes with homozygous deficiency of the AP 
regulatory protein factor H (FH), or with other rare gene variants in FH, C3 or other 
complement genes; (5) identification of additional, rare complement gene variants in 
sporadic cases of DDD; (6) genome wide association studies (GWAS) indicating that the 
population attributable risk of DDD is influenced by common complement gene variants;     
(7) structural and functional data supporting an effect on AP regulation of some of the 
disease-associated gene variants; and (8) informative animal models in which genetic 
deficiency of the orthologous murine or porcine FH proteins is associated with renal disease 
reminiscent of human DDD.  
In this thesis, I present my experimental work examining the role of complement fragment 
iC3b in DDD. My two research hypotheses are: 
 
Hypothesis 1 
That deficiency of CD11b, the specific leukocyte receptor for iC3b, ameliorates 
experimental renal disease in FH-deficient mice. 
 
Hypothesis 2 
That FH protects the GBM from surface phase C3 activation via the AP. 
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In this Introduction, I provide an overview of complement biology, focusing on the AP and its 
regulation by FH. I summarize the immune role of CD11b, including data implicating the 
iC3b-CD11b interaction in human autoimmune diseases. I describe the key 
clinicopathological features of dense deposit disease, and present an integrated model of 
pathophysiology. I then outline the renal disease models in FH-deficient and CD11b-
deficient animals, and conclude with a discussion of my research aims.  
1.2 The complement system 
The complement system is an immune defense mechanism that recognises and eliminates 
microbial pathogens and damaged host cells [Walport 2001, Ricklin et al. 2010]. It comprises 
over 30 proteins found in plasma and other body fluids or localized to cell membranes. 
These include pattern recognition molecules, proteases, opsonins, anaphylatoxins, the 
membrane attack complex (MAC), complement regulatory proteins and cell surface 
receptors. Complement activation is initiated via three proteolytic pathways, the AP, CP and 
lectin pathway (LP), converging at activation of C3 (Fig. 1). Downstream effects of C3 
activation include: chemotaxis due to the anaphylatoxins C3a and C5a; opsonization, 
whereby cells are tagged with C3 fragments for complement C3 receptor (CR)-dependent 
removal by the mononuclear phagocyte system and stimulation of adaptive immune 
responses; and formation of the MAC (C5b-9) with the capacity for lysing cells. Tight control 
by regulatory proteins protects against indiscriminate complement activation and consequent 
host tissue injury. 
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Figure 1 The pathways of complement activation 
Complement activation via the classical pathway (CP), lectin pathway (LP) or alternative pathway 
(AP) leads to formation of C3 convertases for the activation of intact C3. C3 activation generates the 
anaphylatoxin C3a and opsonin C3b. Amplification of C3 activation via the C3 convertase of the AP 
(C3bBb) is inhibited by factor H (FH). Downstream formation of C5 convertases leads to C5 
activation, releasing the anaphylatoxin C5a together with C5b, which initiates membrane attack 
complex (MAC) formation. Adapted from [Barbour et al. 2014] with permission of Elsevier.  
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1.2.1 C3 activation  
C3 (185kDa) is the most abundant of the complement proteins [Müller-Eberhard et al. 1960]. 
It is an α2-macroglobulin glycoprotein encoded on chromosome 19p13.3-13.2 and produced 
mainly by the liver [Alper et al. 1969]. Plasma concentrations (0.7-1.7 mg/mL) rise ~50% in 
acute phase response [Gabay & Kushner 1999]. Extrahepatic C3 synthesis occurs in 
numerous tissues including the kidney [Morgan & Gasque 1997], which contributes 5% to 
the circulating C3 pool under basal conditions [Tang et al. 1999]. Intact C3 consists of two 
disulfide-linked polypeptide chains, the alpha (α)-chain (110kDa) and beta (β)-chain (75kDa) 
[Janssen et al. 2005], and is biologically inactive. Sequential α-chain cleavage steps 
generate C3 fragments [West et al. 1966]. This is accompanied by major conformational 
rearrangements that determine interaction of the C3 fragments with biological surfaces and 
other components of the complement system including regulatory proteins and receptors 
[Nishida et al. 2006]. The first step (C3 activation) involves cleavage of a single peptide bond 
on the α-chain, releasing a small fragment, the anaphylatoxin C3a (8kDa, Fig. 2). This 
leaves C3b (177kDa), which consists of the cleaved α-chain, now termed α-prime (α’), joined 
to the β-chain. C3 activation occurs at a low rate due to the C3 tickover mechanism or the 
effect of plasma proteases, and is catalyzed by C3-cleaving enzyme complexes (C3 
convertases) [Ruseva & Heurich 2014].  
C3 activation disrupts the internal thioester bond of intact C3, resulting in a conformational 
change that exposes the reactive thioester-containing domain (TED) on the α-chain 
[Janssen et al. 2006]. The highly electrophilic exposed thioester confers on nascent or 
‘metastable’ C3b (designated as C3b*) a capacity for covalent binding to the nucleophilic 
free hydroxyl (-OH) or amine (-NH2) groups found on all biological surfaces [Müller-Eberhard 
et al. 1966, Law & Levine 1977, Tack et al. 1980]. However, in the circulation (fluid phase) 
C3b* is rapidly hydrolysed, with C3b(H2O) no longer able to form covalent bonds on 
surfaces. This allows a window period of only 60s for C3b* surface-binding [Sim et al. 
1981], which is thus restricted to local sites of activation and is only ~10% efficient [Müller-
Eberhard et al. 1967, Law & Dodds 1997]. C3 activation also exposes overlapping N-
terminal sites on the α’-chain of C3b for non-covalent binding to proteins involved in 
formation and dissociation of the AP C3 convertase [Taniguchi-Sidle & Isenman 1994, 
Janssen et al. 2006, Ajees et al. 2006]. 
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Figure 2 C3 activation products 
Cleavage of intact C3 (C3 activation) is followed by sequential FI-mediated cleavage of C3b and iC3b 
utilizing both plasma and membrane cofactors (upper panel). C3 activation is associated with a 
conformational change that exposes the α-chain thioester-containing domain (TED), enabling 
covalent binding of C3b to biological surfaces. Complement receptors are shown below their 
respective C3 ligands.  
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1.2.2 The classical and lectin pathways 
Activation of the CP is typically initiated when the globular heads of C1q, circulating in a 
complex with two C1r and two C1s serine proteases as the C1 proenzyme, recognise and 
bind the fragment crystallized (Fc) portion of IgM or IgG in immune complexes. This leads to 
autoactivation of C1r and its transactivation of C1s, which then cleaves C4 (isotypes A and 
B) generating the proteolytic fragments C4a and C4b. As described above for its homologue 
C3b, C4b presents an electrophilic carbonyl group within its newly exposed thioester domain 
for covalent binding to hydroxyl groups (C4B predominant binding) or amine groups (C4A 
predominant binding) on the CP-activating immune complex or cell surface, followed by 
attachment to C4b of C2. Where the resulting C4bC2 complex adopts a specific spatial 
orientation in relation to the bound C1s, C1s also cleaves C2 yielding C2a (large fragment 
[Kemper et al. 2014]) and C2b. This generates the C3 convertase of the CP, C4b2a, with the 
C2a site acting as a serine protease for C3 activation. The LP becomes activated through 
mannose-binding lectin (MBL) or ficolins (ficolin-1, -2, -3), which circulate in complexes with 
three MBL-associated serine proteases (MASP-1, -2, -3, acting as homologues for C1r and 
C1s) and other non-enzymatic MBL-associated proteins. On binding of MBL or ficolins to 
cell-surface carbohydrates or acetylated molecular patterns, autoactivation of MASP-2 (and 
possibly the other MASP proteins) leads to cleavage of C4 and C2, and formation of the 
identical C3 convertase (C4b2a) as for the CP. Physiological dissociation of C4b2a is 
enhanced by the soluble CP/LP regulator, C4b-binding protein (C4BP).  
1.2.3 The alternative pathway 
In evolutionary terms, the AP is the most ancient of the complement activation pathways, 
and probably predates the development of the adaptive immune system [Farries & Atkinson 
1991]. It was discovered through the demonstration of Ig- and CP-independent C3 activation 
in vitro [Pillemer et al. 1953, Götze & Müller-Eberhard 1971]. Three aspects of C3 activation 
are unique to this pathway: (1) C3 activation via the AP occurs both on surfaces and in 
aqueous solution (‘fluid phase’) due to the generation of a freely diffusing C3 convertase of 
the AP; (2) fluid-phase C3 activation via the AP occurs spontaneously at a low level (so-
called C3 ‘tick-over’ [Nicol & Lachmann 1973]); and (3) the AP constitutes a common 
‘amplification loop’ for C3 activation [Lachmann 2009], irrespective of the initiating trigger of 
C3 activation. 
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1.2.3.1 C3 tickover  
C3 tickover entails low-level, spontaneous activation of C3 in the fluid phase due to 
hydrolysis of C3. It was originally proposed as a solution to the paradox wherein ‘the 
alternate pathway for C3 fixation seems to possess an absolute requirement for fixed C3, 
the product of its reaction’ [Nicol & Lachmann 1973]. Incubation of intact C3 in water at 37°C 
was shown to be associated with slow decay (0.5% per h) of C3 haemolytic activity 
[Pangburn & Müller-Eberhard 1980]. More rapid C3 haemolytic decay during incubation with 
the nucleophile methylamine (CH3NH2) was proportional to the rate at which methylamine 
bound intact C3 (via covalent interaction with the TED [Nishida et al. 2006]). This interaction 
resulted in the acquisition of certain ‘C3b-like’ functional properties, including the ability to 
initiate C3 activation via the AP in normal human serum. As this property had also been 
observed following repeated freeze-thawing of intact C3 in solution, it was postulated that 
‘under physiological conditions…C3b-like C3 arises by nonenzymatic spontaneous thioester-
bond hydrolysis of C3 and thereby effects formation of a steady-state concentration of the 
initial C3 convertase of the alternative pathway of complement activation’ [Pangburn & 
Müller-Eberhard 1980]. Among its C3b-like properties, C3(H2O) is able to form a C3 
convertase of the AP [Pangburn et al. 1981].  
1.2.3.2 C3b amplification  
The C3b amplification loop of the AP was originally demonstrated in vitro as a ‘positive 
feedback mechanism’ wherein C3b participates in formation of the AP C3 convertase 
(C3bBb) for activation of intact C3 to C3b [Müller-Eberhard & Götze 1972]. Mg2+-dependent 
binding of C3b to the inactive plasma serine protease factor B (FB, 93kDa) is followed by 
cleavage of FB to Ba and Bb by the plasma serine protease factor D (FD, 25kDa) [Forneris 
et al. 2010]. This yields C3bBb, the AP C3 convertase, with the Bb component responsible 
for C3 activation [Müller-Eberhard & Götze 1972, Götze & Müller-Eberhard 1976]. C3b 
amplification occurs via the AP in the fluid phase and on surfaces, regardless of the initiating 
pathway of C3 activation [Fearon et al. 1973, Harboe et al. 2004]. However, C3bBb is short-
lived (t½ of ~90s) owing to spontaneous dissociation of Bb from C3b [Fishelson et al. 1984, 
Pangburn & Müller-Eberhard 1986]. Properdin (53kDa) is a glycoprotein that stabilizes 
C3bBb against spontaneous dissociation and prevents interaction of the C3b component 
with complement regulatory proteins [Pillemer et al. 1954, Fearon & Austen 1975, Alcorlo et 
al. 2013]. Properdin is thus the only physiological positive regulator of complement 
activation, and in addition may initiate surface assembly of C3bBb [Kemper et al. 2010].  
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1.2.3.3 Artificial surfaces 
Artificial surfaces used in vitro (e.g. polystyrene-coated receptacles) or in vivo (e.g. vascular 
access and cardiopulmonary devices) may induce C3 activation via the AP. Firstly, 
hydrophobic artificial surfaces with increased density of free –OH or –NH2 groups facilitate 
covalent surface-binding of C3b* from the circulation, anchoring formation of the AP C3 
convertase [Chenoweth 1987]. Secondly, abundant plasma proteins including albumin, IgG 
and fibrinogen are adsorbed onto artificial surfaces, forming a layer of plasma proteins 
capable of binding C3b* covalently [Andersson et al. 2005, Nilsson et al. 2007]. Thirdly, 
adsorption of intact C3 to artificial surfaces may activate it non-proteolytically [Andersson et 
al. 2002]. Based on this observation, it has been argued that C3 tickover represents ‘contact 
activation’ due to surface interfaces including vanishing gas bubbles (formed in vivo by 
cardiopulmonary bypass or in decompression sickness), activated platelets, lipoproteins and 
foreign biomaterials [Nilsson & Nilsson Ekdahl 2012].  
1.2.4 Factor I 
Factor I (FI, 88kDa) is a plasma serine protease encoded on chromosome 4q25 and 
produced mainly by the liver (plasma concentration 35-45μg/mL) [Reynolds et al. 2009, Lay 
et al. 2014]). It was originally identified based on functional ‘inactivation’ of surface-bound 
C3b in vitro [Tamura & Nelson 1967, Lachmann & Müller-Eberhard 1968]. The ability of FI to 
cleave C3b [Abramson et al. 1971, Ruddy & Austen 1971] and inhibit the AP C3 convertase 
[Alper et al. 1972] was subsequently demonstrated in fluid phase assays. In human serum 
depleted of FI, uncontrolled C3 activation via the AP indicated that C3 tickover is ‘normally 
efficiently damped’ by this regulatory protein [Nicol & Lachmann 1973]. In individuals with 
rare homozygous deficiency of FI, secondary depletion of C3, FB and properdin due to 
uncontrolled AP activation results in low plasma levels of these proteins [Alper et al. 1970, 
Vyse et al. 1994]. Circulating C3 is detected almost exclusively in the form of C3b, 
consistent with a physiological requirement for FI in the generation of C3b metabolites.  
FI cleaves the α-chain of C3b, releasing the α-chain C3f fragment (2kDa) to leave iC3b 
(176kDa), which consists of the residual α’-chain joined to the β-chain. FI-mediated C3b 
cleavage is accompanied by a conformational change that sequesters the TED and disrupts 
the FB binding site [Nishida et al. 2006, Alcorlo et al. 2011]. This conformational change 
renders iC3b unable to form the AP C3 convertase [Law et al. 1979]. FI-mediated C3b 
cleavage requires a C3b-binding cofactor, prototypically FH [Pangburn et al. 1977, Harrison 
& Lachmann 1980]. The membrane-expressed regulators CR1 (CD35) and membrane 
cofactor protein (MCP, CD46) are additional FI cofactors expressed on cellular surfaces. A    
. 
 24 
second FI-mediated cleavage step degrades iC3b, generating an α-chain fragment, C3dg 
(40kDa), and C3c (135kDa), which consists of the residual α’-chain joined to the β-chain. FI-
mediated iC3b cleavage utilizes CR1 as the principal cofactor [Medicus et al. 1983].  
On surfaces, efficient FI-mediated cleavage of covalently bound C3b prevents C3b 
amplification via the AP and its downstream effects including MAC formation. It also results 
in a relatively short t½ for surface-attached C3b (~90s) compared to its cleavage product 
iC3b (~35 min) [Ross et al. 1985]. Subsequent FI-mediated cleavage of iC3b (in the 
presence for CR1) leaves surface-bound C3dg, which is further trimmed by proteases to 
C3d (corresponding to the TED) [Lachmann et al. 1982]. Far from being immunologically 
inert, surface-bound iC3b and C3d(g) are important ligands for CRs expressed on 
leukocytes [Ueda et al. 1994]. A critical role for these opsonic C3 fragments in immune 
clearance is underscored by the predisposition of individuals with severe FI deficiency to 
recurrent bacterial infection and immune complex-mediated disease [Nilsson et al. 2011]. 
1.2.5 Factor H 
FH (155kDa) is a plasma glycoprotein that regulates the AP in the fluid phase and on 
surfaces [Nilsson & Müller-Eberhard 1965, Makou et al. 2013]. It is encoded in the regulators 
of complement activation (RCA) cluster of chromosome 1q32 that also contains the genes 
for C4BP, CR1, CR2, MCP, decay accelerating factor (DAF, CD55) and the five FH-related 
(FHR) proteins [Rodriguez de Cordoba et al. 1985]. FH consists of a single chain of 20 
homologous modules each containing ~61 amino acids, termed short consensus repeat 
(SCR) domains, linked by 40 disulfide bridges (Fig. 3) [Rodriguez de Cordoba et al. 2004]. 
Extensive post-translational modification of FH, including N-glycosylation at 8 sites, is 
essential to protein conformation [Fenaille et al. 2007]. FH is constitutively produced by the 
liver, but also extrahepatically [Ferreira et al. 2010]. In a recent, large population study, the 
median plasma FH level in healthy individuals was 226.6μg/mL (range 63.5-847.6μg/mL) 
[Sofat et al. 2013].  
The mechanisms by which FH regulates the AP were originally demonstrated using surface 
(haemolysis) assays with FH purified from normal human plasma [Weiler et al. 1976, Whaley 
& Ruddy 1976]. In the fluid phase, uncontrolled C3 activation via the AP was demonstrated 
in normal human serum depleted of FH [Whaley & Thompson 1978]. Similar to FI deficiency, 
individuals with rare homozygous FH deficiency show secondary depletion of plasma C3, FB 
and properdin due to uncontrolled C3 activation via the AP [Thompson & Winterborn 1981]. 
FH competes with FB for C3b binding and also displaces the Bb fragment from any 
preformed AP C3 convertase, thereby both impeding formation and promoting dissociation 
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of the AP C3 convertase (decay accelerating activity). FH is also a cofactor for FI-mediated 
cleavage of C3b to iC3b (FI cofactor activity). The two major C3b-binding sites on FH are 
located within the amino (N)-terminal SCR domains 1-4 and carboxy (C)-terminal SCR 
domains 19-20, respectively. N-terminal SCR domains 1-4 are necessary and sufficient for 
fluid phase decay accelerating activity and FI cofactor activity [Schmidt et al. 2008b, Wu et 
al. 2009]. FH-like protein 1 (FHL-1, 43kDa), which results from alternative splicing of FH and 
comprises N-terminal SCR domains identical to FH SCR domains 1-7 and four additional C-
terminal amino acids, is also capable of fluid phase AP regulation [Friese et al. 1999]. 
The C-terminal C3b-binding site of FH plays a critical role in FH-mediated regulation of the 
AP on surfaces [Ferreira et al. 2006]. Despite recognising the C3d moiety of C3b, the C-
terminal binding site interacts only weakly, if at all, with the C3b cleavage products iC3b and 
C3d(g) [Alcorlo et al. 2011]. Glycosaminoglycans (GAGs) and sialylated carbohydrates on 
cellular surfaces enhance the interaction of FH with surface-bound C3b. This was originally 
demonstrated through desialylation of sheep erythrocytes, which abrogated their protection 
by FH against AP-mediated haemolysis in in vitro assays [Fearon 1978, Pangburn & Müller-
Eberhard 1978]. Similarly, deficiency of GAGs on zymosan and rabbit erythrocytes was 
shown to mediate resistance of these AP-activating surfaces to FH regulatory activity 
[Kazatchkine et al. 1979, Meri & Pangburn 1990]. Subsequently, binding of FH to a wide 
array of cellular surfaces has been demonstrated in vitro, for example using cultured human 
vascular endothelial cells (HUVEC) [Jozsi et al. 2004, Jokiranta et al. 2005]. Several GAG-
binding sites on the FH molecule include one on SCR 20 that overlaps with the C3b-binding 
site [Hellwage et al. 2002, Schmidt et al. 2008a]. Structural studies indicate that FH adopts a 
bent-back FH conformation in which N-terminal binding to C3b facilitates complement 
regulation, with simultaneous C-terminal binding to the same C3b molecule and to adjacent 
surface GAGs [Aslam & Perkins 2001, Morgan et al. 2011]. 
1.2.6 Factor H-related proteins 
The five structurally related FHR proteins are encoded downstream of the FH gene in the 
RCA cluster. C-terminal SCR domains are highly conserved between FH and the FHR 
proteins. By contrast the FHR proteins lack the first four N-terminal SCR domains that 
mediate the complement regulatory activity of FH (and FHL-1). Instead, distinct N-terminal 
SCR domains 1 and 2 are highly conserved on FHR-1, -2 and -5 and these are important in 
FHR dimerization [Goicoechea de Jorge et al. 2013]. The FH-FHR locus is prone to large 
genomic deletions, insertions and rearrangements (detected as copy number variation) 
[Jozsi & Zipfel 2008]. 
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Figure 3 The factor H protein family 
FH consists of 20 short consensus repeat (SCR) domains. Those at the C-terminus (depicted in 
yellow) mediate surface recognition and are common to the five FHR proteins (FHR-4 has two 
isoforms, FHR-4A and FHR-4B). By contrast, N-terminal SCR domains 1-4 mediating FH complement 
regulatory function (red) are found only on FH and FHL-1. The N-terminal SCR domains 1 and 2 are 
highly conserved on FHR-1, FHR-2 and FHR-5 (blue) but not FHR-3 and FHR-4A/B. Reproduced from 
[Barbour et al. 2015] with permission from Oxford University Press (License No 3510930508784). 
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1.2.7 C5 activation 
Binding of additional C3b molecules to the C3 convertases yields the C5 convertases, 
C3bC4bC2a and C3bC3bBb, for activation of C5 [Pangburn & Rawal 2002]. C5 (190kDa) is 
structurally related to C3 and C4, and comprises an α-chain (115kDa) and β-chain (75kDa). 
C5 activation by cleavage of the α-chain releases the potent anaphylatoxin C5a and C5b, 
which initiates MAC formation. The MAC inserts pores into the lipid bilayer of cell surfaces, 
culminating in cellular activation or lysis [Tegla et al. 2011].  
1.2.8 In vitro and ex vivo studies of surface phase alternative pathway activation 
1.2.8.1 Rabbit haemolysis assay 
The rabbit haemolysis assay utilizes the susceptibility of unsensitized rabbit erythrocytes 
(ER) to AP-dependent lysis following incubation in normal human serum (NHS) [Platts-Mills & 
Ishizaka 1974]. This property has led to the routine use of ER in the laboratory evaluation of 
human sera for AP defects. The key mechanisms by which AP-dependent ER lysis occurs 
were elucidated in a series of experiments using purified human AP components [Fearon & 
Austen 1977b]. ER or sheep erythrocytes (ES) were coated with C3b by incubation in Mg2+-
containing buffer with C3, FB and FD. AP-dependent haemolysis was then triggered through 
a second incubation with FB, FD and properdin in buffer to which heterologous (rat) serum 
was added (as a source of C3-C9).  
Previous studies had shown that haemolysis of C3b-coated ES in rat serum could be 
reduced through prior incubation in human FH (especially in combination with human FI) 
[Weiler et al. 1976, Whaley & Ruddy 1976]. It was now demonstrated that: (1) the relative 
reduction in haemolysis achieved through prior incubation with FI with or without FH was 
much greater for ES than ER [Fearon & Austen 1977b]; (2) following an initial incubation with 
FB, FD and properdin, a subsequent incubation with FH led to dissociation of the AP C3 
convertase on C3b-coated ES but not C3b-coated ER (based on the extent of haemolysis 
during a final incubation with rat serum); and (3) whereas ER lysis following incubation in 
buffer containing C3, FB, FD, properdin, FI and FH was associated with C3 activation 
(based on haemolytic decay of the supernatant), neither lysis nor C3 activation occurred 
using ES. Based on these experiments, and earlier results using zymosan [Fearon & Austen 
1977a], the authors concluded that ‘activators of the alternative pathway, such as zymosan 
and Er [ER], provide privileged sites that protect C3b deposited by the low grade fluid phase 
reaction and the P,C3b,Bb [properdin-stabilized AP C3 convertase] formed at that site from 
the action of regulatory proteins, resulting in membrane-associated amplified C3 cleavage’ 
[Fearon & Austen 1977b].  
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Next, the authors assessed whether ‘increased C3b fixation by Er resulted from deposition 
by particle-bound amplification C3 convertase rather than by fluid phase convertase’ [Fearon 
& Austen 1977b]. Incubation of ES in solution containing purified AP components and FH led 
to 10% C3 activation at 60 minutes, with negligible cell surface uptake of (radiolabelled) C3. 
By contrast, incubation of ER in the presence of FH led to 64% C3 activation after only 15 
minutes, with surface uptake of 12.4% of total cleaved C3 at 60 minutes. In the absence of 
FH, activation of total C3 occurred within 15 minutes, and was associated with surface 
uptake of only 0.14% and 0.16% C3 on ER and ES, respectively. The authors concluded that 
‘deregulation of endogenous controls at the surface of Er but not Es results in local 
deposition of C3b by formation and function of surface-bound amplification convertase. In 
the absence of the regulatory protein, β1H [FH], the fluid phase reaction spontaneously 
advances to amplification, consuming C3 and [F]B, so that specific deregulation at the 
surface of Er with concomitant accumulation of C3b cannot occur’ [Fearon & Austen 1977b].  
1.2.8.2 Renal proximal tubular C3 staining 
Renal proximal tubular cells may provide an AP-activating surface. Incubation of normal rat 
or human cryosections ex vivo with NHS led to preferential C3 deposition on the apical 
(luminal) side of proximal tubules that was AP-dependent [Camussi et al. 1982, Camussi et 
al. 1983]. This was also demonstrated using human cultured proximal tubular epithelial cells 
(PTEC), but not HUVEC [Biancone et al. 1994, Gaarkeuken et al. 2008]. AP-dependent C3 
deposition on cultured human PTEC following incubation with urinary proteins from 
proteinuric patients was attributed to the ability of tubular epithelium to provide a ‘protected 
site’ from AP regulation [Peake et al. 2002]. However, human FH has been shown to bind to 
human cultured PTEC [Buelli et al. 2009, Zaferani et al. 2012, Nagamachi et al. 2014]. 
Tubular staining for FH has also been reported on human renal sections [Licht et al. 2007]. 
The degree to which FH binds to the apical surface of PTEC may be influenced by surface 
expression and/or sulfation of GAGs [Buelli et al. 2009, Zaferani et al. 2012]. 
C3 deposition on the apical surface of cultured murine TEC following incubation of WT 
serum was enhanced in the presence of a recombinant mouse FH fragment comprising C-
terminal SCR domains 19-20 [Renner et al. 2010]. This was attributed to competitive 
inhibition of full-length FH on the TEC surface by the recombinant FH fragment. The authors 
concluded that ‘regulation of complement by factor H is inadequate to prevent spontaneous 
complement activation on the apical surface of the cells’ [Renner et al. 2010]. However, by 
addition to WT mouse serum of supraphysiological purified FH from WT mice, C3 deposition 
on the TEC surface was reduced, indicating that ‘at a high enough concentration factor H is 
capable of suppressing CAP activation on the TEC surface’ [Renner et al. 2011]. 
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1.2.9 Membrane-expressed regulators 
CR1 is a multifunctional type 1 transmembrane glycoprotein comprising up to 44 SCR 
domains and expressed on most peripheral blood cells [Krych-Goldberg & Atkinson 2001]. 
Its complement regulatory functions include decay accelerating activity for the C3 and C5 
convertases and cofactor activity for FI-mediated cleavage of C3b and iC3b [Fearon 1979, 
Ross et al. 1982, Medicus et al. 1983]. Soluble CR1 (sCR1) is present at low physiological 
concentrations in plasma as a result of surface cleavage of membrane-bound CR1 on 
leukocytes [Yoon & Fearon 1985, Danielsson et al. 1994].  
MCP is a type 1 transmembrane protein comprising 4 SCR domains that is expressed on all 
nucleated cells and has cofactor activity for FI-mediated C3b cleavage [Seya et al. 1986]. 
Soluble MCP has also been detected in small amounts, typically in association with cancer 
or immune diseases [Seya et al. 1995].  
DAF is a glycophosphatidylinositol (GPI)-anchored protein comprising four SCR domains, 
and is expressed on peripheral blood cells, with decay accelerating activity for C3 and C5 
convertases [Medof et al. 1984]. CD59 is a GPI-linked inhibitor of MAC formation expressed 
on erythrocytes and leukocytes [Meri et al. 1990].  
In the kidney, DAF, MCP and CD59 are ubiquitously expressed in all three glomerular cell 
types (mesangial cells, endothelial cells and podocytes) whereas CR1 is expressed 
exclusively on podocytes [Ichida et al. 1994, Nangaku 1998, Naik et al. 2013]. MCP is the 
only membrane-expressed regulatory protein detected in renal tubules (on the basolateral 
aspect of cortical collecting ducts and proximal tubules) [Ichida et al. 1994]. Cytokine-
enhanced FH production has been demonstrated using cultured PTEC and mesangial cells 
[Zhou et al. 2001].  
1.2.10 Complement receptors 
Of the five recognised CRs, the SCR modular receptors CR1 and CR2 (CD21) and the beta-
2 (β2)-integrins CR3 (CD11b/CD18, αMβ2, macrophage-1 antigen [Mac-1]) and CR4 
(CD11c/CD18, αXβ2, p150,95) recognise distinct C3 α-chain sites [van Lookeren Campagne 
et al. 2007]. CRIg is a member of the Ig superfamily expressed on tissue resident 
macrophages in the liver, where it binds the β-chain of C3b and iC3b and is important in 
phagocytosis [Helmy et al. 2006]. CRIg may also function as an inhibitor of the C3/C5 
convertases [Wiesmann et al. 2006]. The anaphylatoxin chemotactic receptors C3aR 
(55kDa) and C5aR (CD88) are G-coupled receptors present on peripheral blood leukocytes 
and tissue-derived cells, and mediate important proinflammatory responses [Wetsel 1995]. 
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CR1 was originally identified through its role as the C3b/C4b receptor on erythrocytes in 
immune adherence [Nelson 1953, Rothman et al. 1975]. It binds the C3c moiety of C3b and 
has reduced affinity for iC3b [Kalli et al. 1991]. In addition to erythrocytes, it is expressed on 
myeloid leukocytes, follicular dendritic cells (FDCs) and B and T cells [Khera & Das 2009]. 
Its expression on myeloid leukocytes facilitates cooperation with Fc-gamma receptor (FcγR) 
and CR3 in phagocytosis [Sutterwala et al. 1996].  
CR2 is expressed mainly on B cells and FDCs, and binds the C3d moiety of iC3b and 
C3d(g) [Weis et al. 1984, van den Elsen & Isenman 2011]. Under conditions of limiting 
antigen, co-ligation of CR2 and the B cell antigen receptor (BCR) by C3d lowers the 
threshold dose of antigen required for B cell signalling leading to clonal expansion [Carter et 
al. 1988, Matsumoto et al. 1991]. Trapping of C3d-oponized antigen by CR2-expressing 
FDCs in germinal centres facilitates antigen presentation and induction of B cell immunity 
[Carroll & Isenman 2012]. The molecular adjuvant effects of C3d mediated via CR2 have 
been shown as more potent than those of complete Freund’s adjuvant (CFA) [Dempsey et 
al. 1996].   
1.2.10.1 β2-integrins 
CR3/Mac-1 and CR4 were originally identified based on their specificity for the iC3b 
fragment and their expression on a distinct cell population from that expressing CR1 and 
CR2 [Ross & Lambris 1982]. They are members of the leukocyte-restricted β2-integrin 
subfamily, also comprising lymphocyte function-associated antigen 1 (LFA-1, or 
CD11a/CD18, αLβ2) and CD11d/CD18 (αDβ2) [Tan 2012]. The broader integrin family of 24 
heterodimers constitutes the major adhesion receptors in metazoa [Hynes 2002]. Each β2-
integrin consists of a common, smaller β2-subunit and a variable, larger α-subunit that are 
non-covalently associated. Both the α-subunit and β2-subunit comprise a large extracellular 
domain, a single pass transmembrane domain and a cytosolic tail [Arnaout 1990]. The 
presence of CR3/Mac-1 on human leukocytes was first shown using phagocyte-specific 
monoclonal antibodies [Springer et al. 1979]. CR3/Mac-1 was subsequently recognised as 
the phagocyte receptor for iC3b [Beller et al. 1982, Wright et al. 1983]. It is the predominant 
β2-integrin on neutrophils and is also expressed on monocytes/macrophages and myeloid 
dendritic cells (DCs) as well as lymphoid natural killer (NK) cells, γδ-T cells and a minor 
subset of B cells [Arnaout 1990, Ross 2000, Graff & Jutila 2007, Griffin & Rothstein 2011]. 
CR4 is expressed on a similar cell population and has many ligands in common with 
CR3/Mac-1, including iC3b [Chen et al. 2012].  
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Integrins are constitutively inactive, with activation mediated via bidirectional signalling 
between the extracellular and cytosolic integrin domains [Hynes et al. 2002]. This paradigm 
of integrin activation is commonly referred to as ‘outside-in’ and ‘inside-out’ signalling [Tan 
2012]. Binding of extracellular ligands to integrins leads to transduction of outside-in signals 
through the cell membrane, culminating in cellular processes including adhesion, 
phagocytosis and cytokine production. Inside-out signaling involves transmission of 
intracellular signals, including those produced through stimulation of adjacent cell surface 
receptors, to the cytosolic tail. This induces conformational changes in the extracellular 
domains that are associated with a high-affinity ligand-binding state [Diamond & Springer 
1994, Luo et al. 2007]. Thus an inactive integrin is converted from its bent extracellular 
conformation to an extended conformation, and its ligand-binding domain from a closed 
conformation to an open one [Springer & Dustin 2012]. Inside-out signalling is less clearly 
established for Mac-1/CR3 than other members of the β2-integrin subfamily (notably LFA-1) 
[Fagerholm et al. 2006]. Clustering of integrins on cellular surfaces is an additional 
determinant of avidity for ligand-dependent cellular processes [Ley et al. 2007]. 
1.2.10.2 The iC3b-CD11b interaction 
The CD11b subunit of CR3/Mac-1 is a 165kDa glycoprotein encoded by the integrin alpha M 
(ITGAM) gene on chromosome 16p11.2. It confers specificity of CR3/Mac-1 for a wide range 
of structurally unrelated endogenous ligands and pathogen molecules [Yakubenko et al. 
2002]. Many of these, including iC3b, intracellular adhesion molecule (ICAM)-1 (CD54), 
fibrinogen and heparin, bind overlapping binding sites within the CD11b inserted (I)-domain 
[Diamond et al. 1993, Diamond et al. 1995]. The I-domain contains a metal ion-dependent 
adhesion site (MIDAS) in which Mg2+ coordinates ligand binding [Stewart & Hogg 1996]. 
iC3b ligation of CD11b-expressing leukocytes is critical to phagocytosis of complement-
opsonized particles, immune complexes and apoptotic cells [Arnaout et al. 1983, Takizawa 
et al. 1996, Dupuy & Caron 2008] and to antigen presentation during induction of peripheral 
immune tolerance [Hammerberg et al. 1998, Sohn et al. 2003]. Both CD11b and CD11a 
(LFA-1) bind ICAM-1, leading to leukocyte adhesion and transendothelial migration 
[Diamond et al. 1990, Ley et al. 2007]. Cytotoxicity and adhesion are thus viewed as the 
classic CD11b-mediated leukocyte functions [Ross 2000], whereas a wide array of other 
CD11b ligands contribute to novel roles including oxidative burst and degranulation, and 
apoptosis [Tan 2012]. The I-domains of CD11b [Ueda et al. 1994, Ustinov & Plow 2005] and 
CD11c (CR4) [Malhotra et al. 1986] recognise distinct iC3b moieties. CD11b binds the C3d 
moiety of iC3b with high affinity, but interacts only weakly with the iC3b cleavage product 
C3d(g) [Bajic et al. 2013]. CD11c interacts with the C3c moiety [Chen et al. 2012].  
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1.2.10.3 CD11b in human disease  
The importance of β2-integrins in innate immunity was elucidated in patients with leukocyte 
adhesion deficiency type 1 (LAD-1), an autosomal recessive disorder characterized by 
recurrent bacterial infection [Arnaout et al. 1982, Fischer et al. 1983]. LAD-1 is associated 
with variants in the ITGB2 gene encoding CD18 that result in reduced expression or 
dysfunction of Mac-1/CR3, LFA-1 and CR4 [Kishimoto et al. 1987, Hogg et al. 1999]. A case 
is reported of CD11b deficiency with normal antigenic levels of CD18, in a patient with non-
healing lower limb ulcers [Darveaux et al. 2014].  
Single nucleotide polymorphisms (SNPs) in ITGAM are associated with increased risk of 
developing systemic lupus erythematosus (SLE) based on GWAS. Most strongly associated 
is a missense variant at exon 3 of ITGAM (230G>A, rs1143679, Arg77His). Arg77His occurs 
with 9-11% frequency in populations of European and African descent, with an odds ratio of 
1.4-2.2 for development of SLE [Harley et al. 2008, Nath et al. 2008, Hom et al. 2008]. 
Additional GWAS have shown association of Arg77His specifically with renal manifestations 
of SLE [Yang et al. 2009, Kim-Howard et al. 2010, Warchol et al. 2011, Sanchez et al. 2011, 
Toller-Kawahisa et al. 2014].  
The functional effect most strongly associated with Arg77His is impaired phagocytosis of 
iC3b-coated targets by CD11b-expressing monocytes/macrophages or neutrophils 
[MacPherson et al. 2011, Rhodes et al. 2012, Fossati-Jimack et al. 2013]. This 
polymorphism has also been identified as the Mart alloantigen in neonatal autoimmune 
neutropenia [Simsek et al. 1996, Sachs et al. 2004]. Rare SLE-associated ITGAM variants 
have also been identified in individuals with impaired CD11b-dependent phagocytosis 
[Roberts et al. 2014]. An earlier study noted impaired phagocytosis of iC3b-coated cells in a 
patient with SLE in whom an abnormal iC3b-binding epitope on CD11b appeared to have a 
genetic basis [Witte et al. 1993]. 
1.2.11 Complement in T cell responses 
An emerging concept in complement biology is that the generation of complement activation 
products by immune cells plays a critical role in adaptive immunity [Kolev et al. 2014]. For 
example, during the interaction of cognate APCs and T cells, the production and activation 
of C3 and C5 mediates T cell co-stimulation [Strainic et al. 2008]. It appears that intracellular 
complement activation and receptor systems may also be important in induction of T cell –
mediated responses [Liszewski et al. 2013]. Conversely, immune cell-derived complement 
activation products may contribute to negative regulation of T cells (for example, via the 
interaction of C3b with MCP) [Le Friec et al. 2012]. 
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1.3 The glomerular basement membrane 
The glomerular capillary wall (GCW) comprises three layers: (1) the GBM, an acellular, 
extracellular matrix (ECM); (2) on its vascular aspect, a layer of fenestrated endothelium with 
an overlying glycocalyx (composed of glycoproteins, glycolipids and proteoglycans); and (3) 
on its urinary aspect, the podocyte layer (visceral epithelial cells) [Slater et al. 2011, Suh & 
Miner 2013]. The adult GBM is composed of three layers in turn: (1) the lamina densa; (2) on 
its endothelial/vascular side, the lamina rara interna; and (3) on its epithelial/urinary side, the 
lamina rara externa. The lamina rara interna and externa are composed largely of GAGs, 
especially heparan sulfate and hyaluronic acid. The lamina densa is composed of a fine 
(~3nm), filamentous meshwork in which several glycoproteins are present in addition to 
GAGs. Although these glycoproteins are common to all basement membranes, specific 
isoforms are found in the lamina densa of the GBM. Thus polymerised laminin-521 (α5β2γ1) 
provides the basic scaffold for incorporation of collagen type IV (α3α4α5), nidogen/entactin-1 
and -2 and the heparan sulfate proteoglycans agrin and perlecan in the GBM [Miner 2011]. 
Some of the matrix components are secreted by podocytes to maintain GBM structure and 
function [Pavenstadt et al. 2003]. Others, including fibronectin, a plasma glycoprotein also 
found in other ECM and on cell surfaces, are probably derived from the circulation. GBM 
protein composition may be altered in association with pathological GBM thickening, for 
example in diabetic nephropathy [Mason & Wahab 2003]. Atypical proteoglycans are also be 
identified within the GBM in certain disease states (e.g. podocan secreted by podocytes in 
HIV-associated nephropathy) [Ross et al. 2003]. 
The GBM is generally believed to be devoid of membrane-expressed complement regulatory 
proteins [Zipfel 2006]. A single study reported that CR1 is present in human foetal GBM 
[Appay et al. 1988]. Binding of plasma FH to the GBM has been reported based on indirect 
immunofluorescence (IF) staining and immuno-EM of normal human kidney sections [Licht 
et al. 2007]. The primary antibody used was said to be specific for N-terminal FH domains, 
aIthough cross-reactivity with common epitopes on FHR proteins and/or FHL-1 was not 
strictly excluded. Elsewhere a linear IF staining pattern for FH in normal kidney specimens 
or C3 glomerulopathy biopsy samples has been attributed to GBM-binding of FH [Meri et al. 
1992, Clark et al. 2013]. Aside from the question of cross-reactivity, this pattern could 
equally be consistent with FH binding/expression in other layers of the GCW including the 
endothelium [Vaziri-Sani et al. 2006, Bridoux et al. 2011]. 
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1.4 Dense deposit disease 
1.4.1 Histological features 
DDD is defined by the appearance on electron microscopy (EM) of extremely dark 
(osmiophilic), ribbon-like, intramembranous dense deposits transforming the GBM [Cook H. 
T. & Pickering M.C. 2015] (Fig. 4a,b). Electron-dense deposits are also sometimes seen in 
the basal lamina of Bowman’s capsule, tubular basement membrane (TBM) and mesangium 
[Berger & Galle 1962, Joh et al. 1993, Nasr et al. 2009]. Even at high magnification, these 
deposits lack substructure. On light microscopy (LM), reduplication of the GBM and 
thickening of the GCW may be visualized by double contours or ‘tram tracks’ on silver stain 
(Fig. 4c). Together with mesangial expansion and hypercellularity, this constitutes a 
membranoproliferative pattern [Cook H. T. & Pickering M. C. 2015]. However, in one series 
in 69 patients with DDD, a mesangioproliferative pattern (43% of biopsies) was more 
common than a membranoproliferative one (25% of biopsies) [Walker et al. 2007]. 
Crescentic GN (17%) and an acute proliferative and exudative pattern of ‘diffuse 
endocapillary proliferation with numerous macrophages and neutrophils’ (12%) were also 
observed. Recurrence of DDD may even produce crescentic GN following renal 
transplantation [Hoschek et al. 2002, Braun et al. 2005]. For these reasons, the term MPGN 
type 2 [Mathew & Kincaid-Smith 1971, Habib et al. 1975] is no longer used for DDD. 
IF or immunohistochemistry (IHC) using immunoperoxidase shows intense glomerular 
staining for C3, corresponding to the dense deposits seen on EM [Cook H. T. & Pickering 
M.C. 2015]. Thus C3 is detected in the mesangium and in a variably linear or granular 
pattern in the GCW (Fig. 4d,e), whereas little or no glomerular Ig or early CP components 
(C1q and C4) are detected [Berger et al. 1969]. Isolated or predominant C3 is indicative of 
C3 activation via the AP. C3-dominant staining is seen not only in DDD, but also in cases 
where the GCW deposits are subendothelial rather than intramembranous, or otherwise lack 
the classic appearance of DDD [Bariéty et al. 1971]. In one series of 19 such cases, the term 
glomerulonephritis C3 (or C3 glomerulonephritis, C3GN) was proposed [Servais et al. 2007]. 
The term C3 glomerulopathy has since been introduced for all forms of GN involving ‘a 
disease process due to abnormal control of complement activation, deposition, or 
degradation and characterized by predominant glomerular C3 fragment deposition with 
electron-dense deposits on electron microscopy’ [Pickering et al. 2013]. Recognizable 
entities within C3 glomerulopathy include those with distinct morphology (DDD and electron-
dense intramembranous GBM transformation) or aetiology (CFHR5 nephropathy and the 
presence of an abnormal FHR-5 protein [Gale et al. 2010]). The more common histological 
lesion of MPGN type 1 is characterized by glomerular deposition of C3 and IgG, consistent     
.        . 
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Figure 4 Histological features of dense deposit disease 
(a) Electron microscopy (EM) showing typical osmiophilic, ribbon-like electron-dense deposits 
(indicated by arrow) within the lamina densa (middle layer) of the glomerular basement membrane 
(GBM). Reproduced from [Barbour et al. 2013a] with permission of Oxford University Press (License 
No 3510930958829). (b) EM showing characteristic osmiophilic deposits (arrow). (c) Light microscopy 
with silver stain showing a membranoproliferative pattern with double contours of the GBM (arrow). 
(d) Immunofluorescent and (e) immunoperoxidase staining of glomerular capillary wall C3 and some 
granular mesangial C3. Reproduced from [Barbour et al. 2013b] with permission of Elsevier.
a.   
d.                 e.     
  
b.                 c.     
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with immune complex formation. MPGN type 1 is therefore not included in the classification 
of C3 glomerulopathy, although some overlap probably exists, in light of reports of MPGN 
type 1 in association with genetic complement abnormalities (discussed below). 
1.4.2 Clinical features  
Estimated prevalence per million population ranges from 1-2 C3 glomerulopathy cases 
(inclusive of DDD) [Medjeral-Thomas et al. 2014] to 2-3 DDD cases [Smith et al. 2011]. DDD 
is traditionally viewed as a diagnosis of childhood and young adulthood, with recent series 
showing a younger age at diagnosis for DDD than C3GN [Servais et al. 2012, Medjeral-
Thomas et al. 2014]. However, one recent DDD series included numerous patients aged 
over 60 years [Nasr et al. 2009]. Some studies indicate that DDD is more common in 
females than males (~2:1 ratio) [Nasr et al. 2009, Wang et al. 2012], although most show no 
sex differences in DDD (or C3GN) [Walker et al. 2007, Servais et al. 2012, Lu et al. 2012, 
Medjeral-Thomas et al. 2014]. DDD presents clinically as nonspecific intrinsic renal disease, 
comprising any or all features of haematuria, proteinuria, peripheral oedema, hypertension 
and renal failure [Appel et al. 2005]. It is associated with extrarenal conditions of acquired 
partial lipodystrophy [Misra et al. 2004] and ocular drusen [Duvall-Young et al. 1989]. These 
conditions may also be associated with other types of C3 glomerulopathy and MPGN 
[Barbour et al. 2013b]. Similarly, an association with monoclonal gammopathy of 
undetermined significance (MGUS) has been reported in adults with DDD [Sepandj & Trillo 
1996, Hill & Desmond 2007, Nasr et al. 2009, Sethi et al. 2010] and C3GN [Bridoux et al. 
2011, Zand et al. 2013]. No renal clinical or pathological features appear to distinguish the 
MGUS-associated forms of C3 glomerulopathy from non-MGUS-associated forms. 
Increased prevalence of type I diabetes mellitus was also reported in families with a DDD-
affected member in a self-reporting study [Lu et al. 2012].  
Prognosis of DDD is poor, with 10-year progression to ESKD of 40-50% [Smith et al. 2007, 
Servais et al. 2012, Lu et al. 2012]. Renal survival may be reduced in adults compared to 
children [Nasr et al. 2009, Servais et al. 2012]. Reduced GFR at diagnosis appears to 
predict progression to ESKD [Nasr et al. 2009, Servais et al. 2012, Medjeral-Thomas et al. 
2014]. Crescentic GN may predict poor renal outcome, although this is inconsistent between 
studies, as is the case with numerous other pathologic variables [Barbour et al. 2013b]. 
Prognosis may be slightly better for C3GN than DDD [Medjeral-Thomas et al. 2014]. In 
CFHR5 nephropathy, progression to ESKD is more common in males than in females for 
reasons that are not understood [Athanasiou et al. 2011]. Following renal transplantation, 
histological recurrence of DDD and C3GN is common, although the impact of this on graft 
survival is controversial [Braun et al. 2005, Little et al. 2006, Zand et al. 2014]. 
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1.4.3  Pathophysiology 
In DDD, dense deposits containing C3 fragments accumulate within the lamina densa, 
leading to disruption of the GBM and consequent renal functional injury (e.g. proteinuria). In 
addition to causing dense transformation of the GBM, C3 activation leads to downstream 
proinflammatory pathways mediating progressive renal failure. For example, acute 
glomerular inflammation may be due to MAC activation, with a linear staining pattern for 
C5b-9 sometimes observed in patients with DDD [Cook H. T. & Pickering M.C. 2015]. 
Immune cells recruited to the glomerulus in response to anaphylatoxins mediate chronic 
inflammation with ongoing release of proinflammatory cytokines.  
Limited evidence from human biopsy studies implicates iC3b as the specific C3 activation 
product present within the GBM deposits, with additional support from a model of C3 
glomerulopathy in FH-deficient mice (discussed below in section 1.5.1). The presence within 
the glomerulus of immune cells expressing CD11b, the specific leukocyte receptor for iC3b, 
has not been directly assessed in DDD, although the findings of a biopsy study in patients 
with MPGN type 1 may be relevant [Soma et al. 1998]. This showed that CD11b+ cells were 
prominent in the glomerulus, especially in peripheral capillary loops (similar to the C3 
staining pattern). The glomerular CD11b+ cell count also correlated with both the intensity of 
C3 staining and the degree of proteinuria. It was therefore suggested that the interaction of 
CD11b on myeloid cells with subendothelial deposits of C3 was important in disease 
progression. Although expression of CD11b+ on glomerular cells mainly correlated with that 
of CD15, a neutrophil/monocyte marker, glomerular cells expressing the 
monocyte/macrophage marker, CD68+, are also frequently noted in patients with MPGN 
[Soma et al. 1994, Yang et al. 1998, Wu et al. 2012]. 
Clinicopathological overlap between C3 glomerulopathy and post-infectious GN (PIGN) is 
exemplified by: (1) DDD case series in which renal symptoms are preceded by respiratory 
tract infection [Habib et al. 1975, Nasr et al. 2009, Wang et al. 2012]; (2) C3 abnormalities in 
many cases of PIGN, including a transient fall in plasma C3 and the presence of glomerular 
C3 without Ig [Cook H. T. & Pickering M. C. 2015]; (3) EM showing the presence in many 
DDD/C3GN cases of subepithelial, hump-like dense deposits classically associated with 
post-streptococcal GN [Walker et al. 2007, Nasr et al. 2009]; and (4) case reports showing 
persistent renal disease following a diagnosis of PIGN, in which biopsies and/or genetic 
association data were later consistent with C3 glomerulopathy [Sandhu et al. 2012, Vernon 
et al. 2012, Meleg-Smith 2012, Sethi et al. 2013]. One possible interpretation is that infection 
may initiate or exacerbate the disease process that leads to C3 glomerulopathy (Fig. 5), for 
example via exogenous (or cryptogenic endogenous) triggers of complement activation. 
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Figure 5 Pathophysiology of DDD and other forms of C3 glomerulopathy  
Triggers of C3 activation (depicted at centre) may be exogenous (e.g. infection) or endogenous (i.e. C3 tickover). C3 activation generates C3b molecules for 
attachment to surfaces including the GBM. In health (upper panel), C3b amplification via the AP is tightly controlled by FH in the circulation and on surfaces. 
In theory, any surface-attached C3b is then metabolized, leaving C3 fragments (iC3b, C3d) attached to the GBM, and releasing FH back into the circulation. In 
the setting of abnormal FH (bottom left panel), uncontrolled C3 activation generates excessive C3 fragments in the circulation, which may accumulate along 
the GBM. Alternatively, enhanced FH de-regulation due to abnormal FHR proteins (bottom right panel) may be one mechanism by which C3 accumulates 
along the GBM despite intact FH. Reproduced from [Barbour et al. 2015] with permission from Oxford University Press (License No 3511371147517). 
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1.4.4 Associated complement abnormalities 
Low plasma C3 levels are identified in ~80% of DDD cases, compared to only ~40% of 
C3GN cases [Nasr et al. 2009, Servais et al. 2012, Medjeral-Thomas et al. 2014]. AP 
functional studies typically show impaired AP function in patients with DDD, including both 
those with severe FH deficiency [Levy et al. 1986, Schejbel et al. 2011, Rusai et al. 2013] 
and those with detectable plasma FH levels [Sethi et al. 2010, Hawfield et al. 2013]. This 
has generally been attributed to chronic secondary depletion of C3 and/or other AP 
substrates [Seelen et al. 2005], as a result of acquired or inherited factors. One study 
reported that a diagnostic panel comprising assays for C3NeFs, anti-FB and anti-FH 
autoantibodies, and FH genetic sequence variants yields one or more positive findings in 
almost 90% of DDD cases [Zhang et al. 2012]. Taken together, these data suggest that 
uncontrolled C3 activation occurs in the circulation in DDD, whereas normal plasma C3 
levels in many cases of C3GN may indicate that abnormal AP control is restricted to 
surfaces, specifically within the glomerulus. For example, in familial C3GN (including CFHR5 
nephropathy) associated with genetically abnormal FHR proteins, enhanced ‘FH 
deregulation’ on the GBM surface has been proposed as one disease mechanism. 
1.4.4.1 Autoantibodies  
C3NeF, first described in a patient with ‘persistent hypocomplementemic glomerulonephritis’ 
[Spitzer et al. 1969], is an autoantibody that binds a neo-epitope on C3bBb, stabilizing it 
against spontaneous and FH-mediated decay and prolonging its C3-cleaving action [Daha et 
al. 1976]. A second type of C3NeF was found to display slower C3 and C5 activation 
[Mollnes et al. 1986] and properdin dependence [Clardy et al. 1989]. C3NeFs are more 
common in DDD than C3GN or MPGN type 1 [Schwertz et al. 2001, Servais et al. 2012], 
especially properdin-independent C3NeFs [Tanuma et al. 1990]. However, plasma levels of 
C3NeF often do not correlate with clinical parameters of disease [Appel et al. 2005, Zhang et 
al. 2012]. In addition, C3NeFs are occasionally seen in post-streptococcal GN [Fremeaux-
Bacchi et al. 1994], lupus nephritis [Walport et al. 1994] and membranous nephropathy [Niel 
et al. 2015]. Hence a role of C3NeFs in specific causation of C3 glomerulopathy is unlikely.  
Enhanced AP C3 convertase activity has also been demonstrated in association with 
autoantibodies that bind to native FB [Strobel et al. 2010, Zhang et al. 2012] or both FB and 
C3b [Chen et al. 2011] in patients with DDD. An early report concerned a patient with C3 
glomerulopathy and circulating monoclonal  light chain dimers targeted to SCR 3 of FH 
[Meri et al. 1992, Jokiranta et al. 1999]. The light chain dimers blocked N-terminal-
dependent binding of FH to C3b, producing increased C3 activation via the AP in vitro. A 
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patient with a possible diagnosis of DDD was later reported with monoclonal IgG- anti-FH 
autoantibodies against N-terminal SCR domains impairing FI cofactor activity [Nozal et al. 
2012]. High-titre anti-FH autoantibodies targeted against N-terminal SCR domains and 
associated with AP effects were reported in two further patients with DDD and MPGN 
[Goodship et al. 2012]. However, they were also detected in healthy individuals. 
1.4.4.2 Family studies 
Family studies have shown a genetic basis for a small number of cases of C3 
glomerulopathy (Table 1). The first report in which the genetic variant was characterized 
concerned two brothers with autosomal recessive ‘atypical dense intramembranous deposit 
disease’ in association with very low plasma C3, C5, FB and FH levels [Levy et al. 1986]. 
Renal immunostaining showed C3 without Ig in the glomerulus (granular mesangial and 
linear pattern) but not the TBM or renal arteries, with discontinuous intramembranous and 
subendothelial dense deposits on EM. Genetic assessment in the elder brother revealed a 
homozygous missense FH variant mapping to SCR 7 [Dragon-Durey et al. 2004]. Both 
consanguineous parents and two other children had half-normal FH levels (without renal 
disease), consistent with heterozygosity for the FH variant causing FH deficiency (so-called 
type 1 variant). A case of endocapillary GN with predominant glomerular C3 was later 
described in an infant with a homozygous type 1 FH variant mapping to SCR 2 (the result of 
paternal isodisomy) [Schejbel et al. 2011]. A young girl with C3GN was also described with a 
homozygous type 1 FH variant mapping to SCR 16 [Rusai et al. 2013]. A different amino 
acid substitution at the identical FH protein domain, resulting in non-secretion of FH from 
cells both in vivo and in vitro, had earlier been reported in a family with autosomal recessive 
type 3-collagen glomerulopathy [Vogt et al. 1995, Ault et al. 1997, Schmidt et al. 1999].  
Before these reports of familial C3 glomerulopathy, severe FH deficiency had been found to 
co-segregate with the alternative renal lesion of thrombotic microangiopathy (TMA) in one 
family [Thompson & Winterborn 1981]. Renal TMA is characterized by microvascular 
endothelial injury and associated thrombosis in renal arterioles and glomerular capillaries. 
Aetiology of renal TMA due to genetic or acquired abnormalities in complement regulation is 
commonly referred to as atypical haemolytic uraemic syndrome (aHUS) [Barbour et al. 
2012]. Renal TMA lacks well-defined electron dense deposits and C3 accumulation, and 
hence is pathologically distinct from C3 glomerulopathy. A number of family studies have 
since shown renal TMA rather than C3 glomerulopathy in association with homozygous FH 
deficiency [Pickering & Cook 2008, Sethi et al. 2009, Habibi et al. 2010, Wilson et al. 2013, 
Michaux et al. 2014]. In one aHUS pedigree a family member developed C3 glomerulopathy 
following renal transplantation (later complicated by allograft TMA) [Boyer et al. 2008].  
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Original report Diagnosis 
Affected family 
member (case N
o
) 
Glomerular 
IF/IHC 
EM deposits C3 levels C3NeF FH levels 
Abnormal 
protein 
Rare genetic variant 
[Berry et al. 1981] 
MPGN 3 Brother 
C3 2+, IgM/C1q 
2+, IgG/IgA 1+ 
Subendothelial, 
subepithelial 
Low 
    
MPGN 1 Sister 
C3 3+, 
C1q/IgG/IgM 1+ 
Subendothelial 
[Marder et al. 
1983] 
MPGN 3 1st brother (III.1) C3 pos, Ig pos Subend, subepi 
Low Neg Normal 
  Idiopathic GN 2nd brother (III.2) C3 pos, Ig neg Subepithelial 
[Levy et al. 1986, 
Dragon-Durey et al. 
2004] 
Atypical DDD 
Elder brother (III.3) 
C3 pos, Ig neg 
Discontinuous 
IM, mesangial 
Very low 
Neg Very low 
 
Homozygous missense FH 
exon 9 (SCR 7 Cys431Ser) 
Younger brother (III.5) 
  
[Linshaw et al. 
1987] 
Mild GN 
Mother C3 3-4+, Ig 0-1+ 
IM, subend, 
subepi, mesang Low Pos 
   
Son 
  
[Lopez-Larrea et al. 
1987] 
MPGN 
1st sister 
  
Very low Neg Undetect 
  
2nd sister 
3rd sister 
[Herrin & Bartsocas 
1989] 
DDD Father (1) 
 
  
    
DDD 1st daughter (2) 
Discontinuous 
subepi, mesang 
Low 
?early MPGN 2nd daughter (3) C3/IgM trace mes Small 
 
[Power et al. 1990, 
Wong et al. 2014] 
MPGN (+PLD) 
Mother (1.2) 
C3 pos, IgM > 
IgG/IgA Subendothelial, 
mesangial 
Very low 
Pos  
 
Heterozygous missense  
FH exon 3                        
(SCR 2 Arg38Ser) 1st son (2.1) 
 
Normal Normal 
[López-Trascasa et 
al. 1991] 
MPGN 1 4th male sibling  Subendothelial Low Pos 
   
MPGN 2 Maternal cousin  
Low-
normal 
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Original report Diagnosis 
Affected family 
member (case N
o
) 
Glomerular 
IF/IHC 
EM deposits C3 levels C3NeF FH levels 
Abnormal 
protein 
Rare genetic variant 
[Neary J. J. et 
al. 2002, Neary 
J. et al. 2002, 
Malik et al. 
2012] 
C3 
glomerulopathy 
Father (105) 
C3 pos, Ig neg 
IM, subend, 
subepi, mesang 
Normal 
Neg Normal 
Hybrid       
FHR-312-FHR-1                       
Heterozygous hybrid    
gene with deletion of   
FHR-3 exons 4-6                         
(SCRs 3-5)                            
and FHR-1 exon 1 
Elder son (212)   
Younger son (213) 
IM, 
subendothelial, 
subepithelial 
Low-
normal 
Daughter (214) 
Normal 
Paternal aunt (103) 
 
 
Paternal aunt's 
daughter (223) 
Subend, subepi, 
mesangial    
[Licht et al. 
2006, Habbig et 
al. 2009] 
C3GN 
Elder sister (1) 
C3 pos, Ig neg 
IM, subend, 
mesangial 
Low Pos 
Slightly           
reduced 
FH224ΔGln 
Homozygous single codon 
deletion FH exon 6       
(SCR 4 224ΔGln) Younger sister (2) 
[Boyer et al. 
2008] 
C3GN/aHUS Boy (2) 
C3 pos, Ig/C1q/C4 
neg (2
nd
 allograft)  
Low 
 
Low 
 
Homozygous nonsense    
FH exon 17                      
(SCR 15 Tyr899Ter) aHUS First cousin   Low 
[Motoyama et 
al. 2009]   
MPGN 1 
1st daughter (1) 
C3 pos, Ig neg 
Subend (LM) Very low 
 
   Mother (2) Subendothelial Undetect Neg 
[Martinez-
Barricarte et al. 
2010] 
DDD 
Mother (II.2) 
Elder twin son (III.1)   
Younger twin son (III.2) 
C3 pos,  
mild C1q/IgA/IgM 
IM osmiophilic 
ribbons, 
mesangial 
Low-
normal 
Neg Normal C3923ΔAspGly 
Heterozygous deletion of 
two codons in C3 exon 21 
(923ΔAspGly) 
[Gale et al. 
2010] 
(Cypriot)              
CFHR5 
nephropathy 
Mother (Family 1 IV-5)  
Son (1 V-4) 
Great uncle (1 II.1) 
Aunt (1 IV.1) 
Uncle (Family 2 III.2) 
C3 pos,  
C1q/C4/Ig neg 
Subendothelial, 
mesangial > 
subepithelial 
Normal Neg Normal FHR-51212-9 
Heterozygous internal 
duplication of                      
FHR-5 exons 2-3                
(SCRs 1-2) 
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Original report Diagnosis 
Affected family 
member (case N
o
) 
Glomerular 
IF/IHC 
EM deposits C3 levels C3NeF FH levels 
Abnormal 
protein 
Rare genetic variant 
[Schejbel et al. 
2011] 
Endocapillary 
GN 
Daughter 
C3 pos, weak 
C4/C1q/IgM 
IM, 
subepithelial 
Very low  Very low  
Paternal isodisomy: 
homozygous missense FH 
exon 4 (SCR 2 Pro139Ser) 
[Rusai et al. 
2013] 
C3GN Daughter 
C3 pos, C1q/ 
IgG/IgA/IgM neg 
Mesangial > 
subendothelial 
Undetect Neg Undetect 
 
Homozygous missense     
FH exon 21                         
(SCR 16 Cys959Ser) 
[Ozaltin et al. 
2013] 
Glomerular 
TMA with 
MPGN 
Brother (Family UT-062 V-2) 
 
Normal 
   
Homozygous coding 
variant in diacylglycerol 
kinase ε gene (DGKE) 
Brother (UT062 V-3) 
C3 pos Subendothelial Brother (UT-062 V-4) 
Brother (UT-062 V-6) 
[Tortajada et al. 
2013] 
C3 
glomerulopathy 
Son (GN29) 
Diffuse C3, mes 
IgM, neg IgG 
IM, mesangial 
Slightly 
low 
Neg Normal FHR-112341-5 
Heterozygous internal 
duplication of FHR-1      
exons 2-5                          
(SCRs 1-4) Mother (GN29M) 
Diffuse C3,        
neg IgG/IgM 
Subend, subepi, 
mesangial 
DDD Maternal grandfather (GN29GF) 
      
[Medjeral-
Thomas et al. 
2013] 
C3GN 
Index male (III-5) 
GCW C3,              
neg IgA/IgG/IgM 
Segmental 
subend, IM 
Normal Neg Normal 
FHR-51212-9 
Heterozygous internal 
duplication of                
FHR-5 exons 2-3              
(SCRs 1-2) 
Maternal male cousin 
(III-2) 
C3 pos (allograft) 
Subend, mesang 
(native); IM, 
subend (graft)    
[Chen et al. 
2013] 
C3 
glomerulopathy  
Sister (#635) GBM > mesang 
C3c, neg Ig 
Ribbon-like IM > 
mesangial Very low Neg 
Normal Hybrid           
FHR-212-FHR-5 
Heterozygous hybrid    
gene with deletion of   
FHR-2 exons 4-5 (SCRs 3-4) Brother (#638) 
  
[Imamura et al. 
2015] 
C3GN Daughter 
GCW, mesang C3; 
neg Ig 
Subend, mesang Very low 
  FBSer367Arg 
Heterozygous missense    
FB exon 8 (Ser367Arg) 
MPGN 1 Mother   Low 
Subend subendothelial; Subepi subepithelial; IM intramembranous; Mesang mesangial; Undetect undetectable. Adapted from [Barbour et al. 2013b] with permission of Elsevier  
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The reasons for this phenotypic variance are unclear. However mechanistic insights into C3 
glomerulopathy and aHUS have derived from functional characterization of the genetic 
defects in some cases together with the study of animal models (discussed below). Notably, 
the familial aHUS-associated type 1 FH variants have invariably mapped to the C-terminal 
SCR domains 15-20 responsible for FH surface recognition. C-terminal clustering of mainly 
heterozygous FH variants has been noted in familial and (more common) sporadic cases of 
aHUS [Warwicker et al. 1998, Rodriguez et al. 2014]. In most of these cases, plasma FH 
levels are normal (type 2 mutations). These clinical data implicate impaired AP control on 
endothelial surfaces in aHUS pathogenesis [Richards et al. 2001, Caprioli et al. 2001]. 
Both autosomal recessive and autosomal dominant C3 glomerulopathy are described in 
families with type 2 FH variants mapping to N-terminal SCR domains. Two sisters developed 
autosomal recessive C3GN in association with a homozygous FH variant in SCR 4 [Licht et 
al. 2006, Habbig et al. 2009]. Circulating FH displayed impaired C3b-binding, decay 
accelerating activity and FI cofactor activity in vitro. By contrast, binding to heparin, C3d and 
HUVEC was normal. A mother and son developed autosomal dominant MPGN with 
predominant glomerular C3 in association with a heterozygous FH variant in SCR 2 [Power 
et al. 1990, Wong et al. 2014]. A recombinant FH fragment (SCR domains 1-4) comprising 
this genetic variant showed reduced C3b-binding and complement regulatory activity in vitro 
compared to a non-variant SCR1-4 fragment. The reasons for a dominant negative effect of 
the abnormal FH protein on AP regulation remain unclear.  
Autosomal dominant DDD was also reported in a mother and twin sons with a heterozygous 
C3 variant producing a gain of function in vitro [Martinez-Barricarte et al. 2010]. C3 encoded 
by the variant C3 allele was identified as the dominant circulating form of C3 in these 
patients. Although this C3 molecule could not be cleaved by the AP C3 convertase, it was 
activated by proteases and also formed C3(H2O). It then formed an AP C3 convertase that 
was resistant to FH-mediated decay accelerating and FI cofactor activity. On surfaces, DAF-
mediated decay accelerating activity and MCP-mediated FI cofactor activity were intact. 
Thus uncontrolled activation of the C3 encoded by the normal C3 allele was restricted to the 
fluid phase. In two earlier family studies, C3 glomerulopathy was associated with 
hyperfunctional C3 molecules [Marder et al. 1983, Linshaw et al. 1987]. Autosomal dominant 
C3GN was also reported in association with a heterozygous FB variant producing a putative 
gain of function [Imamura et al. 2015]. 
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Autosomal dominant C3GN associated with a heterozygous copy number variation in FHR-5 
in two Greek Cypriot families led to the designation ‘CFHR5 nephropathy’ [Gale et al. 2010]. 
The subsequent identification of numerous affected individuals across Cyprus with an 
identical gene variant is consistent with a founder effect. The clinical phenotype is of 
microscopic and episodic macroscopic haematuria, and progression to ESKD, mostly in 
males (for unknown reasons). Autosomal dominant C3GN has since been reported in 
association with other FHR copy number variations. Strikingly, all these cases involve 
internal duplication of exons or formation of hybrid genes, resulting in abnormal circulating 
FHR proteins with duplicated N-terminal SCR domains 1 and 2. These SCR domains on 
FHR-1, -2 and -5 contain a dimerization motif that facilitates formation of FHR homodimers, 
heterodimers [Goicoechea de Jorge et al. 2013] and even larger complexes [Tortajada et al. 
2013]. Compared to dimeric recombinant FHR proteins, monomeric recombinant FHR 
proteins lacking the dimerization motif show less avidity for ligands including C3b both in 
vivo [Goicoechea de Jorge et al. 2013] and in vitro [Tortajada et al. 2013, Goicoechea de 
Jorge et al. 2013]. As FHR-1, -2 and -5 lack the complement regulatory domains of FH, 
competition for surface C3b appears to influence the degree to which C3b amplification is 
inhibited (predominant FH binding) or allowed to proceed (predominant FHR binding) on 
surfaces. This effect of abnormal FHR proteins, referred to as FH deregulation, has been 
shown in vitro through enhanced lysis of guinea pig erythrocytes in the presence of FH. 
Autosomal recessive MPGN/glomerular TMA with positive glomerular C3 staining was 
associated with a homozygous variant in the gene encoding diacylglycerol kinase epsilon 
(DGK) in a large family (denoted as UT-062) [Ozaltin et al. 2013]. The mechanism by which 
DGK, an intracellular lipid kinase expressed in podocytes, influences glomerular disease 
has not been determined. Additional studies have reported homozygous or compound 
heterozygous DGKE variants in patients with aHUS, some of whom also have complement-
associated gene variants [Lemaire et al. 2013, Sanchez Chinchilla et al. 2014]. 
1.4.4.3 Other genetic associations 
Additional rare or novel genetic variants in complement-related genes have been reported in 
individuals with C3 glomerulopathy (albeit without family data supporting disease causation). 
For example, one series identified rare FH, FI and MCP variants in 18% of patients with 
DDD, C3GN or MPGN type 1 [Servais et al. 2012]. GWAS have also identified common 
allelic variants in FH and C3 associated with increased or reduced risk of DDD [Abrera-
Abeleda et al. 2011]. In some cases, in vitro AP effects have been attributed to the at-risk 
variant, supporting the disease association [Heurich et al. 2011]. The term ‘complotype’ has 
been coined for the pattern of complement gene variants that appears to influence an 
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individual’s risk of C3 glomerulopathy and/or other complement-related diseases [Harris et 
al. 2012]. For example, FH risk haplotypes comprising the single nucleotide polymorphism 
(SNP) Tyr402His on SCR 7 or Ile62Val on SCR 1 confer common susceptibility to DDD and 
age-related macular degeneration (AMD) [Hageman et al. 2005, Pickering et al. 2007]. SCR 
7 contains one of the GAG-binding sites, with some functional data indicating that the 402H 
variant of FH and FHL-1 displays reduced binding to GAGs and Bruch’s membrane (the 
macular ECM) [Clark et al. 2013, Clark et al. 2014].  
1.4.5 Treatment 
No treatment is proven as beneficial in DDD. A 1992 randomized controlled trial 
demonstrated benefit with alternate day prednisolone in 70 children with MPGN, of whom 14 
had DDD [Tarshish et al. 1992]. Long-term plasma infusion was effective and well tolerated 
in the report of familial C3GN related to a circulating abnormal FH protein [Licht et al. 2006]. 
Elsewhere plasma infusion/exchange is reported with only mixed success in DDD [Appel et 
al. 2005]. Case reports attributing a disease-modifying effect in patients with C3 
glomerulopathy to the anti-CD20 monoclonal antibody rituximab are fewer than those 
showing no effect at all. Eculizumab (Soliris®, Alexion Pharmaceuticals, USA) is a 
humanized monoclonal IgG1-κ anti-human C5 antibody approved for use in patients with 
paroxysmal nocturnal haemoglobinuria and atypical HUS. Off-label use of eculizumab was 
assessed in a prospective trial of 6 patients with native or post-transplant recurrent DDD or 
C3GN, 3 of whom showed a clinical response over a median 1-year treatment period 
[Bomback et al. 2012]. Glomerular accumulation of eculizumab was noted in post-treatment 
biopsy specimens [Herlitz et al. 2012]. Published case reports in over a dozen patients with 
C3 glomerulopathy show an 86% rate of clinical response to eculizumab, raising the 
possibility of publication bias (Table 2). On the basis of these limited data, patients in whom 
eculizumab appears most likely to be effective include those with biopsies showing active 
renal inflammation and/or glomerular C5b-9 deposition. Patients require vaccination against 
meningococcal infection prior to beginning eculizumab treatment, although this does not 
eliminate risk especially in the setting of concurrent immunosuppressive therapy (e.g. post-
transplantation) [Struijk et al. 2013]. A Phase 1 clinical trial in children and adults with DDD 
(NCT01791686) is evaluating recombinant human sCR1 therapy following promising 
preclinical data in vitro [Chen et al. 2013] and in vivo [Couser et al. 1995, Zhang et al. 2013]. 
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Table 2 Reported use of eculizumab for C3 glomerulopathy including DDD 
Report 
Study design 
(number of 
patients) 
Reported Diagnosis                                
(treatment age/sex) 
Treatment 
duration 
(months) 
Clinical 
response 
[Daina et al. 2012] Case report DDD (22/F) 11 Yes   
[Vivarelli et al. 2012] Case report DDD (17/M) 18 + 9 Yes   
[McCaughan et al. 2012] Case report Allograft recurrent DDD (29/F) 2.5 Yes   
[Bomback et al. 2012] Prospective, 
open-label, 
uncontrolled 
trial (6) 
DDD (22/M) 12 Yes   
 
DDD (42/M) 9 No   
  
Allograft recurrent DDD (32/M)  12 Yes   50% 85% 
  
C3GN (25/M) 12 No   
  
Allograft recurrent C3GN (22/M) 12 No   
  
Allograft recurrent C3GN (20/M) 12 Yes   
[Gurkan et al. 2013] Case report Allograft recurrent C3GN (21/M) 12 Yes   
[Besbas et al. 2014] Case report C3 glomerulopathy (16/F) 10 No   
[Kerns et al. 2013] Case report C3 glomerulopathy (16/M) 3.5 Yes   
[Rousset-Rouviere et al. 2014] Case report DDD (10/M) 6.5 Yes   
[Ozkaya et al. 2014] Case report DDD (14/F) 7 Yes   
[Berthe-Aucejo et al. 2014] Case report DDD (17/M) 3.5 No   
[Sanchez-Moreno et al. 2014] Case report Allograft recurrent DDD (14/F) 30 Yes   
[Le Quintrec et al. 2014] Case series (3)  C3 glomerulopathy (27/F) 15 Yes   
  
Allograft recurrent                               
C3 glomerulopathy (63/F) 
28 Yes   
  
C3 glomerulopathy (45/M) 6 Yes   
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1.5 Animal models 
1.5.1 Experimental C3 glomerulopathy 
Murine FH is structurally and functionally very similar to human FH [Kristensen & Tack 1986, 
Cheng et al. 2006]. Mice with homozygous FH deficiency (Cfh-/-) were engineered through 
targeted deletion of exon 3 (encoding SCR 1) in embryonic stem cells [Pickering et al. 2002]. 
Cfh-/- mice have proved to be an informative experimental model of C3 glomerulopathy. An 
earlier model was described in FH-deficient Norwegian Yorkshire piglets (now extinct) 
[Høgåsen et al. 1995]. Porcine dense deposit disease/MPGN type 2 was due to a 
homozygous mutation that affected SCR 20, preventing FH secretion [Hegasy et al. 2002].  
Cfh-/- mice on a 129/Sv×C57BL/6 mixed genetic background develop albuminuria and 
MPGN with ~25% mortality at 8 months. Plasma levels of C3 and C5 are extremely low, and 
C3 is detected within the glomerulus in a florid linear pattern [Pickering et al. 2002, 
Goicoechea de Jorge et al. 2011]. By contrast, mesangial IgG is seen only after MPGN 
develops. Electron-dense deposits are seen within the GCW, initially in the subendothelial 
layer, and stain positively for C3 on immuno-EM [Pickering et al. 2002]. C3 accumulation 
along the GBM is the earliest pathological renal abnormality detected in Cfh-/- mice, as also 
reported in FH-deficient piglets [Jansen et al. 1998]. Cfh-/- mice crossed with FB-deficient 
mice (Cfb-/-), which are unable to form the AP C3 convertase, do not show glomerular C3 
accumulation or spontaneous renal disease. This indicates that pathogenesis is dependent 
on uncontrolled C3 activation via the AP [Pickering et al. 2002]. Transplantation of kidneys 
from mice with combined homozygous deficiency of FH and C3 (Cfh-/-.C3-/-) into Cfh-/- 
recipients results in the appearance of linear C3, which therefore derives from the circulating 
C3 pool rather local renal C3 synthesis [Rose et al. 2008]. Laser dissection microscopy 
followed by western blot identified C3 β-chain and α’-chain fragments in glomerular tissue 
from Cfh-/- mice, consistent with the presence of iC3b (with or without C3d[g]) along the 
GBM. Accordingly, linear C3 was also detected using specific antibodies that recognise a 
C3d epitope on iC3b and C3d(g) [Paixão-Cavalcante et al. 2009, Ruseva et al. 2013]. 
Injection of purified murine FH [Paixão-Cavalcante et al. 2009] or human FH [Fakhouri et al. 
2010] restores plasma C3 levels in Cfh-/- mice to normal at 24h. This is accompanied by a 
significant reduction in linear C3 staining, and the appearance of mesangial and 
tubulointerstitial C3. Daily administration of human FH for 5 days results in negative linear 
and mesangial C3 staining and significantly reduces linear C3d staining. Following 
transplantation of kidneys from Cfh-/- mice into WT recipients, linear C3 staining is absent at 
five weeks [Alexander et al. 2007]. In FH-deficient piglets, a single infusion of WT porcine 
plasma or purified porcine FH led to a sustained rise in plasma C3 levels [Høgåsen et al. 
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1995]. Weekly WT plasma infusions increased median survival and reduced histological 
severity of MPGN in comparison to untreated animals [Høgåsen et al. 1995]. The critical role 
of FH deficiency in pathogenesis is underscored by absence of glomerular C3 or progressive 
renal disease in mice deficient in CR1-related gene/protein-y (Crry) [Ruseva et al. 2009]. 
This is despite uncontrolled C3 activation via the AP due to deficiency of this rodent-specific, 
membrane-expressed regulator [Li et al. 1993]. 
FI-deficient mice (Cfi-/-) have very low plasma levels of C3 (in the form of C3b) [Rose et al. 
2008]. This is similar to severe FI deficiency in humans, which has never been reported in 
association with C3 glomerulopathy (notwithstanding several reports of immune complex GN 
[Nilsson et al. 2011]). The renal phenotype in Cfi-/- mice consists of mesangial C3 
accumulation and nodular mesangial expansion without MPGN [Rose et al. 2008]. 
Remarkably, mice with combined homozygous deficiency of FH and FI (Cfh-/-.Cfi-/-) were 
shown to have an identical plasma C3 profile and renal phenotype to Cfi-/- mice. Injections 
of serum from Cfh-/-.C3-/- mice (as a source of murine FI) into Cfh-/-.Cfi-/- mice resulted in 
cleavage of circulating plasma C3b and the appearance of linear C3 staining, similar to that 
observed in Cfh-/- mice [Rose et al. 2008]. These data showed that cleavage of C3b to iC3b 
by circulating FI was critically required for C3 accumulation along the GBM and consequent 
glomerular inflammation and injury in FH-deficient mice [Rose et al. 2008].  
1.5.2 Experimental aHUS 
Cfh-/- mice with transgenic expression of a murine FH protein comprising SCR domains 1-15 
(Cfh-/-.FHΔ16-20) do not develop DDD [Pickering et al. 2007]. The FHΔ16-20 protein in 
plasma displayed impaired binding to heparin and HUVEC in vitro. In Cfh-/-.FHΔ16-20 mice, 
plasma C3 levels are significantly higher than in Cfh-/- mice, indicating that FHΔ16-20 is able 
to regulate C3 activation via the AP in vivo. As the transgenic mice generally show only mild 
mesangial and endothelial C3 accumulation, it appears that the C-terminal SCR domains 
responsible for FH surface recognition are not required to prevent C3 accumulation along 
the GBM. Also unlike Cfh-/- mice, Cfh-/-.FHΔ16-20 mice frequently develop spontaneous 
renal TMA and mesangiolysis, supporting the role of impaired AP surface regulation (on the 
endothelium) in aHUS pathogenesis. Accompanying deficiency of C5 in Cfh-/-.FHΔ16-20 
mice abrogates renal TMA without altering plasma C3 levels or the glomerular C3 staining 
pattern [Goicoechea de Jorge et al. 2011]. In Cfh-/- mice (on a DBA/2 background), 
accompanying C5 deficiency ameliorated spontaneous MPGN at 1 year and protected 
against experimentally induced acute glomerular inflammation using the heterologous NTN 
model [Pickering et al. 2006]. These studies led to the clinical evaluation of eculizumab in 
patients with aHUS or C3 glomerulopathy.  
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1.6 Studies in CD11b-deficient mice 
CD11b has an identical cellular distribution in mice and humans [Ault & Springer 1981]. At 
baseline, CD18-deficent mice (lacking all four β2-integrins) have increased circulating 
leukocyte and neutrophil counts and increased susceptibility to bacterial infections, similar to 
human LAD-1 [Wilson et al. 1993, Scharffetter-Kochanek et al. 1998, Etzioni et al. 1999]. By 
contrast, mice with homozygous CD11b deficiency (CD11b-/-) display WT levels of 
circulating leukocytes and neutrophils, with no increase in rates of spontaneous infection 
[Coxon et al. 1996, Ding et al. 1999] (except for one study [Lu et al. 1997]). Consistent with 
human data, neutrophils from CD11b-/- mice show adhesion and complement-dependent 
phagocytosis in vitro [Rothlein & Springer 1985, Coxon et al. 1996, Lu et al. 1997]. However 
in vivo studies in CD11b-/- mice have produced conflicting results in a variety of inducible 
disease models including peritonitis, GN and sepsis (Table 3). Reasons for this include: (1) 
the differing anatomic sites and inflammatory stimuli examined; (2) the opposing roles of 
CD11b-expressing immune effector cell types under the different experimental conditions; 
(3) the variable cellular processes mediated via CD11b ligation, culminating in both 
protective and deleterious functions; and (4) redundancy of Mac-1/CR3 and LFA-1 in 
mediating leukocyte adhesion. In one adroit summary, ‘complex biological circuits predict 
dual and sometimes opposing roles for the same receptor that is cell type and context 
dependent’ [Rosetti et al. 2012].  
The first renal studies in CD11b-/- mice showed protection in the heterologous NTN model 
(discussed in Chapter 4). However, recent studies have instead shown increased severity of 
experimentally induced immune complex GN in CD11b-/- mice. These include a lupus 
passive transfer model using mice with selective neutrophil transgenic expression of human 
FcγRIIA (Fcγ+/+.hFcγRIIA or Fcγ-/-.hFcγRIIA) or FcγRIIA and FcγRIIIB                            
(Fcγ-/-.hFcγRIIA/IIIB). Mice were sensitized with subcutaneous (s.c.) human IgG/CFA 
injection followed by immunization via two i.v. injections of serum from patients with SLE. 
This led to increased day 10 glomerular neutrophil influx, day 14 albuminuria and day 21 
mesangial expansion, hypercellularity and crescents (~5% of glomeruli affected) in 
transgenic mice with accompanying CD11b deficiency [Rosetti et al. 2012]. Glomerular 
macrophage influx was minor, and monocyte/macrophage depletion using clodronate prior to 
lupus serum transfer had no effect on susceptibility to renal injury. A pristane-induced model 
of immune-complex-mediated multiorgan injury was associated with increased proteinuria 
and glomerular hypercellularity in CD11b-/- mice [Shi et al. 2013]. Induction of complement-
mediated tubulointerstitial nephritis by transplantation of kidneys from Crry-/-.C3-/- donors 
into C3-sufficient mice was also associated with more severe disease in recipients with 
accompanying CD11b deficiency [Chaves et al. 2014]. 
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Table 3 Disease models in CD11b-/- mice 
Disease/study Induction method Cellular response:  CD11b-/- versus WT Disease outcome: CD11b-/- versus  WT 
Peritonitis/colitis       
[Coxon et al. 1996] i.p. thioglycollate ↑ nφ, Mφ (peritoneum)   
[Lu et al. 1997] i.p. thioglycollate ↔ nφ (peritoneum)   
[Cao et al. 2005] i.p. thioglycollate ↑ Mφ (peritoneum)   
[Abdelbaqi et al. 2006] oral dextran sodium sulfate (DSS) ↓ nφ, Mφ, ↑ plasma cells (colon) n/s ↑ colitis 
Nephritis       
[Tang et al. 1997] i.v. rabbit NTS ↓ early (2-4h) nφ (glomerulus) ↓ 4-8h albuminuria 
[Hirahashi et al. 2009] i.v. rabbit NTS×2 then LPS ↓ 4-24h nφ (glomerulus); ↓ NE ↓ glomerular thrombosis (day 4) 
[Rosetti et al. 2012] s.c. human IgG/CFA then i.v. human lupus 
serum ×2 (Fcγ+/+.hFcγRIIA, Fcγ-/-.hFcγRIIA or              
Fcγ-/-.hFcγRIIA/IIIB mice) 
↑ nφ (glomerulus, synovium) ↑ proteinuria, nephritis, arthritis  
[Ding et al. 2013] i.v. apoptotic thymocytes (anti-snRNP Ig 
transgenic mice) 
↑ anti-snRNP Ig, ANA IgG (plasma); ↑ IgG 
(glomerulus) 
 
[Chaves et al. 2014] renal transplantation from Crry-/-.C3-/- mice ↑ M1 Mφ (kidneys) ↑ tubulointerstitial nephritis 
[Shi et al. 2014] i.p. pristane early (16h) ↑ nφ, later ↓ nφ, M1 Mφ (peritoneum, 
lungs); ↑ eosinophils, M2 Mφ (peritoneum) 
↓ DPH, mortality 
[Shi et al. 2013]   ↑ nφ (glomerulus) ↑ proteinuria, glomerular hypercellularity  
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Disease/study Induction method Cellular response: CD11b-/- versus WT Disease outcome: CD11b-/- 
Sepsis       
[Rosenkranz et al. 1998] caecal ligation/puncture ↓ nφ; ↓ mast cells at baseline (peritoneum) ↑ mortality 
[Prince et al. 2001] i.p. Streptococcus pneumoniae ↑ nφ (peritoneum) ↑ bacteraemia, mortality 
[Rijneveld et al. 2005] intranasal Streptococcus pneumoniae ↑ nφ (pulmonary airspace) ↑ pneumonia, bacteraemia 
[Gao et al. 2005] i.p. Escherichia coli ↓ nφ (pulmonary airspace) ↓ lung vascular injury 
[Morrison et al. 2008] footpad inoculation with Ross River virus transient ↑ Mφ, NK cells, T cells (synovium, muscle) ↓ arthritis/myositis 
[Zhang et al. 2009] i.p. poly I:C ↑ inflammation (liver) ↑ hepatocellular injury, mortality 
[Han et al. 2010] i.p LPS, poly I:C, CpG oligodeoxynucleotides ↑ inflammation (lung); ↑ proinflammatory cytokines (serum) ↑ mortality (versus CD11b+/-) 
 
i.p. Escherichia coli ↑ proinflammatory cytokines (serum) ↑ mortality 
 
i.v. Listeria monocytogenesis ↑ proinflammatory cytokines (serum) ↓ bacteraemia 
[Zhou et al. 2013] i.p. poly I:C ↓ proinflammatory cytokines (serum, liver)  
[Liu et al. 2014] caecal ligation/puncture ↔ nφ (lung) ↑ mortality 
Brain ischaemia-reperfusion injury      
[Soriano et al. 1999] Transient MCA occlusion n/s ↓ nφ (brain) ↓ cerebral infarct volume 
[Arumugam et al. 2004] Transient MCA occlusion ↓ late (24h) nφ (brain) ↓ cerebral infarct volume 
Allergic pulmonary inflammation     
[Kanwar et al. 2001] i.p. ova with alum, then intranasal ova  ↑ eosinophils (pulmonary airways) ↑ bronchial hyperreactivity 
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Disease/study Induction method Cellular response: CD11b-/- versus WT Disease outcome: CD11b-/- versus WT 
Arthritis       
[Ji et al. 2002] i.p. serum transfer from K/B×N mice ↔ leukocytes (synovium)   
[Watts et al. 2005] i.p. serum transfer from K/B×N mice n/s ↑ leukocytes (synovium)   
Experimental allergic encephalomyelitis     
[Bullard et al. 2005] s.c. MOG + CFA ↓ leukocytes in late disease (spinal cord) ↓ active/passive demyelinating disease 
Thrombohaemorrhagic vasculitis     
[Hirahashi et al. 2006] intradermal LPS + TNF n/s ↓ nφ (skin); ↓ NE ↓ thrombosis and (absent) haemorrhage 
Bullous pemphigoid       
[Liu et al. 2006] intradermal rabbit IgG anti-mouse BP180 early (4h) ↑ nφ, later (12-24h) ↓ nφ (skin); late ↓ NE ↓ (absent) skin blisters 
Immune tolerance       
[Ehirchiou et al. 2007] oral low-dose ova, then i.v. ova/CFA ↑ TH-17 cells (draining lymph nodes) ↑ delayed-type hypersensitivity 
[Ling et al. 2014] intranasal HY peptide + LPS in female mice 
then syngeneic male skin graft 
↓ primed T cells (spleen) ↓ skin graft rejection 
Allogeneic transplantation       
[Shimizu et al. 2008] allo-mismatched cardiac transplantation ↓ nφ, Mφ, CD8+ T cells (heart) ↓ allograft rejection 
Tumour angiogenesis       
[Soloviev et al. 2014] s.c. cancer cells or Matrigel + growth factor ↓ nφ, Mφ (tumours, Matrigel implant) ↓ tumour angiogenesis 
LPS lipolysaccharide; MCA middle cerebral artery; MOG myelin oligodendrocyte glycoprotein; Mφ macrophages; NE neutrophil elastase; NK natural killer; nφ neutrophils;                                                 
poly I:C polyinosinic:polycytidylic acid; n/s non-significant; TNF tumour necrosis factor 
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1.7 Aims of my project 
The overarching aim of my doctoral thesis is to examine the role of iC3b in DDD. My specific 
aims are: 
1.7.1  To define the contribution of CD11b to spontaneous renal disease associated 
with FH deficiency. 
I approached this experimentally by examining the spontaneous renal phenotype in Cfh-/- 
mice with accompanying deficiency of CD11b. I present these experiments in Chapter 3. 
1.7.2  To define the contribution of CD11b to experimentally induced renal injury.  
I assessed the response of Cfh-/- mice with accompanying CD11b deficiency to accelerated 
NTN (ANTN). I further assessed the role of CD11b in ANTN independent of FH deficiency. 
These experiments are discussed in Chapter 4. 
1.7.3  To assess the functional domains of FH necessary for prevention or treatment 
of DDD. 
I examined the therapeutic effect of a novel recombinant human ‘mini-FH’ protein comprising 
SCR domains 1-5 and 18-20 in Cfh-/- mice. These experiments, undertaken as part of a 
collaborative project, are detailed in Chapter 5. 
1.7.4  To assess C3 activation on the GBM in the setting of FH deficiency.  
I utilized in vitro assays to assess the ability of GBM components to activate C3 in the 
presence or absence of FH. Comparison was with AP-activating surfaces including zymosan 
and rabbit erythrocytes. These experiments are presented in Chapter 6. 
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2. CHAPTER TWO: MATERIALS AND METHODS 
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2.1 Antibodies 
Antibodies are summarized in Table 4. 
2.2 Experimental mice   
C57BL/6 mice were purchased from Harlan Ltd (Bicester, UK). Cfh-/- mice were generated 
as previously described [Pickering et al. 2002]. Cfh-/-, C3-/- [Wessels et al. 1995] and 
CD11b-/- mice [Coxon et al. 1996] were back-crossed for 10 generations onto a C57BL/6 
background. C3-/-.Cfh-/- and Cfh-/-.Cfi-/- mice were generated by intercrossing the 
respective strains as previously described [Rose et al. 2008]. Cfh-/-.CD11b-/- mice, 
developed by intercrossing the Cfh-/- and CD11b-/- strains, were born at the expected 
Mendelian ratios and were viable and fertile under specific pathogen-free conditions. 
Animals were housed in the animal facility at Imperial College London and all experiments 
were conducted in accordance with institutional guidelines under my supervisor’s UK Home 
Office project licences (PPL 70/6877 and 70/7850) and my personal licence (PIL 70/23892).  
Experiments were performed in age- and weight-matched mice (unless specified otherwise 
in the Results). Prior to each experiment, all mice tested negative for dipstick haematuria (0) 
and proteinuria (≤ 1+) using Hema-Combistix® urine reagent strips (Siemens, Germany, 
Product N° 2877). In some experiments, blood was collected at serial time-points via tail 
venesection onto ethylene diamine tetraacetic acid (EDTA) dipotassium salt Microvette® 
tubes (Sarstedt, Germany, Product N° 16.444), with prompt chilling on ice. At the conclusion 
of each experiment, terminal anaesthesia was induced by intraperitoneal (i.p.) injection of 
300µL of 25% v/v Hypnorm® fentanyl citrate/fluanisone (VetaPharma, UK) and 25% v/v 
Hypnovel® midazolam (Roche, Switzerland) in double-distilled water (ddH2O). Blood was 
collected via cardiac puncture onto EDTA-coated Microvette® tubes (Sarstedt, Product N° 
16.444), with prompt chilling on ice. Plasma separation by centrifugation of whole blood for 
10 minutes at 16,060×g was followed by pooling and storage in 0.6mL microtubes at -80°C. 
All mice were killed by Schedule 1. Kidneys were collected onto phosphate buffered saline 
(PBS) for IF microscopy or fixative for LM (either Bouin’s solution [Sigma-Aldrich, USA, 
Product N° HT101128] or formalin for mice found dead). 
 57 
Table 4 Antibodies 
 
 
Primary conjugated antibodies Conjugate Assay Concentration Manufacturer Product N° 
Goat polyclonal IgG anti-human C3 HRP ELISA/western blot 1 in 10,000/1 in 3,000 Cappel
TM
, USA 0855237 
Goat polyclonal IgG anti-mouse C3  HRP ELISA 1 in 25,0000  Cappel
TM
, USA 0855557 
Sheep polyclonal IgG anti-mouse IgG HRP ELISA 1 in 1000 Jackson ImmunoResearch, USA 515-035-062 
Goat anti-mouse IgG AP ELISA 1 in 3000 Sigma-Aldrich, USA A3438 
Mouse monoclonal IgG1 anti-goat/sheep IgG FITC Immunostaining 1 in 100 Sigma-Aldrich, USA F4891 
Goat polyclonal IgG anti-mouse C3 FITC Immunostaining 1 in 200  Cappel
TM
, USA 0855500 
Rabbit polyclonal anti-human fibrin(ogen)  FITC Immunostaining 1 in 800  Dako, Denmark F0111  
Rat monoclonal IgG2a anti-mouse CD68  Alexa Fluor 488 Immunostaining 1 in 100  BioLegend, USA 137012  
Rat monoclonal IgG2a anti-mouse CD11b Alexa Fluor 488 Immunostaining 1 in 100 BioLegend, USA 101217  
Goat polyclonal IgG anti-human C3 FITC Immunostaining/FACS 1 in 500/1 in 50 Cappel
TM
, USA 0855167  
Goat polyclonal anti-mouse IgG-Fc portion  FITC Immunostaining/FACS 1 in 200/1 in 50 Sigma-Aldrich, USA F5387 
Mouse monoclonal IgG1 anti-human FH (OX24) Biotin Immunostaining 1 in 25 See Methods and Materials  
Goat polyclonal IgG anti-mouse C3d Biotin Immunostaining 1 in 10 R&D Systems, USA BAF2655  
Goat polyclonal anti-PNA Biotin Immunostaining 1 in 400 Vector Labs, USA BA-0074  
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Primary unconjugated antibodies Conjugate Assay Concentration Manufacturer Product N° 
Rabbit polyclonal IgG anti-mouse albumin   Radial 
immunodiffusion 
1 in 150 AbD Serotec, UK 0220-1829 
Rabbit polyclonal IgG anti-fibronectin   ELISA 1 in 1,000 Sigma-Aldrich, USA F3648 
Rabbit polyclonal IgG anti-laminin  ELISA 1 in 1,000 Sigma-Aldrich, USA L9393 
Rabbit polyclonal IgG anti-collagen type IV   ELISA 1 in 4,000 Abcam, UK ab6586  
Goat polyclonal IgG anti-mouse C3  ELISA (capture) 1 in 8,000 Cappel
TM
, USA 0855463 
Goat anti-human C5 antisera  Western blot 1 in 2,500 Quidel, USA A306 
Goat anti-human FH antisera  Western blot 1 in 20,000 Quidel, USA A312 
Rabbit polyclonal anti-human FHR-5   Western blot 1 in 1,000 Abnova, Taiwan H00081494-D01P 
Goat anti-mouse C3 antisera  Western blot 1 in 4,000  Cappel
TM
, USA 0855444 
Goat anti-human FI antisera   Western blot 1 in 20,000 Quidel, USA A313 
              Secondary conjugated antibodies 
Goat polyclonal anti-rabbit IgG  AP ELISA 1 in 30,000 Sigma-Aldrich, USA A3812 
Monoclonal mouse IgG1 anti-goat/sheep IgG  HRP Western blot 1 in 2,000 - 20,000 Sigma-Aldrich, USA A9452 
Polyclonal swine anti-rabbit Ig  HRP Western blot 1 in 2,000 Dako, Denmark P021702-2 
Streptavidin PE Immunostaining 1 in 400 BD Pharmingen
TM
, USA 554061 
Streptavidin Alexa Fluor 555 Immunostaining 1 in 150-200 Invitrogen, USA S-21381 
Avidin  Alexa Fluor 488 Immunostaining 1 in 200-400  Invitrogen, USA A-21370 
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2.3 Urine analysis 
Dipstick haematuria and proteinuria were assessed throughout the experiments using 
Hema-Combistix®. At the end of some experiments, mice were placed into individual 
metabolic cages for 16h collection of urine. Albuminuria was then assessed by radial 
immunodiffusion [Ruseva et al. 2013]. 1.2% agarose deoxyribonucleic acid (DNA) pure 
grade Electran® (VWR, USA, Product N° 443666A) was dissolved in PBS using a microwave 
oven, followed by temperature equilibration at 55°C in a water bath. 150µL rabbit polyclonal 
IgG anti-mouse albumin antibody (AbD Serotec, UK, Product N° 0220-1829) was added per 
10mL of the agarose solution, and gels poured onto 3 inch glass plates and allowed to set 
for 30 minutes at RT. 6µL equidistant wells were punched in the gels using a hollow metal 
tube, with the glass plates as the base. 5µL mouse urine samples were added to the wells, 
with 5µL purified mouse albumin (Sigma-Aldrich, USA, Product N° A3139) added separately 
as a positive control in doubling dilutions starting at 2mg/mL in PBS. The gels/glass plates 
were placed in a wet box overnight at 4°C. After washing three times for 30 minutes in PBS 
using a large reservoir, with separation of the gels from the glass plates, each gel was 
placed onto the hydrophobic side of an equivalent-sized piece of GelBond® film (Cambrex, 
USA, Product N° 53750) for transfer. Wet Whatman® 3mm cellulose chromatography paper 
(Sigma-Aldrich, USA, Product N° 3030917) was placed on top, followed by a stack of paper 
towels, a flat tile, and finally a weight. The transfer apparatus was left for 1h at RT, after 
which the gelbond was removed and dried with a hairdryer until transparent. It was then 
immersed in 0.2% w/v Coomassie Brilliant Blue R250 (Sigma-Aldrich, UK, Product N° 
27815) in buffer (45% v/v methanol, 10% v/v acetic acid in ddH2O) for 30 minutes, followed 
by intermediate destaining buffer for 30 minutes and pure destaining buffer (20% methanol, 
10% acetic acid in ddH2O) for 30 minutes. After drying overnight at RT, the gelbond was 
examined under a measuring eyepiece. The square of the diameter of precipitin circles for 
the albumin standard was plotted against concentration on a logarithmic scale, and a 
sigmoid curve obtained. The albumin concentration of mouse urine samples was calculated 
from this standard curve using linear regression.  
2.4 Assessment of plasma for renal and haematological function 
Plasma urea was measured using an enzymatic ultraviolet method as part of a kit 
(Boehringer Mannheim/R-Biopharm, Germany, Product N° 10542946035). This assay 
measures urea concentration based on the oxidization of nicotinamide adenine dinucleotide 
(NADH) that occurs (in the presence of glutamate dehydrogenase) due to ammonia, which is 
generated by hydrolyzation of urea only in the presence of urease. Mouse plasma samples 
were diluted 1 in 10 in PBS. 1 tablet of NADH was dissolved per 1mL of triethanolamine 
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buffer/2-oxoglutarate, with 100µL/well of this solution added to 96-well flat-bottom Nunc 
Maxisorp® plates (Thermo Scientific, USA, Product N° 442404) together with 200µL/well 
ddH2O and 10µL/well duplicates of the diluted plasma samples. Purified urea 140mg/L 
(5mmol/L) and PBS were used as positive and negative controls, respectively. 2µL of urease 
was then added to one of the duplicate wells for each sample. After mixing, wells were left at 
room temperature (RT) for 5 minutes before absorbance was read at 340nm. 2µL/well of 
glutamate dehydrogenase was then added to all wells. After mixing, wells were left for 20 
minutes at RT before absorbance was read at 340nm. For all mouse plasma specimens, the 
difference between the optical density (OD) before and after the NADH oxidation reaction 
was between 0.1 and 1.0, with plasma urea concentration calculated as specified by the kit 
manufacturer.  
Haematocrit was calculated using EDTA-treated blood in ammonium-heparin capillary tubes 
(Hirschmann®-Laborgeräte, Germany, Product N° 9100418) following centrifugation at 
13,000rpm in a Mikro 20 centrifuge (Hettich, Germany) for 5 minutes. The packed cell height 
is expressed as a percentage of total height. Peripheral blood smears were prepared on 
SuperFrost® glass slides (VWR, USA, Product N° 631-0117) and stained using the Diff Quik 
staining kit (Polysciences, USA, Product N° 24606-500). Red cell fragments were quantified 
as the number per 200 red blood cells counted using a BX40 microscope (Olympus, Japan). 
2.5 Measurement of mouse plasma C3 by sandwich ELISA 
Nunc-Immuno™ MicroWell™ Maxisorp™ 96-well, flat-bottom, polystyrene enzyme-linked 
immunosorbent assay (ELISA) plates (Sigma Aldrich, USA, Product No 442404) were coated 
with 50µL/well of 1 in 8,000 goat polyclonal IgG anti-mouse C3 antibody (CappelTM, USA, 
Product N 0855463; 4mg/mL) in coating buffer (0.1 M NaHCO3 pH 9.5) and left overnight at 
4°C. After washing with 200µL/well of 0.1% v/v TWEEN® 20 Detergent (Calbiochem, 
Germany, Product N° 655204) in PBS (PBST), plates were incubated with 100µL/well of 2% 
w/v bovine serum albumin (BSA, Sigma-Aldrich, USA, Product N° A7030] in 0.1% PBST for 
1h at RT. After washing twice, plates were incubated with 50µL/well of each mouse plasma 
specimen diluted 1 in 12,000 in 2% BSA/0.1% PBST for 1h at RT. For the standard curve 
[Rose et al. 2008], murine serum amyloid P component (Calbiochem, Germany, Product N° 
565193), which contains mouse C3 protein at a concentration of 263mg/mL, was used in 
doubling dilutions commencing at 1 in 500. Control sera from an unmanipulated Cfh-/- 
mouse and a WT mouse were also tested for each assay. After washing five times, plates 
were incubated with 50µL/well of 1 in 25,0000 horseradish peroxidase (HRP)-conjugated 
goat polyclonal IgG anti-mouse C3 antibody (CappelTM, USA, Product N 0855557) in 0.1% 
PBST for 1h at RT. After washing five times, the assay was developed using 50µL/well of 
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tetramethylbenzidine (TMB) substrate reagents and 20µL/well of 2N sulfuric acid, and the 
absorbance read at 450nm. The OD for the standard was plotted against known C3 
concentration on a logarithmic scale, and a sigmoid curve obtained. C3 concentration of 
mouse plasma samples was calibrated against the standard curve using linear regression.  
2.6 Detection of mouse proteins in plasma by western blot 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
using the Mini-PROTEAN® Tetra Cell (Bio-Rad, USA, Product N° 165-8003). For separation 
of mouse C3 under reducing questions, a 1.0mm-thick 10% polyacrylamide resolving gel 
was poured containing 33% v/v ProtoGel® (30% polyacrylamide, National Diagnostics, USA, 
Product N° EC890), 26% v/v ProtoGel® resolving buffer (National Diagnostics, USA, Product 
N° EC892) 0.15% w/v ammonium persulfate (APS) and 0.15% v/v N,N,N′,N′-
tetramethylethylenediamine (TEMED) in ddH2O. For separation of mouse C5 under non-
reducing conditions, a 7.5% polyacrylamide resolving gel was poured using 25% v/v 
ProtoGel® 30% solution and the other reagents. After the resolving gel had set, a 4% 
polyacrylamide stacking gel containing 13% v/v ProtoGel® 30% solution, 25% ProtoGel® 
stacking buffer (National Diagnostics, USA, Product N° EC893), 1% w/v APS and 0.3% v/v 
TEMED in ddH2O was then poured on top and a 10-tooth comb inserted. Once set, the gel 
was placed into electrophoresis buffer (25mM Tris hydroxymethylaminomethane, 192mM 
glycine, 0.1% SDS [Sigma Aldrich, USA, Product N° 05030]) and the comb removed. 
Stored mouse plasma samples were thawed and diluted in NuPAGE® lithium dodecyl sulfate 
(LDS) buffer 4 (Life Technologies, USA, Product N NP007) with (reducing) or without (non-
reducing) 5% v/v 2-mercaptoethanol (MCE, Sigma-Aldrich, USA, Product N° 63689). 
Specimens containing 1μL of plasma were loaded into wells in the stacking gel. As a control 
for C5 western blot, 0.1µg purified human C5 protein (hC5, Quidel, USA, Product N A403) 
was used. ColorPlus™ pre-stained protein ladder with a range of 10-230kDa (New England 
BioLabs, USA, Product N P7711S) was loaded into a separate well for each gel.  
Proteins were separated by SDS-PAGE at 170mV constant voltage supplied by a 
PowerPacTM Basic Power Supply (Bio-Rad, USA, Product N° 164-5050). The gel was then 
separated from the glass plates in a reservoir containing transfer buffer (25mM Tris 
hydroxymethylaminomethane, 192mM glycine, 20% v/v methanol in ddH2O). A transfer 
cassette was then assembled in transfer buffer using the Mini Trans-Blot Module (Bio-Rad, 
USA, Product N° 170-3935). On the cathode side, pieces of Whatman® 3mm cellulose 
chromatography paper (Sigma-Aldrich, 3030917) were loaded first, followed by the gel, 
followed by a similar-sized 0.45µm pore-size polyvinylidene fluoride (PVDF) Immobilon-P 
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membrane (Merck-Millipore, Germany, Product N° IPVH00010) that had been activated for 
15 seconds in methanol, followed by pieces of chromatography paper on the anode side. 
Electrophoretic protein transfer was performed in transfer buffer at 100mV for 1h. 
Following transfer, nonspecific binding was blocked using 20mL of 5% w/v non-fat dry milk 
(NFDM, Marvel, UK) in PBS for 1h at RT. The membrane was then incubated overnight at 
4°C in detecting antibodies diluted in 5% NFDM/PBS as follows: 1 in 4,000 goat anti-mouse 
C3 antisera (CappelTM, USA, Product No 0855444), 1 in 20,000 goat anti-human FI antisera 
(Quidel, USA, Product No A313) or 1 in 2,500 goat anti-human C5 antisera (Quidel, USA, 
Product N A306). After washing three times in 0.1% PBST and reblocking with 5% 
NFDM/PBS for 1h at RT, secondary detection was with 1 in 2,000 (for mouse C3), 1 in 5,000 
(for mouse C5) or 1 in 20,000 (for mouse FI) HRP-conjugated mouse monoclonal IgG1 anti-
sheep/goat IgG (Sigma-Aldrich A9452) in 5% NFDM/PBS for 1h (for mouse C3 and FI) or 30 
minutes (for mouse C5) at RT. After washing three times, the membrane was covered in 
Pierce enhanced chemiluminescence (ECL) western blot substrate A+B (Thermo Scientific, 
Belgium, Product N° 32106) followed by dark room exposure using Amersham Hyperfilm 
ECL films (GE Healthcare, UK, Product N° 28-9068-37).  
2.7 Plasma IgG quantification by ELISA 
For measurement of murine IgG against sheep IgG, 96-well flat-bottom Nunc-Immuno™ 
MicroWell™ plates (Thermo Scientific, USA, Product N° 167008) were coated with 
100µL/well of 3.5µg/mL sheep serum IgG (Sigma-Aldrich I5131) in coating buffer (0.1M 
NaHCO3 pH 9.6) overnight at 4°C. After washing three times with 0.05% PBST, nonspecific 
binding was blocked using 100µL/well 1% BSA/PBS for 1h at 37°C. After washing three 
times, 100µL/well mouse plasma samples were added in doubling dilutions beginning at 1 in 
100 in 1% BSA/PBS, with incubation at 37°C for 1h. As a positive control, pooled sera for 
mice immunized with sheep IgG in CFA was used. After washing three times, captured 
mouse IgG was detected using 100µL/well of 1 in 1000 HRP-conjugated sheep polyclonal 
IgG anti-mouse IgG antibody (Jackson ImmunoResearch, USA, Product N° 515-035-062, 
0.8mg/mL) in 0.05% PBST for 1h at RT. After washing three times, the assay was developed 
using 50µL/well TMB substrate reagents (BD Biosciences 555214) and 25µL/well of 2N 
sulfuric acid (BD Biosciences DY994) at RT and absorbance was read at 450nm and 
540nm. The OD at 540nm was subtracted from that at 450nm for each well, with results 
expressed as the minimal IgG titre (i.e. maximal mouse plasma dilution) at which the 
OD450nm-540nm was at least double that for blocking buffer alone.  
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2.8 Light microscopy 
Mouse kidneys collected onto Bouin’s solution were removed after 3h and transferred to 
70% v/v ethanol in ddH2O for storage. All kidneys in fixative were processed for LM by Ms 
Lorraine Lawrence. Briefly, the kidneys were embedded in paraffin wax, and 3µm sections 
were mounted on glass slides and dried overnight at 37°C. Sections were then stained with 
periodic acid-Schiff (PAS) and covered with glass coverslips. Sections were visualized using 
an Olympus BX40 microscope and photographs taken using a Retiga 2000R digital camera 
(QImaging, Canada) and Image-Pro Plus® 7.0 software (Media Cybernetics, USA). Histology 
was assessed for 50 glomeruli per section in a blinded manner. Glomerular neutrophils were 
counted based on the appearance of typical basophilic, multi-lobed nuclei within capillary 
lumens. PAS-positive (PAS+) material was assigned a score between 0 and 4 for the 
number of glomerular quadrants affected. Crescents were assessed based on characteristic 
morphology of circumferential cellular lesions inside Bowman’s capsule compressing the 
glomerular tuft. MPGN was assessed by glomerular cell counts and by ranking of specimens 
in terms of mesangial expansion from 1 (least prominent) to 21 (most prominent). Original 
magnification is provided for each image. 
2.9 Renal immunostaining for mouse proteins 
Unfixed kidneys were embedded in OCT embedding matrix (CellPath Ltd, UK) and snap 
frozen in isopentane for storage at -80° C. 5µm coronal cryosections were obtained using a 
Bright OTF5000 cryostat (A-M Systems, USA) and mounted on SuperFrost® glass slides 
(VWR, USA, Product N° 631-0910) coated with 0.1% poly-L-lysine (Sigma-Aldrich, USA), 
before fixing in acetone and storage at -80°C. Thawed sections were encircled with a Pap 
pen (The Binding Site, UK, Product N° AD100.1) and the slides then placed into a closed 
chamber to prevent evaporation of applied solutions.  
Immunostaining was performed by pipetting 60μL of each solution onto sections and 
incubating at RT. Detection of glomerular sheep IgG in NTS-injected mice was with 1 in 100 
fluorescein isothiocyanate (FITC)-conjugated mouse monoclonal IgG1 anti-goat/sheep IgG 
antibody (Sigma-Aldrich, USA, Product N° F4891) in PBS for 1h. For detection of mouse C3, 
IgG or fibrin/fibrinogen, sections were blocked using 20% v/v goat serum (Sigma-Aldrich, 
USA, Product N° G9023) in PBS for 30 minutes. After tapping off, detection was with 1 in 
200 FITC-conjugated goat polyclonal IgG anti-mouse C3 antibody (CappelTM, USA, Product 
N° 0855500, 4mg/mL), 1 in 200 FITC-conjugated goat polyclonal anti-mouse IgG-Fc portion 
antibody (Sigma-Aldrich, USA, Product N° F5387) or 1 in 800 FITC-conjugated rabbit 
polyclonal anti-human fibrin(ogen) antibody (Dako, Denmark, Product N° F0111, 1.6mg/mL) 
in PBS for 1h.  
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For detection of mouse C3d, sections were blocked using 2% BSA/PBS for 30 minutes. After 
rinsing, the Biotin Blocking System (Dako, Denmark, Product No X-0590) was applied. C3d 
was detected using 1 in 10 biotinylated goat polyclonal IgG anti-mouse C3d antibody (R&D 
Systems, USA, Product N° BAF2655) in 2% BSA/PBS for 1h, followed by rinsing three 
times. Secondary detection was with 1 in 400 Alexa Fluor® 488-conjugated avidin (Invitrogen 
A-21370) or 1 in 400 phycoerythrin (PE)-conjugated streptavidin (BD PharmingenTM, USA, 
Product N° 554061, 0.5 mg/mL) for 1h. 
Co-staining was performed for peanut (Arachis hypogaea) agglutinin (PNA) and either CD68 
or CD11b. The Biotin Blocking System was applied, followed by blocking in 1 in 10 Carbo-
FreeTM blocking solution (Vector Laboratories, USA, Product No SP-5040) in ddH2O. After 
rinsing, PNA staining was performed using 1 in 400 biotinylated goat polyclonal anti-PNA 
antibody (Vector Laboratories, USA, Product No BA-0074, 1mg/mL) for 30 minutes. This 
antibody binds to glycan moieties with a terminal β-galactose residue at the core-1 branch of 
O-linked glycans. This was followed by rinsing in 0.1% PBST and then PBS. Visualization 
was with 1 in 200 Alexa Fluor® 555-conjugated streptavidin (Invitrogen S-21381) mixed with 
either 1 in 100 Alexa Fluor® 488-conjugated rat monoclonal IgG2a anti-mouse CD68 
antibody (BioLegend, USA, Product N° 137012, 0.5mg/mL) or 1 in 100 Alexa Fluor® 488-
conjugated rat IgG2a anti-mouse CD11b (BioLegend, USA, Product N° 101217, 0.5mg/mL), 
followed by rinsing in 0.1% PBST and then PBS.  
After rinsing three times, all slides were mounted using VECTASHIELD® HardSet™ 
Mounting Medium with 4',6'-diamidino-2-phenylindole (DAPI, Vector Laboratories, USA, 
Product N° H-1500) and glass cover slips (BDH, USA, Product N° 406/0188/52). Sections 
were visualized using a BX40 microscope with a BX-FLA vertical fluorescence illuminator 
(Olympus, Japan). IF photographs were taken using a Retiga 2000R digital camera 
(QImaging, Canada) and Image-Pro Plus® 7.0 software (Media Cybernetics, USA). 
Comparisons between sections used equivalent exposure times. 
Quantitative IF for C3 and C3d was assessed for 10 glomeruli per section using Image-Pro 
Plus® 7.0 software (Media Cybernetics). Mean fluorescence intensity (MFI) is expressed in 
arbitrary fluorescence units (AFU). Representative images were obtained from the median 
section in each experimental group. Glomerular fibrin/fibrinogen positivity was assessed by 
counting fibrin-positive (fibrin+) glomerular quadrants for 50 glomeruli. For CD68-positive 
(CD68+) or CD11b-positive (CD11b+) cells, 20 glomeruli per section were identified on the 
basis of clustered DAPI-positive cell nuclei. Images obtained enabled bright signals for CD68 
or CD11b to be counted as glomerular cells within the PNA-negative glomerular area. 
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2.10 Nephrotoxic nephritis 
Sheep IgG against mouse GBM (NTS) was prepared as previously described [Pickering et 
al. 2002]. In accelerated NTN (ANTN), mice received i.p. injection of 200µL water-in-oil 
emulsion containing 200µg sheep serum IgG (Sigma-Aldrich, USA, Product N° I5131) and 
sterile Dulbecco’s PBS in 100µL vortexed CFA [Pickering et al. 2002]. The emulsion was 
prepared by vigorous mixing in a glass bottle using a glass syringe and fine-bore (21 gauge) 
needle, until a sample drop did not dissipate in cold water [Stills & Bailey 1991]. Five days 
later, mice received i.v. tail vein injection of 200µL 10% v/v NTS in sterile Dulbecco’s PBS. In 
heterologous NTN, mice received an identical i.v. NTS dose to that used for ANTN but 
without prior antigen sensitization using IgG/CFA. 
2.11 Subcutaneous base-of-tail immunization 
Mice received s.c. base-of-tail injection of 100µL emulsion containing 50µg 4-hydroxy-3-
nitrophenylacetyl (NP4)-haptenated chicken gammaglobulin (CGG, Biosearch Technologies, 
USA, Product N° N-5055A-5) and sterile Dulbecco’s PBS in 50µL CFA. 
2.12 Measurement of murine IgG response to hapten by sandwich ELISA 
96-well flat-bottom Nunc Maxisorp® plates (Thermo Scientific, USA, Product N° 442404) 
were coated with 50µL/well of 5µg/mL 4-hydroxy-3-nitrophenyl (NP)16-conjugated BSA 
(Biosearch Technologies, USA, Product N° N-5050M-10) in coating buffer (100mM boric 
acid [H3BO3], 25mM sodium tetraborate, 75mM NaCl; pH 8.3) for 3h at 37°C. After washing 
three times with PBS, plates were blocked in 100µL/well blocking buffer (PBS 0.5% BSA, 
0.02% w/v sodium azide [NaN3]) for 1h at RT. After discarding the blocking buffer, 50µL/well 
duplicate 1 in 500 mouse plasma samples in sample buffer (PBS 2% BSA, 0.02% NaN3, 
0.05% TWEEN® 20) were added, with incubation overnight at 4°C. Single samples were also 
added to an uncoated well as a control for nonspecific binding. As a standard, duplicate 
pooled mouse plasma samples from primary NP4-CGG-immunized WT mice were added in 
doubling dilutions beginning at 1 in 100 in sample buffer. After washing five times, captured 
mouse IgG was detected using 50µL/well of 1 in 3000 alkaline phosphatase (ALP)-
conjugated goat anti-mouse IgG antibody (Sigma-Aldrich, USA, Product N° A3438) in 
sample buffer for 5h at 4°C. After washing five times, the assay was developed using 
50µL/well of ALP substrate reagents (SigmaFAST p-nitrophenyl phosphate tablet set, 
Sigma-Aldrich, USA, Product N° N-2770) at RT and the absorbance read at 405nm. The OD 
for uncoated wells was subtracted from the OD for coated wells for each sample. The OD for 
the standard was plotted against percentage concentration on a logarithmic scale, and a 
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sigmoid curve obtained. The IgG titre of mouse plasma samples was calibrated against the 
standard curve using linear regression, and is expressed in arbitrary units. 
2.13 Administration of human FH reagents in mice  
Cfh-/- mice were injected i.p. with recombinant human FH reagents or full-length human 
plasma-derived FH (hFH) in PBS, or PBS alone. hFH was either purified from human plasma 
by Dr Kevin Marchbank at Newcastle University, Institute of Cellular Medicine, Newcastle 
upon Tyne, or acquired commercially from Complement Technology, USA (Product N° 
A337). The reagents used, and doses and volumes injected, are presented in Chapter 5, 
Table 10. Recombinant human mini-FH and FH1-5 were produced by Dr Kevin Marchbank 
and Dr Eva-Maria Nichols at Newcastle University. Briefly, the FH1-5 expression vector was 
generated by PCR amplification of SCR domains 1-5 from a pBluescript vector containing 
the FH cDNA. Primers were designed to introduce a SalI restriction site at the 3’ end and a 
hexa histidine tag, stop codon and NheI restriction site at the 5’ end. For mini-FH, SCR 
domains 1-5 were amplified with primers introducing SalI/KpnI restriction sites at 3’/5’ ends 
and SCR domains 18-20 were amplified with primers introducing a KpnI restriction site and 
hexa histidine tag at the 3’ end and stop codon and NheI restriction site at the 5’ end. Both 
constructs were cloned into the pDR2EF1α mammalian expression vector using the 
SalI/NheI restriction sites and transfected into Chinese Hamster Ovary (CHO) cells. The 
proteins were purified using nickel-affinity chromatography. Mini-FH was polished by affinity 
chromatography using OX24 antibody. Mini-FH and FH1-5 were functionally validated by a 
number of in vitro tests carried out at Newcastle University. 
In a separate experiment, 12 week-old Cfh-/-.C3-/- mice were exsanguinated via cardiac 
puncture under terminal anaesthesia. Blood was collected into TubeOne® 1.5mL 
microcentrifuge tubes (Starlab, Germany, Product N° S1615-5500) and allowed to clot for 10 
minutes at RT and on ice for a further 1h. Pooled serum was separated by centrifugation and 
stored at -80°C. Cfh-/-.Cfi-/- mice were injected i.p. with hFH (Comp Tech, A137) or via tail 
vein injection with 400μL of pooled Cfh-/-.C3-/- serum or PBS. Tail vein injections were 
performed by my supervisor and by Dr Marieta Ruseva. 
2.14 Detection of injected human FH reagents by western blot 
SDS-PAGE was performed using 1µL mouse plasma in a 10% gel under reducing 
conditions. Detection of injected FH reagents was with 1 in 20,000 goat anti-human FH 
antisera (Quidel, USA, Product N A312) in 5% NFDM/PBS overnight at 4°C. After washing 
three times in 0.1% PBST and reblocking with 5% NFDM/PBS for 1h at RT, secondary 
detection was with 1 in 20,000 HRP-conjugated mouse monoclonal IgG1 anti-sheep/goat IgG 
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(Sigma-Aldrich A9452) in 5% NFDM/PBS for 1h at RT. Blots were developed as described 
above. 
2.15 Renal immunostaining for injected human FH reagents 
Mouse monoclonal IgG1 anti-human antibody (OX24, 1mg/mL) was prepared from 
hybridoma tissue culture and biotinylated by Dr Kevin Marchbank. Use of the Biotin Blocking 
System was followed by application of 1 in 25 biotinylated OX24 in PBS for 1h at RT. After 
rinsing, visualization was with 1 in 400 PE-conjugated streptavidin (BD PharmingenTM 
554061), 1 in 150 Alexa Fluor® 555-conjugated streptavidin (Invitrogen, USA, Product N° S-
21381) or 1 in 200 Alexa Fluor® 488-conjugated avidin (Invitrogen, USA, Product N° A-
21370) in PBS for 1h at RT. Representative images were obtained from the median section 
in each experimental group. 
2.16 Human sera and purified proteins 
NHS was pooled from healthy donors following cubital fossa venesection into BD 
Vacutainer® glass serum tubes (BD, USA, Product N 366430) with clotting for 45 minutes at 
RT and for 1h on ice [Lachmann 2010]. Serum was separated from whole blood by 
centrifugation at 16,060×g for 10 minutes at 4°C. The supernatant was carefully removed 
and stored as single-use aliquots in Axygen® 0.6mL microtubes (Corning, USA, Product N 
MCT-060-C) at -80°C. Human depleted sera and purified proteins were purchased from 
Complement Technology, USA (Table 5). The sera are depleted of FH, FI, C3 or C5 by 
immunoaffinity chromatography and stored in 0.1mM EDTA. On arrival (on dry ice), sera 
were thawed by hand and promptly transferred onto ice to minimise spontaneous 
complement activation. They were then pipetted into microtubes on ice for storage as single-
use aliquots at -80°C. For each assay, human sera were thawed by hand and kept on ice for 
short period prior to use. Human purified proteins were also stored at -80°C. 
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Table 5 Human complement-depleted sera and purified complement proteins 
Human reagent Manufacturer Product N° 
Factor H-depleted human serum (FH
dpl
HS) Complement Technology, USA A337 
Factor I-depleted human serum (FI
dpl
HS) Complement Technology, USA A338 
C3-depleted human serum (C3
dpl
HS)  Complement Technology, USA A314 
C5-depleted human serum (C5
dpl
HS)  Complement Technology, USA A320 
Human purified C3 protein (hC3)  Complement Technology, USA A113 
Human purified factor H protein (hFH)  Complement Technology, USA A137 
 
 
 
2.17 Water bath incubation of human sera/proteins 
Human sera (NHS or FHdplHS) were prepared in microtubes on ice at a 50% v/v 
concentration in incubation buffer (PBS with a final concentration of 10mM EGTA and 5mM 
MgCl2; pH 7.4) [Des Prez et al. 1975]. FH
dplHS was also prepared to which hC3 was added 
at 1.0mg/ml serum (FHdplHS+hC31.0mg/mL), or hFH protein at 0.05mg/mL serum 
(FHdplHS+hFH0.05mg/mL). Identical amounts of hC3 or hFH were also prepared in buffer without 
serum. Microtubes containing 10µL of each serum/protein preparation were then placed into 
a shaking water bath (Medline, UK, Product N° BS-06) at 37°C. An additional 4µL aliquot of 
each preparation was diluted for western blot in microtubes containing LDS buffer with MCE. 
At 10 minutes and 60 minutes, 4µL aliquots of each of the incubated specimens was also set 
aside for western blot in MCE-containing LDS buffer. western blot samples were heat-
inactivated at 99°C for 3 minutes in a Thriller thermoshaker incubator (Peqlab, Germany, 
Product N° 91-7010) before storage at -80°C.  
A standardized protocol for water bath incubation was subsequently developed using 
triplicate 5.4µL specimens of 50% human sera in incubation buffer with or without 10mM 
EDTA (final concentration) [North & Whaley 2005]. FHdplHS was also prepared in incubation 
buffer containing hFH 0.5mg/mL serum (FHdplHS+hFH0.5mg/mL). After two samples had been 
placed into the water bath, which was then diluted in LDS buffer to which 10mM EDTA had 
been added with or without MCE. One of the incubating samples was removed and set aside 
for western blot at 10 minutes and the other at 60 minutes. 
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2.18 Measurement of C3 activation in human sera using ELISA  
Collagen type IV from human placenta (Sigma-Aldrich, USA, Product N° C7521), laminin 
from human placental liquid (Sigma-Aldrich, USA, Product N° L6274), fibronectin from 
human plasma (BD, USA, Product N° 354008) and zymosan from Saccharomyces 
cerevisiae (Sigma-Aldrich, USA, Product N° Z4250) were stored in sterile Dulbecco’s PBS 
(Sigma-Aldrich, USA, Product N° D8537) at -80°C. 96-well flat-bottom polystyrene microtitre 
plates (Greiner Bio-One, Germany, Product No 655001) were coated with 50µL/well of the 
purified proteins in doubling dilutions beginning at 25µg/mL in coating buffer (0.1M NaHCO3 
pH 9.5), or coating buffer alone. Plates were kept overnight at 4°C. The coating solution was 
then discarded, and plates were washed three times in 0.1% PBST. Nonspecific binding was 
blocked using 100µL/well of blocking buffer (2% BSA/0.1% PBST) for 3h at RT. Blocking 
buffer was discarded and the plates washed three times in PBS.  
Human sera/protein were prepared at a 5% v/v concentration in incubation buffer (PBS; 
10mM EGTA; 5mM MgCl2; pH 7.4) with or without 10mM EDTA. 50µL of duplicate (NHS) or 
triplicate (FHdplHS, FHdplHS+hFH0.5mg/mL or FIdplHS) sera/protein preparations was added to 
wells. Single samples of human sera/proteins in incubation buffer containing 10mM EDTA, 
and of incubation buffer without serum, were also added to wells. Plates were placed in an 
incubator (Gallenkamp, UK) at 37°C, after which additional samples of each serum/protein 
preparation were added to EDTA-containing LDS buffer with MCE for storage at -80°C. After 
incubation for 45 minutes, plates were removed from the incubator and washed three times 
with 0.1% PBST with or without 1M NaCl. Captured human C3 was detected using 50 
µL/well of 1 in 10,000 HRP-conjugated goat polyclonal IgG anti-human C3 antibody 
(CappelTM, USA, Product No 0855237) in blocking buffer for 1h at RT. After washing three 
times with 0.1% PBST, plates were incubated in 50µL/well of TMB substrate reagents (BD, 
USA, Product No 555214), after which the reaction was stopped using 20µL/well of 2N 
sulfuric acid (BD, USA, Product No DY994). The absorbance was read at 450nm using a 
Multiskan Ascent® spectrophotometer (Thermo Scientific, USA) and Ascent Software version 
2.6. Results are expressed as the mean OD. 
Separately, plates were coated overnight with collagen type IV, laminin and fibronectin as 
described above before washing three times. The respective GBM components were 
detected using 50 µL/well of 1 in 1,000 rabbit polyclonal IgG anti-fibronectin antibody 
(Sigma-Aldrich, USA, Product N° F3648, 0.6mg/mL) or anti-laminin antibody (Sigma-Aldrich, 
USA, Product N° L9393, 0.7mg/mL) or 1 in 4,000 rabbit polyclonal IgG anti-collagen type IV 
antibody (Abcam, UK, Product N° ab6586, 1.0mg/mL) in PBS for 1h at RT. After washing        
. 
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plates three times, secondary detection was with 50 µL/well of 1 in 30,000 ALP-conjugated 
goat polyclonal anti-rabbit IgG antibody (Sigma-Aldrich, USA, Product N° A3812) in PBS for 
1h at RT. After washing three times, the assay was developed using 50µL/well of ALP 
substrate reagents (SigmaFAST p-nitrophenyl phosphate tablet set, Sigma-Aldrich, USA, 
Product N° N-2770) at RT, and absorbance was read at 405nm. 
2.19 Measurement of rabbit haemolysis in human sera 
1mL of rabbit blood in Alsever’s solution (TCS Biosciences, UK, Product No RB053, 25mL) 
stored at 4°C was gently pipetted into 10mL of lysis buffer (5mM Na barbitone, 150mM 
NaCl, 10mM EGTA, 7mM MgCl2, 0.01% v/v gelatin from porcine skin [Sigma-Aldrich, USA, 
Product N° G-2500] in ddH2O; pH7.4) in a Sterilin™ tube (Thermo Scientific, USA, Product 
N° Z10PS). Mixing by slow inversion of the tube was followed by centrifugation at 760×g for 
4 minutes at 4°C. The supernatant was then discarded and the sediment gently 
resuspended in 10mL of lysis buffer. Centrifugation and resuspension steps were repeated 
several times until the supernatant was clear [Ruseva & Heurich 2014]. 2% v/v ER sediment 
was then gently resuspended in lysis buffer, with 20µL/well of the ER suspension, or lysis 
buffer alone, added to 96-well round-bottom Nunc™ MicroWell™ polystyrene microtitre 
plates (Thermo Scientific, USA, Product N° 163320). NHS, FHdplHS, FIdplHS, 
FHdplHS+hFH0.5mg/mL, C3dplHS and C5dplHS underwent doubling dilutions in lysis buffer with or 
without 10mM EDTA on ice. C3dplHS was also prepared in lysis buffer to which hC3 was 
added in doubling dilutions beginning at 1.0mg/mL serum. FHdplHS was also prepared in 
lysis buffer, to which hFH was added in doubling dilutions beginning at 0.5mg/mL serum.  
50µL triplicate samples were added to wells containing ER beginning at a final 50% serum 
concentration, and a fourth sample added to wells containing lysis buffer alone. Four 
samples of water (positive control) or lysis buffer were also added to wells, and the plates 
were placed in an incubator at 37°C. A fifth sample of each serum/protein preparation was 
then added to EDTA-containing LDS buffer with MCE for storage at -80°C for western blot. 
After incubation for 1h, plates were centrifuged at 760×g for 4 minutes at 4°C. 50µL/well of 
the supernatant was transferred to 96-well flat-bottom Nunc™ MicroWell™ microtitre plates 
(Thermo Scientific, USA, Product N°, 167008) and spectrophotometry performed at an 
absorbance of 414nm for detection of haem. Samples of supernatant were then set aside for 
western blot. 
For some assays, supernatant left over after incubation in non-lytic sera was discarded, and 
the ER pellet was gently resuspended on the plate in 50µL of lysis buffer followed by 
recentrifugation. These steps were repeated once. Fresh FHdplHS, NHS or C3dplHS                  
. 
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underwent doubling dilutions beginning at 20% v/v in lysis buffer, with triplicate 50µL/well 
serum samples used to resuspend the ER pellets, and a fourth sample added to an empty 
well. Plates were reincubated for 1h at 37C, before centrifugation and spectrophotometry as 
above. For all assays, the OD for sera/protein preparations incubated in wells not containing 
ER was subtracted from the mean OD of the respective preparations in ER-containing wells. 
The value obtained for each preparation was divided by that for the positive control (water), 
with the results expressed as mean percent haemolysis due to H2O. 
2.20 FACS of rabbit erythrocytes following incubation in human sera 
Following a single incubation of ER suspension in non-lytic sera, the ER pellet obtained by 
centrifugation was gently resuspended in 200µL/well of wash buffer (1% BSA in PBS) to 
which 10mM EDTA had been added, followed by centrifugation and removal of the 
supernatant. This was repeated twice using wash buffer, after which the ER pellet was 
resuspended in 40µL/well of wash buffer, and 20µL transferred to each of two wells on 
round-bottom Nunc™ MicroWell™ plates. 20µL of 1 in 50 FITC-conjugated goat polyclonal 
IgG anti-human C3 antibody (CappelTM, USA, Product N 0855167) in wash buffer was then 
added to one of the resuspended ER pellets, and 1 in 50 FITC-conjugated goat polyclonal 
IgG anti-mouse IgG-Fc (Sigma-Aldrich, USA, Product N F5387) added to the other. The 
plate was placed on ice for 1h and then centrifuged. After washing three times with 
200µL/well of wash buffer, the ER pellets were resuspended in 330µL of wash buffer and 
transferred to 1.2mL glass microtubes (Alpha Laboratories, UK, QS845) for fluorescence-
activated cell sorting (FACS) analysis using a BD FACSVerse™ flow cytometer (BD 
Biosciences, USA) and FlowJo software version 7.6.5 (FlowJo, USA). C3 staining of ER 
gated according to erythrocyte size and granulosity. Results are expressed in the text as MFI 
and on the histogram as Mean, Comp-FITC-A::FITC-A. Positive C3 staining for a small 
number of ER incubated in C5dplHS exceeded the measurement scale, and was excluded 
from the plot. 
2.21 Detection of human proteins by western blot 
SDS-PAGE was performed using a 10% polyacrylamide gel for separation of human C3 
under reducing questions, and FH and FHR-5 under non-reducing conditions, and a 7.5% 
gel for separation of human C5 under non-reducing conditions. For the standardized assays, 
0.28µL serum samples were used for detection of C3 and C5 detection. For the earlier (non-
standardized) water bath incubation assays 0.5µL serum samples were used for C3 
detection. Freshly prepared 1µL NHS, FHdplHS and FHdplHS+hFH0.5mg/mL samples were used 
.  
 72 
for FH and FHR-5 detection (additionally, 0.1µL samples for FH detection). As controls, 
0.28µg hC3, 0.03µg hFH and 0.01µg hC5 (Quidel, A403) were used. Following transfer, 
membrane blocking was performed using 5% NFDM/PBS for 1h at RT. Membranes were 
then incubated for 1h at RT in detecting antibody diluted in 5% NFDM as follows: 1 in 3,000 
HRP-conjugated goat polyclonal IgG anti-human C3 antibody (CappelTM 0855237); 1 in 
2,500 goat anti-human C5 antisera (Quidel, A306) followed by washing three times with 
0.1% PBST, reblocking in 5% NFDM/PBS for 1h at RT, and secondary detection with 1 in 
5,000 HRP-conjugated mouse monoclonal IgG1 anti-goat/sheep IgG antibody (Sigma-
Aldrich, USA, Product N° A9452) for 30 minutes at RT; 1 in 20,000 goat anti-human FH 
antisera (Quidel, A312), followed by washing three times and secondary detection with 1 in 
20,000 HRP-conjugated mouse monoclonal IgG1 anti-goat/sheep IgG antibody (Sigma-
Aldrich A9452) for 30 minutes at RT; or 1 in 1,000 rabbit polyclonal anti-human FHR-5 
antibody (Abnova, Taiwan, Product N° H00081494-D01P, 1.08mg/mL), followed by washing 
three times and secondary detection with 1 in 2,000 HRP-conjugated swine polyclonal anti-
rabbit Ig antibody (Dako, Denmark, Product N° P021702-2, 1.3mg/mL) for 45 minutes at RT. 
Western blots were developed as above. 
2.22 Renal immunostaining following incubation with human sera 
Kidneys for incubation in human sera/protein were obtained from C3-/- mice with or without 
i.v. tail vein injection of 200µL 10% v/v sheep NTS in sterile Dulbecco’s PBS (Sigma-Aldrich 
D8537) 4h prior to sacrifice. For incubation in human sera/protein, sections were first 
blocked with 2% BSA for 30 minutes at RT. NHS, FHdplHS, FHdplHS and FHdplHS+hFH0.5mg/mL 
were prepared on ice at dilutions ranging from 1 in 10 to 1 in 80 in incubation buffer (PBS 
10mM EGTA 5mM MgCl2 pH 7.4) with or without 10mM EDTA. 5.4µL samples of 50% 
FHdplHS in incubation buffer underwent prior water bath incubation for 1h at 37°C before 
dilution in incubation buffer. hC3 was prepared in incubation buffer without serum at a 
concentration equivalent to 1.0mg/mL serum. The blocking solution was tapped off from the 
slides, and 60μL/section of each serum/protein preparation was applied to the sections. The 
closed chamber was placed into an incubator at 37°C. Additional samples were then added 
to EDTA-containing LDS buffer with MCE for storage at -80°C for western blot. After 1h, the 
slides were removed from the chamber and rinsed three times in PBS in a glass 200mL 
reservoir. Human C3 was detected using 1 in 500 FITC-conjugated goat polyclonal IgG anti-
human C3 antibody (CappelTM, USA, Product N 0855167) in PBS for 1h at RT. 
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2.23 Statistics 
Data were analysed and p values calculated using GraphPad Prism® 6.00 for Windows 
(GraphPad Software, San Diego California USA, www.graphpad.com). For comparison of 
two groups, Mann Whitney test (Chapters 3 and 4) or Student’s t-test (Chapter 5) were used. 
For comparison of three or more groups, Kruskal-Wallis test and Dunn’s multiple 
comparisons test for all comparisons (Chapters 3 and 4) or one-way ANOVA and 
Bonferroni’s multiple comparisons test for all comparisons (Chapter 5) were used, unless 
specified otherwise. Correlation coefficients (r) were determined using the Spearman test 
(Chapters 3 and 4) or Pearson test (Chapter 5). Survival curves were analysed using the log 
rank test. A p value of <0.05 is reported as significant.  
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3. CHAPTER THREE: ROLE OF CD11B IN THE 
SPONTANEOUS PHENOTYPE OF 
FACTOR H-DEFICIENT MICE 
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3.1 Introduction 
In this chapter, I assessed the role of iC3b in dense deposit disease from the standpoint of 
CD11b, its specific leukocyte receptor. I utilized the uniquely informative FH-deficient mouse 
model of experimental C3 glomerulopathy, in which spontaneous renal disease occurs due 
to accumulation of iC3b (± C3d) along the GBM [Pickering et al. 2002, Rose et al. 2008, 
Paixão-Cavalcante et al. 2009]. My hypothesis was that deficiency of CD11b would 
ameliorate experimental renal disease in FH-deficient mice (hypothesis 1) through 
abrogation of the iC3b-CD11b interaction. In order to test this, I evaluated the spontaneous 
renal phenotype in mice with homozygous deficiency of FH and/or CD11b. I monitored a 
cohort of ten female mice with combined homozygous deficiency of FH and CD11b          
(Cfh-/-.CD11b-/-). In addition, I monitored five female Cfh-/- mice and six female CD11b-/- 
mice, with comparison of the spontaneous renal phenotype in all three groups at 8 months. 
A similar timeframe has previously been sufficient for the development of MPGN and 
albuminuria in Cfh-/- mice [Pickering et al. 2002, Ruseva et al. 2013].  
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3.2 CD11b deficiency enhances albuminuria in 8-month old FH-deficient mice  
Weights were well-matched between groups when first measured at four months of age 
(Table 6). One Cfh-/-.CD11b-/- mouse developed 2+ dipstick haematuria and distress, 
necessitating humane sacrifice at 6 months. All other mice remained well and were 
haematuria-free until termination of the experiment, with survival at eight months being no 
different between groups (p = 0.5769).  
Prior to sacrifice at 8 months of age, mice were placed into individual metabolic cages and 
urine collected for 16h overnight. 16h urinary albumin excretion was increased in              
Cfh-/-.CD11b-/- mice compared to Cfh-/- mice (median urinary albumin excretion              
Cfh-/-.CD11b-/- 173.2µg/16h versus Cfh-/- 74.8µg/16h; p = 0.0475, Fig. 6a) but not CD11b-/- 
mice (100.9µg/16h; p versus Cfh-/-.CD11b-/- = 0.6828). The urine albumin concentration 
was increased in Cfh-/-.CD11b-/- mice compared to CD11b-/- mice (median urinary albumin 
concentration Cfh-/-.CD11b-/- 164.7µg/mL versus CD11b-/- 75.6µg/mL; p = 0.0387, Fig. 6b) 
but not Cfh-/- mice (118.6µg/mL; p versus Cfh-/-.CD11b-/- = 0.3745). Urine volume in Cfh-/- 
mice was significantly reduced compared to CD11b-/- mice (median Cfh-/- 0.5mL/16h versus 
CD11b-/- 1.4mL/16h, p = 0.0189, Fig. 6c) but not Cfh-/-.CD11b-/- mice (median 1.2mL/16h; 
p versus Cfh-/- = 0.2982). The median value for proteinuria in CD11b-/- of 100.9µg/16h 
clearly exceeded that in previous studies of WT mice (albumin excretion of 0µg/24h), 
although the range of values in those larger cohorts was similar [Pickering et al. 2002, 
Ruseva et al. 2013].  
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Table 6 Spontaneous renal phenotype in 8-month old mice 
  Cfh-/-.CD11b-/- Cfh-/- CD11b-/- 
N° of mice assessed/sex 10/F 5/F 6/F 
Weight at 4 months (g) 22.3 (20.3-24.8) 24.0 (21.8-25.3) 23.9 (22.9-2.8.8) 
Survival to 8 months  90% 100% 100% 
Urine analysis 
Haematuria (N
o 
of mice) 
      
1/10 0/5 0/6 
Albumin excretion (µg/16hr) 173.2* [72.5-987.2] 74.8 [33.8-141.2] 100.9 [76.2-176.8] 
Albumin concentration (µg/mL) 164.7
†
 [70.5-1606.2] 118.1 [78.7-207.7] 75.6 [59.1-106.8] 
Urine volume (mL/16h) 1.2 [0.5-1.6] 0.5
†
 [0.4-1.2] 1.4 [1.1-1.9] 
Plasma biochemistry  
Urea (mmol/L) 
 
13.3
††
 [9.7-44.5] 11.5 [7.3-15.1] 4.4 [2.8-8.2] 
C3 (µg/mL) 14.3
††
 [1.1-43.5] 10.0
†
 [5.8-18.9] 268.1 [230.0-341.5] 
Glomerular Histology 
Mean cells (N
o
) 
  
53.4*
††
 [40.8-75.9] 
  
36.6 [35.0-44.4] 
  
35.5 [33.6-38.2] 
Mesangial expansion (rank) 15 [1-21] 11 [8-15] 8 [2-17] 
Crescents (N° of mice) 1/10 0/5 0/6 
Mean PAS+ quadrants (N
o
) 0.1 [0.0-0.2] 0.0 [0.0-0.1] 0.1 [0.0-0.1] 
Mean neutrophils (N
o
) 0.3* [0.1-1.9] 0.0 [0.0-0.1] 0.1 [0.0-0.1] 
Glomerular IF 
Mean CD68+ cells (N°) 4.3 [0.9-9.9] 1.90 [1.2-3.1] 2.0 [0.2-3.4] 
Mean C3 (AFU) 120.1
†
 [69.5-129.5] 131.1
††
 [102.7-134.6] 34.3 [27.8-59.6] 
Mean C3d (AFU) 37.0 [21.8-46.6] 41.4 [37.3-50.9] n/a 
Mean IgG (AFU) 36.9 (13.2-51.1] 37.2 (15.5-66.5] 43.4 (28.8-67.5] 
Data expressed as median [range]. n/a not assessed.  
*p < 0.05, **p < 0.01 versus Cfh-/- †p < 0.05, ††p < 0.01 versus CD11b-/-  
Analysis by Kruskal-Wallis and Dunn’s tests except survival (log-rank test) and linear C3d (Mann-Whitney) 
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Figure 6 Albuminuria in 8-month old mice 
(a) Urinary albumin excretion in female Cfh-/-.CD11b-/- (n=8), Cfh-/- (n=5) and CD11b-/- (n=6) mice 
was calculated in μg/16h on the basis of (b) albumin concentration in μg/mL and (c) urine volume in 
mL/16h. The sick Cfh-/-.CD11b-/- mouse sacrificed at 6 months is shaded green. Horizontal bars 
denote median values. *p < 0.05 (Kruskal-Wallis/Dunn’s). 
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3.3 CD11b deficiency does not influence plasma urea levels in 8-month old FH-
deficient mice  
Renal failure is not usually observed in 8 month-old Cfh-/- mice. Here an enzymatic 
ultraviolet assay was used to assess plasma urea levels, and showed no difference between 
Cfh-/-.CD11b-/- and Cfh-/- mice (median plasma urea Cfh-/-.CD11b-/- 13.3mmol/L versus 
Cfh-/- 11.5mmol/L; p = 0.0912, Fig. 7). The sick Cfh-/-.CD11b-/- mouse alone had a 
markedly increased plasma urea level. As a result, plasma urea levels were increased only 
for the Cfh-/-.CD11b-/- group in comparison to CD11b-/- mice (4.4mmol/L; p versus          
Cfh-/-.CD11b-/- = 0.0012). This compares with a normal urea of 4.3-10mmol/L in mice based 
on a previous study [Wolfensohn & Lloyd 1998].  
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Figure 7 Plasma urea levels in 8-month old mice 
Plasma urea levels are shown at 8 months in mmol/L. The sick mouse is shaded green. Horizontal 
bars denote median values. **p < 0.01 (Kruskal-Wallis/Dunn’s).  
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3.4 CD11b deficiency does not influence plasma C3 or C5 in FH-deficient mice 
Uncontrolled C3 activation via the AP in Cfh-/- mice is associated with low plasma C3 and 
C5 levels. Plasma C3 levels were evaluated by an ELISA using a polyclonal anti-mouse C3 
antibody, and showed no difference between Cfh-/-.CD11b-/- and Cfh-/- mice (median 
plasma C3 Cfh-/-.CD11b-/- 14.3mg/L versus Cfh-/- 10.0µg/mL, p > 0.9999, Fig. 8a). C3 
levels were markedly lower in either group compared to CD11b-/- mice (median plasma C3 
CD11b-/- 268.1mg/L; p versus Cfh-/-.CD11b-/- = 0.0039; p versus Cfh-/- = 0.0112).  
The C3 activation state was assessed by western blot of plasma from three mice in each 
group using anti-mouse C3 antisera. In Cfh-/-.CD11b-/- mice, the α-chain of intact C3 and α’-
chain of C3b were not detected, with only α’-chain fragments (and the β-chain) evident (Fig. 
8b). An identical appearance was seen in three Cfh-/- mice. These findings are consistent 
with excessive C3 activation in both groups of FH-deficient mice. In three CD11b-/- mice, 
presence of the α-chain of intact C3 and absence of α’-chain fragments closely resembles 
the C3 profile in WT mice [Rose et al. 2008, Paixão-Cavalcante et al. 2009].  
C5 western blot using cross-reactive anti-human C5 antisera has been used to assess 
differences in the C5 activation state in FH-deficient mice [Ruseva et al. 2013]. This showed 
an identical band for intact C5 to that of human recombinant C5 (MW 190kDa) in CD11b-/- 
mice but not Cfh-/-.CD11b-/- or Cfh-/- mice (Fig. 8c). These data are consistent with 
equivalent depletion of C5 in both these groups of FH-deficient mice. A second band present 
at ~75kDa in CD11b-/- mice only is likely to represent the β-chain of murine C5. This is 
absent from the corresponding blot using secondary antibody alone (Fig. 8d). 
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Figure 8 Plasma C3 levels and activation state in 8-month old mice   
(a) C3 in μg/mL was measured in plasma from Cfh-/-.CD11b-/-, Cfh-/- and CD11b-/- mice by ELISA. 
The sick mouse is shaded green. Horizontal bars denote median values. *p < 0.05, **p < 0.01 
(Kruskal-Wallis/Dunn’s). (b) C3 western blot under reducing conditions. (c) C5 western blot under 
non-reducing conditions. (d) Appearance of WB using the secondary antibody alone, as used for 
both the C3 and C5 western blots.  
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3.5 CD11b deficiency enhances the severity of MPGN in 8-month old FH-deficient 
mice 
Previously, MPGN in Cfh-/- mice on the mixed 129/Sv×C57BL/6 genetic background was 
characterized at 8 months by mesangial matrix expansion, mesangial hypercellularity, 
peripheral capillary loop thickening with accumulation of PAS-positive material and a double-
contour appearance of the GBM [Pickering et al. 2002]. Here, LM in 8-month old               
Cfh-/-.CD11b-/- mice revealed MPGN with prominent mesangial expansion and diffuse 
hypercellularity (Fig. 9a). Chronic renal injury in Cfh-/- mice was fairly mild and glomerular 
morphology in CD11b-/- mice was unremarkable (Fig. 9b,c). The sick Cfh-/-.CD11b-/- mouse 
had a distinct glomerular lesion characterized by crescents in 100% of glomeruli, mesangial 
expansion and hypercellularity and GCW thickening (Fig. 9d). Thickening of the GCW was 
not prominent in any other mice on LM. 
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Figure 9 Renal PAS staining in 8-month old mice 
Representative LM images (400×) are shown of glomeruli in (a) Cfh-/-.CD11b-/-, (b) Cfh-/- and            
(c) CD11b-/- mice. (d) A circumferential crescent (indicated by arrow) in the sick Cfh-/-.CD11b-/- 
mouse. 
 
 
 
 
 
 
Cfh-/-.CD11b-
/- 
a. Cfh-/-.CD11b-/-                    b. Cfh 
 
c. CD11b-/-                                    d. Cfh-/-.CD11b-/- (sick mouse)  
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3.6 CD11b deficiency enhances glomerular hypercellularity in 8-month old FH-
deficient mice 
Histological assessment revealed increased glomerular cells in Cfh-/-.CD11b-/- mice 
compared to both Cfh-/- mice (median glomerular cells Cfh-/-.CD11b-/- 53.4 versus Cfh-/- 
36.6; p = 0.0438, Fig. 10a) and CD11b-/- mice (35.5; p versus Cfh-/-.CD11b-/- = 0.008). 
Mesangial expansion was assessed by ranking the sections for severity, from 1 (least 
severe) to 21 (most severe), with no difference observed between groups (median rank    
Cfh-/-.CD11b-/- 15 versus Cfh-/- 11 versus CD11b-/- 8; p = 0.5375, Fig. 10b). PAS-positive 
material was virtually absent from glomerular capillary loops, with no difference between 
groups (median score for PAS-positive quadrants per glomerular cross-section                
Cfh-/-.CD11b-/- 0.09, Cfh-/- 0.04, CD11b-/- 0.05; p = 0.3571, Fig. 10c). Neutrophils were 
rare, albeit significantly increased in Cfh-/-.CD11b-/- compared to both other groups (median 
neutrophils per glomerular cross-section Cfh-/-.CD11b-/- 0.25 versus Cfh-/- 0.06, p = 0.0223; 
versus   CD11b-/- 0.02; p = 0.0006, Fig. 10d).  
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Figure 10 Glomerular histological assessment in 8-month old mice 
(a) Mean number of glomerular cells per glomerulus and (b) ranking of severity of mesangial 
expansion (from lowest, 1, to highest, 21) in Cfh-/-.CD11b-/-, Cfh-/- and CD11b-/- mice. Mean 
number of (c) glomerular quadrants containing PAS-positive material and (d) glomerular neutrophils. 
The sick mouse is shaded green. Horizontal bars denote median values. *p < 0.05, ***p < 0.001 
(Kruskal-Wallis/Dunn’s). 
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3.7 Glomerular hypercellularity and albuminuria are correlated in Cfh-/-.CD11b-/- 
mice 
Glomerular hypercellularity and 16h urinary albumin excretion were the most prominent 
histological and functional markers, respectively, of progressive renal disease in                
Cfh-/-.CD11b-/- mice. I therefore assessed the correlation of these parameters. In the         
Cfh-/-.CD11b-/- group, correlation of hypercellularity and 16h urinary albumin excretion was 
very high (r = 0.92, p = 0.0005, Fig. 11). With the inclusion of the Cfh-/- and CD11b-/- 
groups, in which neither glomerular hypercellularity nor albuminuria were prominent, 
correlation of these parameters was reduced (r = 0.53; p = 0.0122).  
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Figure 11 Correlation of glomerular hypercellularity and urinary albumin excretion  
Histological (glomerular hypercellularity) and functional (urinary albumin excretion in μg/16h) were 
correlated across all three groups (Spearman, *p < 0.05) and in the Cfh-/-.CD11b-/- group alone 
(Spearman, ***p <0.001). The sick mouse is shaded green.  
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3.8 CD11b deficiency does not influence glomerular C3 or C3d staining in FH-
deficient mice 
In both Cfh-/-.CD11b-/- and Cfh-/- mice, renal immunostaining using a polyclonal anti-mouse 
C3 antibody revealed a linear C3 pattern in the glomerulus, consistent with C3 accumulation 
along the GBM, whereas extraglomerular C3 was absent (Fig. 12a,b). By contrast, in 
CD11b-/- mice, a WT pattern of sparse, granular mesangial C3 together with C3 staining of 
Bowman’s capsule and the tubulointerstitium was seen (Fig. 12c). MFI of glomerular C3 
staining was no different between Cfh-/-.CD11b-/- and Cfh-/- mice (median MFI                
Cfh-/-.CD11b-/- 120.1 AFU versus Cfh-/- 131.1 AFU; p = 0.7535, Fig. 12g), but was 
increased in either case compared to CD11b-/- mice (median 34.3 AFU; p versus Cfh-/-
.CD11b-/- = 0.0123; p versus Cfh-/- = 0.0015).  
Renal immunostaining was also performed using an antibody against the C3d moiety of 
mouse iC3b and C3d(g) [Paixão-Cavalcante et al. 2009]. This revealed a linear C3d staining 
pattern Cfh-/-.CD11b-/- and Cfh-/- mice, corresponding to the pattern seen using the 
polyclonal anti-C3 antibody, whereas C3d was not detected in CD11b-/- mice (Fig. 12d-f). 
The intensity of linear C3d staining was no different between Cfh-/-.CD11b-/- and Cfh-/- mice 
(median MFI Cfh-/-.CD11b-/- 36.0 AFU versus Cfh-/- 41.4 AFU; p = 0.0753, Fig. 12h).  
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Figure 12 Renal C3 and C3d staining in 8-month old mice. 
Representative images (400×) of glomeruli in Cfh-/-.CD11b-/-, Cfh-/- and CD11b-/- mice showing        
(a-c) direct IF staining using FITC-labelled antibody against C3 (d-f) indirect IF staining using 
biotinylated anti-C3d antibody and FITC-labelled avidin. (g) Mean fluorescence intensity (MFI) for 
glomerular C3 staining in arbitrary fluorescence units (AFU). (h) MFI in AFU for glomerular C3d. The 
sick mouse is shaded green. Horizontal bars denote median values. *p < 0.05, **p < 0.01 (Kruskal-
Wallis/Dunn’s). 
 
 
 
a. C3: Cfh-/-.CD11b-/-        b. C3: Cfh-/-           c. C3: CD11b-/- 
   
d. C3d: Cfh-/-.CD11b-/-        e. C3d: Cfh-/-           f. C3d: CD11b-/- 
   
g.       h.    
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3.9 CD11b deficiency does not influence glomerular IgG staining in FH-deficient 
mice 
A faint granular pattern of glomerular IgG accumulation was seen in all groups (Fig. 13a-c), 
with the exception of the sick Cfh-/-.CD11b-/- mouse, in which a striking linear IgG staining 
pattern was seen (Fig. 13d). No difference in intensity of glomerular IgG staining was seen 
between the three groups (median MFI of glomerular IgG Cfh-/-.CD11b-/- 36.85 AFU, Cfh-/- 
37.3 AFU, CD11b-/- 43.4 AFU; p = 0.4577, Fig. 13e).  
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Figure 13 Renal IgG staining in 8-month old mice 
(a-c) Representative images (400×) of glomeruli in Cfh-/-.CD11b-/-, Cfh-/- and CD11b-/- mice 
showing direct IF staining using FITC-labelled antibody against IgG. (d) A distinct IgG staining pattern 
in the sick Cfh-/-.CD11b-/- mouse. (e) MFI in AFU for glomerular IgG. The sick mouse is shaded green. 
Horizontal bars represent median values.   
 
 
 
 
 
 
 
 
a. IgG: Cfh-/-.CD11b-/-        b. IgG: Cfh-/-            c. IgG: CD11b-/- 
   
d. IgG: Cfh-/-.CD11b-/- (sick mouse)  e. 
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3.10 Renal CD11b+ cells are absent in CD11b-deficient mice 
CD11b+ cells were identified in renal tissue through direct IF staining. Simultaneous indirect 
IF staining was performed using an anti-PNA antibody that has been used to stain proximal 
and/or distal tubules in several species, with negative glomerular staining [Phillips et al. 
2001, Kakani et al. 2012]. CD11b+ cells were thus enumerated within glomeruli bordered by 
PNA-positive tubulointerstitial cells. Renal CD11b+ cells were not detected in either of the 
genetically CD11b-deficient groups, and were seen within the glomerulus only in Cfh-/- mice 
(median CD11b+ cells Cfh-/- 1.2 versus Cfh-/-.CD11b-/- 0.0, p = 0.0001; versus CD11b-/- 
0.0, p = 0.0006, Fig. 14a-d). This compares to a CD11b+ glomerular cell count in one 
previous study of unmanipulated, younger C57BL/6 mice of approximately 0.3 [Masaki et al. 
2003]. 
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Figure 14 Assessment of glomerular CD11b+ cells in 8-month old mice  
Representative images (400×) of glomeruli in (a) Cfh-/-.CD11b-/-, (b) Cfh-/- and (c) CD11b-/- mice 
showing direct IF staining with FITC-labelled (green) antibody against CD11b, with indirect IF staining 
using biotinylated anti-PNA antibody and AF555-labelled (red) streptavidin. (d) Assessment of 
glomerular CD11b+ cell number. Horizontal bars denote median values, ***p < 0.001 (Kruskal-
Wallis/Dunn’s). 
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3.11 Cfh-/-.CD11b-/- mice show a nonsignificant trend towards increased glomerular 
CD68+ cells compared to Cfh-/- and CD11b-/- mice at 8 months 
Staining for CD11b is commonly used to identify glomerular macrophages in murine models 
of GN including accelerated nephrotoxic nephritis (ANTN) [Lee et al. 2014]. In order to 
compare groups, some of which had genetic CD11b deficiency, macrophages were instead 
assessed by staining for CD68. CD68 is a myeloid lysosomal glycoprotein expressed in all 
monocytes/macrophages and, to a lesser extent, DCs in both humans [Kelly et al. 1988, 
Holness & Simmons 1993] and mice (where it is sometimes called microsialin) [Ramprasad 
et al. 1996]. CD68 may in fact be more reliable than other macrophage markers including 
CD11b and F4/80 for numerical assessment of glomerular macrophages [Masaki et al. 
2003]. There was a nonsignificant trend towards increased glomerular CD68+ cells in Cfh-/-
.CD11b-/- mice (median CD68+ cells Cfh-/-.CD11b-/- 4.3, Cfh-/- 1.9, CD11b-/- 2.0; p = 
0.2311, Fig. 15a-e). Similar CD68+ macrophages in the glomeruli of Cfh-/- and CD11b-/- 
suggest that CD68 expression is not upregulated on CD11b-negative macrophages. These 
values compare to a CD68+ glomerular cell count of approximately 0.5 in a previous study 
[Masaki et al. 2003]. 
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Figure 15 Assessment of glomerular CD68+ cells in 8-month old mice 8-month old mice. 
Representative images (400×) of glomeruli in (a) Cfh-/-.CD11b-/-, (b) Cfh-/- and (c) CD11b-/- mice, 
and (d) the sick Cfh-/-.CD11b-/- mouse, showing direct IF staining with FITC-labelled (green) antibody 
against CD68, with indirect IF staining using biotinylated anti-PNA antibody and AF555-labelled (red) 
streptavidin. (e) Assessment of glomerular CD68+ cell number. The sick mouse is shaded green. 
Horizontal bars denote median values. 
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3.12 CD11b deficiency does not influence the renal phenotype in 2-4-month old FH-
deficient mice 
The spontaneous renal phenotype was compared in 2-4-month old Cfh-/-.CD11b-/- (n=31) 
and Cfh-/- (n=7) mice. Both groups contained a mix of male and female mice, none having 
haematuria or >1+ proteinuria on dipstick urinalysis. Plasma urea was not elevated in either 
group (median Cfh-/-.CD11b-/- 11.0mmol/L versus Cfh-/- 10.8mmol/L; p = 0.8850, Fig. 16a) 
and plasma C3 levels were uniformly low (median Cfh-/-.CD11b-/- 6.5μg/mL versus Cfh-/- 
10.4μg/mL; p = 0.1366, Fig. 16b). The number of glomerular cells was no different between 
groups (median glomerular cells Cfh-/-.CD11b-/- 33.2 versus Cfh-/- 32.3; p = 0.2229 Fig. 
16c). Glomerular neutrophils and PAS-positive material were virtually absent (Fig. 16e,f). A 
linear C3 staining pattern was seen in the glomeruli of all assessed mice, with no difference 
in intensity between groups (median MFI Cfh-/-.CD11b-/- 122.1 AFU, Cfh-/- 118.3 AFU;       
p = 0.1307, Fig. 16d). 
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Figure 16 Plasma biochemistry and LM in 2-4-month old mice 
No difference was observed between Cfh-/-.CD11b-/- and Cfh-/- mice in (a) plasma urea, (b) plasma 
C3 levels, (c) number of glomerular cells or (d) MFI in AFU of linear glomerular C3. Representative 
LM images (400×) of glomeruli in 2-4-month old (e) Cfh-/-.CD11b-/- and (f) Cfh-/- mice. 
a.      b.    
c.      d.     
    
e. Cfh-/-.CD11b-/-          f. Cfh-/-   
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3.13 Discussion 
Progressive renal disease in Cfh-/- mice is associated with the accumulation of iC3b along 
the GBM. In this chapter, I have shown that accompanying deficiency of CD11b, the specific 
leukocyte receptor for iC3b, exacerbates the spontaneous renal phenotype of FH-deficient 
mice at 8 months. Cfh-/-.CD11b-/- mice developed significantly increased urinary albumin 
excretion (in μg/16h) and glomerular hypercellularity compared to their Cfh-/- counterparts. 
The conclusion that MPGN was more severe in the Cfh-/-.CD11b-/- group was strengthened 
by the high correlation of functional (urinary albumin excretion) and histological (glomerular 
hypercellularity) markers of glomerular injury. A non-significant trend towards increased 
mesangial expansion was also seen in Cfh-/-.CD11b-/- mice (whereas thickening and double 
contours of the GBM were not prominent). These data provide experimental evidence 
negating hypothesis 1, that CD11b deficiency ameliorates experimental renal disease in FH-
deficiency mice. Instead, accompanying CD11b deficiency produced the opposite effect in 
FH-deficient mice, indicating that CD11b plays a protective role in experimental C3 
glomerulopathy. This finding of a protective effect due to CD11b in a spontaneous model of 
GN is a completely novel one. Furthermore, these results raise the intriguing possibility that 
partial renal protection in experimental C3 glomerulopathy is mediated specifically via the 
iC3b-CD11b interaction.  
CD11b is expressed on a wide array of lecucoytes possessing phagocytic (e.g. neutrophils, 
monocytes/macrophage) and/or antigen presenting (e.g. myeloid DCs, monocytes/ 
macrophages)  capabilities. As hypercellularity was the most prominent feature of MPGN in 
this study, glomerular leukocytes were counted. LM revealed scarce neutrophils in all 
groups, albeit significantly increased in Cfh-/-.CD11b-/- compared to Cfh-/- and CD11b-/- 
mice. Neutrophils are short-lived cells, and are seen as a component of glomerular 
inflammation in only the most aggressive forms of GN [Holdsworth & Tipping 2007]. Hence it 
is possible that constant, low-grade neutrophil influx played an important role in functional 
glomerular injury in Cfh-/-.CD11b-/- mice without contributing significantly to hypercellularity.  
Glomerular recruitment of macrophages is a typical feature of proliferative GN in both human 
and murine studies [Holdsworth & Tipping 2007, Duffield 2010]. The functional role of 
macrophages in glomerular inflammation is unclear, since they are a heterogenous cell 
population comprising both proinflammatory and tissue reparative subtypes [Weisheit et al. 
2015]. Here, glomerular macrophages were assessed by direct IF staining for mouse CD68 
as a pan-monocyte/macrophage marker (although the possibility of CD68+ myeloid DCs is 
not excluded [Ferenbach & Hughes 2008]). Despite a greater than twofold increase in 
median glomerular CD68+ cells in the Cfh-/-.CD11b-/- group compared to either Cfh-/- or 
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CD11b-/- mice, the difference between groups was not statistically significant. Nevertheless, 
macrophages clearly form a component of glomerular hypercellularity in Cfh-/-.CD11b-/- 
mice, and hence may contribute to glomerular injury. One possible mechanism involves iC3b 
ligation of CD11b on glomerular macrophages, mediating a protective, anti-inflammatory 
response to evolving glomerular injury. On this analysis, disease exacerbation could be due 
to functionally disabled reparative macrophages and/or disinhibited proinflammatory ones as 
a result of CD11b deficiency.   
Additional macrophage immunophenotyping and functional studies were not performed as 
part of the experimental work for this thesis. However there is some evidence from the 
literature that iC3b ligation of CD11b on macrophages mediates suppression of 
proinflammatory signalling. Firstly, interaction of iC3b and macrophage-expressed CD11b 
has been shown to downregulate proinflammatory cytokines during phagocytosis of 
apoptotic cells [Mevorach et al. 1998, Ricklin et al. 2010]. Secondly, it has been suggested 
that CD11b is a negative regulator of proinflammatory responses mediated by Toll-like 
receptors (TLRs) [Means & Luster 2010]. One method by which CD11b-TLR crosstalk has 
been assessed involves stimulation of macrophages in vitro with TLR and CD11b ligands 
[Duffield 2010]. For example, work undertaken in my supervisor’s laboratory has 
demonstrated that iC3b preligation of CD11b downregulates secretion by WT murine 
macrophages (but not DCs) of the proinflammatory cytokines IL-6 and CCL5 (also known as 
RANTES: Regulated on Activation, Normal T Cell Expressed and Secreted) in response to 
lipopolysaccharide (LPS) stimulation [Ling et al. 2014]. Similar effects have been 
demonstrated using a variety of CD11b ligands including fibrinogen, with TLR4 stimulation of 
murine or human macrophages [Wang L. et al. 2010, Cao et al. 2010, Huynh et al. 2012]. 
Preligation with a synthetic CD11b agonist also inhibited human macrophage secretion of 
TNF in response to synthetic TLR7/8 ligands [Reed et al. 2013].  
In another study, negative regulation of the TLR4-mediated proinflammatory response of 
macrophages due to CD11b in vitro was controversially attributed to inside-out signalling in 
the absence of an extracellular ligand [Han et al. 2010]. In vivo administration of LPS in 
CD11b-/- mice was associated with enhanced proinflammatory immune responses in 
comparison to CD11b+/- mice [Han et al. 2010]. However, the role of LPS as an extracellular 
ligand for CD11b [Van Strijp et al. 1993] was not addressed and thus the possibility of an 
exogenous CD11b ligand could not be excluded. That CD11b ligation by pathogen 
associated molecular patterns (PAMPs) is potentially important in CD11b-TLR crosstalk was 
highlghted in a later study in which polyinosinic:polycytidylic acid (poly:IC) was administered 
in CD11b-/- mice as a TLR3 ligand [Zhou et al. 2013]. Poly:IC was shown to be a novel 
ligand for CD11b on macrophages, enhancing both TLR3-dependent and TLR3-independent 
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proinflammatory pathways. Hence the divergent results of previous studies in which PAMP 
molecules were administered in CD11b-/- mice partly attest the different ligands, immune 
cell types and tissues assessed (Introduction, Table 3).  
As increased glomerular hypercellularity in Cfh-/-.CD11b-/- mice is only partially accounted 
for by neutrophils and CD68+ macrophages, it appears certain that other cell types were 
increased in Cfh-/-.CD11b-/- mice. For example, glomerular T cell infilration was not 
assessed by immunohistochemistry, and could theoretically have contributed to enhanced 
functional injury in Cfh-/-.CD11b-/- mice. However, in one recent biopsy study that included 
patients with MPGN (although not specifically C3 glomerulopathy), glomerular CD31+ 
neutrophils and, especially, CD68+ macrophages were prominent, whereas CD15+ T cells 
were much less numerous [Wu et al. 2012]. The role of T cells in models of GN is further 
discussed in Chapter 4. An additional component of glomerular hypercellularity in             
Cfh-/-.CD11b-/- mice (excluding those cells readily identified in glomerular capillary loops) 
may be due to proliferation of intrinsic glomerular cell types including mesangial and 
endothelial cells. 
3.14 Conclusions 
3.14.1 CD11b deficiency exacerbates the spontaneous renal phenotype in 8-month old FH-
deficient mice (thus negating hypothesis 1). 
3.14.2 This may be attributable to the anti-inflammatory effect of iC3b ligation of CD11b on 
glomerular macrophages, including suppression of TLR-mediated proinflammatory 
signalling. 
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4. CHAPTER FOUR: ROLE OF CD11B IN 
EXPERIMENTALLY INDUCED IMMUNE 
COMPLEX GLOMERULONEPHRITIS  
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4.1 Introduction 
Induction of immune-mediated glomerular injury in experimental animals through the 
administration of exogenous antigens has elucidated disease mechanisms in human GN 
[Becker & Hewitson 2013, Alpers 2014]. One widely used model is nephrotoxic nephritis 
(NTN), reported as early as 1900 in rabbits [Lindemann 1900] and later as a model of 
human GN [Masugi & Tomizuka 1931]. In heterologous NTN, administration of an anti-GBM 
antibody preparation (termed nephrotoxic serum, NTS) produces biphasic renal injury 
[Hammer & Dixon 1963, Assmann et al. 1985]. The initial phase involves glomerular 
inflammation secondary to binding of the anti-GBM antibody. As the anti-GBM antibody is 
raised in a different species (typically rabbit or, as in my experiments, sheep) from the 
experimental animal (mouse or rat) this is referred to as the heterologous phase. 
Heterologous phase injury is dependent on glomerular neutrophil influx [Cochrane et al. 
1965, Feith et al. 1996] and C3 activation [Hammer & Dixon 1963, Sheerin et al. 1997, Tang 
et al. 1997, Hebert et al. 1998]. Subsequently, the experimental animal develops an immune 
response to the heterologous anti-GBM antibody, acting ‘as a planted antigen in the 
glomerular capillary wall’ [Unanue et al. 1967]. This results in formation along the GBM of 
immune complexes comprising heterologous anti-GBM antibody and host IgG, and is termed 
the autologous phase. Progressive glomerular injury in the autologous phase mimics 
pathological features of human anti-GBM disease (or Goodpasture’s syndrome) [Sheerin et 
al. 2001]. NTS may also be administered in animals that have been sensitized to 
heterologous antibody through prior immunization with Ig from the same species used to 
generate the heterologous anti-GBM antibody. In this case, ‘accelerated’ autologous phase 
injury occurs due to rapid immune complex formation along the GBM (hence accelerated 
NTN, ANTN). The ANTN model produces significant renal injury at doses of NTS that would 
typically be subnephritogenic in unsensitized mice [Nagai et al. 1982]. In this chapter, I 
present ANTN experiments performed using an established protocol in which mice are 
sensitized using sheep IgG in adjuvant five days prior to injection of sheep anti-mouse GBM 
antibody [Pickering et al. 2002].  
Studies in inbred strains of experimental mice have shown that the renal phenotype of ANTN 
is influenced by genetic background, possibly due to differences in T cell responses to 
antigen. My experiments are performed in C57BL/6 mice, in which ANTN has been 
extensively characterized as a model of human crescentic GN involving a delayed-type 
hypersensitivity (DTH)-like nephritogenic immune response directed by the TH-1 subset of T 
helper cells [Holdsworth et al. 1999, Tipping & Holdsworth 2006]. Glomerular inflammation is 
characterized by infiltration of CD4-positive (CD4+) T cells and CD11b+ [Huang et al. 1997a] 
or CD68+ [Huang et al. 1997b] macrophages. Gene deletion studies in C57BL/6 mice have 
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shown the dependence of crescent formation on (1) CD4+ T helper 1 (TH-1)-associated 
cytokines including interferon (IFN)- [Haas et al. 1995, Kitching et al. 1999] whereas TH-2-
associated interleukin [IL]-4 or IL-10 are protective [Kitching et al. 1998, Kitching et al. 2000]; 
(2) both αβ- and -T cells [Rosenkranz et al. 2000]; (3) the IL-17-secreting CD4+ T cell (TH-
17) transcription factor, retinoid orphan receptor gamma t (RORγt) [Steinmetz et al. 2011]; 
and (4) macrophages (based on the requirement for granulocyte-macrophage colony-
stimulating factor [GM-CSF] but not G-CSF [Kitching et al. 2002]).  
In BALB/c mice, ANTN is instead characterized by a TH-2-mediated response with 
predominant neutrophil influx and glomerular thrombosis (with infrequent crescents) [Huang 
et al. 1997b]. Both C3 activation and autologous Ig appear to contribute significantly to the 
severity of ANTN in BALB/c mice. By contrast, studies in C3-/- C57BL/6 mice have shown 
protection due to C3 activation [Sheerin et al. 2001]. Transplant studies indicated that 
circulating C3, rather than local renal C3 synthesis, mediated this protective effect against 
severe functional and histological renal injury [Sheerin et al. 2001]. Although a study in FB-
deficient (Cfb-/-) mice, which are unable to activate C3 via the AP, showed reduced serum 
urea and albuminuria compared to WT mice, histological injury was very mild in both groups 
[Thurman et al. 2012]. The role of autologous Ig during ANTN in C57BL/6 mice is 
controversial. On one hand, FcR-/- mice lacking the gamma chain common to all Fc 
receptors, which mediate cellular responses to Ig, are protected from acute glomerular injury 
[Park et al. 1998, Tarzi et al. 2002]. Protection in CD40-deficient mice, which are unable to 
produce IgG, IgA or IgE due to defective Ig class switching, further indicates that antigen-
specific IgM is insufficient to produce renal injury. On the other hand, Ig µ-heavy chain-
deficient mice, which do not develop mature B cells or produce antibodies, were not 
protected in one study [Li et al. 1997], although proteinuria was reduced in another 
[Rosenkranz et al. 2000].  
In this chapter, I present my results using the ANTN model in mice with homozygous 
deficiency of FH and CD11b. In previous studies, Cfh-/- mice have shown hypersensitivity to 
both heterologous NTN [Pickering et al. 2006] and ANTN [Pickering et al. 2002]. ANTN in 
Cfh-/- mice on the 129/Sv×C57BL/6 mixed genetic background was characterized by 
increased glomerular thrombosis and mortality compared to WT mice [Pickering et al. 2002]. 
This severe phenotype was abolished in Cfh-/- mice with accompanying deficiency of FB, 
indicating dependence of renal injury on C3 activation via the AP. Hence the ANTN model is 
a potentially informative one regarding disease mechanisms in human C3 glomerulopathy. 
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ANTN has not been reported in CD11b-/- mice. In heterologous NTN, CD11b deficiency was 
shown to be protective against transient glomerular neutrophil influx (at 2h) and albuminuria 
(at 4-8h) following a single injection of rabbit nephrotoxic serum (NTS). This protocol was 
later adapted to induce more severe glomerular injury via two NTS injections followed by 
LPS administration. CD11b-/- mice were protected from glomerular neutrophil influx (at 4-
24h) and glomerular thrombosis and renal failure (at day 4) [Hirahashi et al. 2009].  Similar 
to conventional heterologous NTN, neutrophil depletion prior to disease induction attenuated 
glomerular thrombosis and renal failure in WT mice using the adapted model with LPS 
administration [Hirahashi et al. 2009]. These studies were reminiscent of earlier experiments 
showing a protective effect due to neutralizing anti-CD11b antibodies in heterologous NTN 
performed in WT rats [Wu et al. 1993, Mulligan et al. 1993, Wada et al. 1996, De Vriese et 
al. 1999].  
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4.2 Overview of ANTN experiments 
My original research aim was to assess whether coexistent CD11b deficiency influences the 
renal phenotype of FH-deficient mice following induction of ANTN. Hence this chapter forms 
a component of my experimental work addressing hypothesis 1, that deficiency of CD11b 
ameliorates experimental renal disease in FH-deficient mice. I performed three ANTN 
experiments (Table 7). In the first experiment (ANTN1) I compared Cfh-/-.CD11b-/- and    
Cfh-/- mice (referred to as ANTN1a). I also compared CD11b-/- and WT mice in this 
experiment as control groups for the effect of CD11b deficiency on the ANTN phenotype 
independent of FH deficiency (ANTN1b). The entire first experiment (ANTN1) was 
terminated at day 2 on humane grounds following two deaths in the Cfh-/-.CD11b-/- group. 
Renal functional and histological data are presented for ANTN1a in detail below, revealing 
more severe renal injury in Cfh-/-.CD11b-/- compared to Cfh-/- mice. Owing to the severity of 
the renal phenotype in Cfh-/-.CD11b-/- mice, I did not repeat ANTN1a on humane grounds 
(in accordance with my animal licence).  
ANTN1b is briefly summarized only, as renal failure and histological injury were absent at 
day 2 in both CD11b-/- and WT mice. However, a striking and unexpected finding of ANTN1 
was of early (day 1) haematuria in both of the CD11b-deficient groups (Cfh-/-.CD11b-/- and 
CD11b-/- mice). I therefore moved to additional experiments addressing the effect of CD11b 
deficiency on the ANTN phenotype beyond day 2. In ANTN2 and ANTN3 severe crescentic 
nephritis was observed in CD11b-/- mice.  
 
Table 7 Overview of ANTN experiments 
 Cfh-/-.CD11b-/- Cfh-/- CD11b-/- WT 
ANTN1a (male mice) n = 8 n = 8   
ANTN1b (male mice)   n = 8 n = 8 
ANTN2 (male mice)   n = 5 n = 5 
ANTN3 (female mice)   n = 8 n = 10 
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4.3 CD11b deficiency increases early haematuria in ANTN (ANTN1) 
ANTN was simultaneously induced in 8-10-week old male mice in four groups (all on a 
C57BL/6 background): Cfh-/-.CD11b-/- (n=8), Cfh-/- (n=8), CD11b-/- (n=8), and WT (n=8). At 
this age, light microscopic features of MPGN are not yet evident in Cfh-/ mice [Vernon et al. 
2011] or Cfh-/-.CD11b-/- mice (Chapter 3.12). On day 1 after NTS injection, haematuria 
developed exclusively in 9 out of 15 assessed CD11b-deficient mice (3 out of 7 assessed 
Cfh-/-.CD11b-/- mice and 6 out of 8 CD11b-/- mice, Fig. 17a,b) and none of the 16 Cfh-/- 
and WT mice (median dipstick haematuria 1+ in CD11b-deficient mice versus 0 in CD11b-
sufficient mice; p = 0.0002). Proteinuria was also increased in CD11b-deficient mice (median 
dipstick protein 2+ versus 1+; p = 0.0028, Fig. 17a,c).  
The experiment was terminated on humane grounds on day 2 because of two deaths in the 
Cfh-/-.CD11b-/- group. Post-mortem examination in Cfh-/-.CD11b-/- and CD11b-/- mice 
revealed injected material (water in oil emulsion of sheep IgG in CFA) within the peritoneal 
space (i.e. 7 days after i.p. injection). This material was absent in all CD11b-sufficient 
animals.  
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Figure 17 ANTN1: day 1 urinalysis     
(a) Dipstick urinalysis on day 1 after simultaneous sheep NTS injection in sensitized Cfh-/-.CD11b-/-, 
Cfh-/-, CD11b-/- and WT mice. (b) Haematuria (0-3+) and (c) proteinuria (0-4+) with comparison of 
CD11b–deficient mice (CD11b-/-.Cfh-/- and CD11b-/-) to CD11b-sufficient mice (Cfh-/- and WT). 
Horizontal bars denote median values. **p < 0.01, ***p < 0.001 (Mann-Whitney). 
 
 
  
a.    Cfh-/-              Cfh-/-.CD11b-/-           CD11b-/-                  WT 
Haematuria positive (green) or 
negative (yellow) 
Proteinuria positive (green) or 
negative (yellow) 
b.           c.    
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4.4 CD11b deficiency enhances the susceptibility of FH-deficient mice to ANTN 
(ANTN1a) 
In order to address my original research question regarding the effect of CD11b deficiency 
on experimental renal disease in FH-deficient mice, I compared the data in Cfh-/-.CD11b-/- 
and Cfh-/- mice (Table 8, ANTN1a). Weights were well-matched between groups at baseline 
(median weight Cfh-/-.CD11b-/- 20.3g versus Cfh-/- 22.2g; p = 0.8199). 24h after ANTN 
induction, 3 Cfh-/-.CD11b-/- mice only had developed haematuria (median dipstick haem 0.0 
in both groups; p = 0.0769). Proteinuria was increased in Cfh-/-.CD11b-/- compared to Cfh-/- 
mice (median dipstick protein Cfh-/-.CD11b-/- 2+ versus Cfh-/- 0.5+; p = 0.0289). On day 2, 
there were two deaths in the Cfh-/-.CD11b-/- group, prompting termination of the 
experiment. Blood was not obtained from these two Cfh-/-.CD11b-/- mice, and their kidneys 
were processed for LM but not IF.  
Plasma urea levels were higher in surviving Cfh-/-.CD11b-/- compared to Cfh-/- mice 
(median plasma urea Cfh-/-.CD11b-/- 16.2mmol/L versus Cfh-/- 11.1mmol/L; p = 0.0426; 
Fig. 18a). Plasma C3 levels were increased ~tenfold compared to those in the respective 2-
4-month old groups in Chapter 3 (Fig. 16b). However, there was no difference between 
groups (median plasma C3 Cfh-/-.CD11b-/- 88.3µg/mL versus Cfh-/- 49.1µg/mL; p = 0.7413, 
Fig. 18b). In order to assess the murine IgG immune response to sheep NTS, plasma titres 
of mouse IgG against sheep IgG were assessed. This also revealed no difference between 
groups (median -log2 titre Cfh-/-.CD11b-/- 12.6 versus Cfh-/- 13.1; p = 0.2035, Fig. 18c).  
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Table 8 ANTN1 in Cfh-/-.CD11b-/-, Cfh-/-, CD11b-/- and WT mice 
 ANTN1 (2 days) 
 1a: Cfh-/-.CD11b-/- versus Cfh-/- 1b: CD11b-/- versus WT 
Genotype Cfh-/-.CD11b-/- Cfh-/- CD11b-/- WT 
Sex M M M M 
N° of mice assessed 8 8 8 8 
Age (weeks) 9 9 10 10 
Baseline weight (g) 20.3 [17.3-23.6] 20.2 [18.8-22.4] 23.9 [21.3-25.4] 24.2 [21.8-26.2] 
Survival to day 2 75% 100% 100% 100% 
Urine dipstick day 1     
Haematuria (+) 0.0 [0.0-3.0] 0.0 [0.0] 1.5** [0.0-3.0] 0.0 [0.0] 
Proteinuria (+) 2.0* [1.0-2.0] 0.5 [0.0-2.0] 1.5 [0.0-2.0] 1.0 [0.0-1.0] 
Plasma results day 2
§
 
    Schistocytes (%) 4 [0-7] 0.5 [0-11] 0 [0-1] 0.5 [0-3] 
Urea (mmol/L) 16.3* [12.5-31.7] 11.1 [7.5-20.1] 11.4 [9.5-14.6] 11.1 [7.5-18.0] 
C3 (μg/mL) 88.3 [11.7-107.6] 49.3 [12.8-160.5] 469.3* [310.2-511.4] 358.3 [292.0-456.9] 
IgG (-log2 titre) 12.6 [6.6-12.6] 13.1 [11.6-14.6] 14.64 [13.6-16.6] 13.64 [12.6-15.6] 
Glomerular histology 
    
Mean PAS+   
quadrants (N°) 0.7* [0.0-1.5] 0.0 [0.0-1.0] 0.1 [0.0-0.4] 0.1 [0.0-0.6] 
Mean neutrophils (N
o
) 1.2 [0.1-4.3] 1.4 [0.7-3.0] 1.1 [0.0-1.68] 1.1 [0.1-4.0] 
Glomerular IF
§
 
    
Mean fibrin+ 
quadrants (N°) 0.7[0.0-1.6] 0.0 [0.0-1.2] 0.2 [0.0-0.5] 0.5 [0.0-1.3] 
Mean C3 (AFU) 95.0 [81.2-124.8] 93.3 [79.8-117.2] 53.2 [32.9-90.2] 38.3 [30.0-53.6] 
Mean sheep IgG (AFU) 69.5 [51.4-79.0] 62.7 [38.1-78.6] 75.9 [58.2-118.0] 66.9 [41.8-127.6] 
Mean mouse IgG (AFU) 45.3 [6.4-95.6] 34.4 [17.0-120.4] 86.1* [35.1-124.1] 34.2 [17.0-120.4] 
Data expressed as median [range]. *p < 0.05, **p < 0.01 (Mann-Whitney test).  
§
6/8 mice assessed in Cfh-/-.CD11b-/- group. 
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Figure 18 ANTN1a: day 2 plasma biochemistry 
(a) Plasma urea in mmol/L, (b) plasma C3 in μg/mL and (c) -log2 plasma IgG titre against sheep IgG in 
surviving mice. Horizontal bars denote median values. *p < 0.05 (Mann-Whitney).  
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4.5 CD11b deficiency is associated with early glomerular TMA following induction of 
ANTN in FH-deficient mice (ANTN1a) 
On LM, glomerular TMA was observed in Cfh-/-.CD11b-/- mice but not in Cfh-/- mice (Fig. 
19a,b). This was characterized by PAS-positive material within glomerular capillary lumens, 
and thickening of GCWs with occasional double contours of the GBM in the most severely 
affected Cfh-/-.CD11b-/- mice. Increased glomerular PAS-positive material was seen in    
Cfh-/-.CD11b-/- compared to Cfh-/- mice (median PAS-positive quadrants Cfh-/-.CD11b-/- 
0.7 versus Cfh-/- 0.0; p = 0.0376, Fig. 19c). The number of glomerular neutrophils was no 
different between groups (median neutrophils Cfh-/-.CD11b-/- 1.2 versus Cfh-/- 1.4; p = 
0.6294, Fig. 19d). 
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Figure 19 ANTN1a: day 2 renal PAS staining 
Representative LM images showing PAS-positive material (arrow) within glomerular capillary loops in 
(a) Cfh-/-.CD11b-/- but not (b) Cfh-/- mice. (c) PAS scoring based on number of glomerular quadrants 
(0-4) containing PAS-positive material. (d) Glomerular neutrophil count. The two dead                     
Cfh-/.CD11b-/- mice are highlighted green. Horizontal bars denote median values. *p < 0.05 (Mann-
Whitney).   
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Glomerular TMA in ANTN1a was further assessed by staining for fibrin/fibronogen in the 6 
surviving Cfh-/-.CD11b-/- mice and the 8 Cfh-/- mice. A broken linear staining pattern due to 
subendothelial fibrin accumulation with translucent staining of intracapillary thrombogenic 
material has been reported to be characteristic of glomerular TMA [Lazsik 2015]. Fibrin 
staining was scored based on the number of glomerular quadrants in which it was identified 
(Fig. 20a). As a positive control, a renal section from a mouse with an established 
glomerular TMA phenotype was assessed. Fibrin scores were not significantly increased in 
the Cfh-/-.CD11b-/- mice compared to Cfh-/- mice (median fibrin-positive quadrants          
Cfh-/-.CD11b-/- 0.68 versus Cfh-/- 0.03; p = 0.2488, Fig. 20b). However a high correlation 
coefficient was seen with PAS scores (r = 0.97; p < 0.0001, Fig. 20c).  
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Figure 20 ANTN1a: day 2 glomerular fibrin/fibrinogen staining 
Direct IF staining using a FITC-labelled antibody to fibrin/fibrinogen, with (a) a scoring system (0-4) 
based on number of glomerular quadrants with fibrin-positive staining. (b) Fibrin scores in (surviving) 
Cfh-/-.CD11b-/- and Cfh-/- mice, and (c) correlation of fibrin scores and PAS scores using LM 
(Spearman, ****p < 0.0001). Horizontal bars denote median values. 
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4.6 CD11b deficiency does not influence glomerular staining for sheep IgG or 
mouse IgG or C3 following induction of ANTN in FH-deficient mice (ANTN1a) 
Heterologous (sheep) IgG was detected in a linear staining pattern, consistent with 
accumulation of injected sheep anti-GBM IgG (NTS) along the GBM (Fig. 21a,b). The 
intensity of glomerular sheep IgG was no different between groups (median MFI               
Cfh-/-.CD11b-/- 69.5 AFU versus Cfh-/- 62.7 AFU; p = 0.4855, Fig. 21c). The murine IgG 
immune response was further assessed by renal immunostaining for mouse IgG. This also 
revealed a linear staining pattern, consistent with formation of immune complexes along the 
GBM. No difference in intensity of glomerular mouse IgG was seen between groups (median 
MFI Cfh-/-.CD11b-/- 45.3 AFU versus Cfh-/- 34.4 AFU; p = 0.8352, Fig. 21d-f). A linear C3 
staining pattern in both groups also showed no difference in intensity (median MFI            
Cfh-/-.CD11b-/- 95.0 AFU versus Cfh-/- 93.2 AFU; p = 0.9291, Fig. 21g-i).  
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Figure 21 ANTN1a: day 2 renal sheep IgG, mouse IgG and C3 staining 
Representative images (400×) of glomeruli showing direct IF staining and MFI in AFU for (a-c) sheep 
IgG and (d-f) mouse IgG and (g-i) in Cfh-/-.CD11b-/- and Cfh-/- mice. Horizontal bars denote median 
values. 
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4.7 CD11b deficiency exacerbates ANTN in FH-sufficient mice (ANTN2) 
In ANTN1b, renal failure and histological injury were absent in the CD11b-/- and WT groups 
(Table 8, ANTN1b). However, due to the finding of a significant increase in haematuria at 
day 1 in CD11b-/-, I switched my research focus to the question: ‘does CD11b deficiency 
influence the ANTN phenotype?’. I performed a second ANTN experiment to assess whether 
CD11b-/- mice were more susceptible than WT mice to development of histological injury 
beyond day 2. 12-week-old male CD11b-/- (n=5) and WT (n=5) mice were followed for 10 
days after NTS injection (Table 9, ANTN2). At baseline, there was no difference in weight 
between groups (median CD11b-/- 25.7g versus WT 26.5g; p = 0.6950). All mice survived to 
termination of the experiment on day 10.  
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Table 9 ANTN2 and ANTN3 in CD11b-/- and WT mice 
  ANTN2 (10 days) ANTN3 (10 days) 
Genotype CD11b-/- WT CD11b-/- WT 
Sex M M F F 
N° of mice assessed 5 5 8 10 
Age (weeks) 12 12 22 22 
Baseline weight (g) 25.7 [25.2-28.3] 26.5 [25.1-29.0] 22.1 (22.0-24.2] 22.1 [20.5-24.0] 
Urine dipstick day 1 
 
      
Haematuria (+) 2.0* [0.0-3.0] 0 [0] 2.0*** [0-3.0] 0 [0] 
Proteinuria (+) 2.0 [1.0-4.0] 1.0 [1.0-2.0] 3.0* [1.0-4.0] 0 [1.0-3.0] 
Urine dipstick day 10     
Haematuria (+) 3.0** [3.0] 0 [0.0-2.0] 2.5** [0-3.0] 0 [0-2.0] 
Proteinuria (+) 3.0 [1.0-4.0] 4.0 [1.0-4.0] 2.0 [1.0-4.0] 3.0 [0-3.0] 
Plasma results day 10 
 
      
Urea (mmol/L) 38.8** [10.0-39.4] 6.4 [5.3-8.2] 43.2**** [12.7-43.5] 10.6 [8.6-18.7] 
Haematocrit (%) n/a n/a 23.0 [15-50] 28.5 [18-42] 
C3 (μg/mL) 518 [443.2-676.9] 407.6 [223.7-622.9] 450.7* [280.0-554.5] 298.1 [224.4-394.2] 
IgG (-log2 titre) 13.6** [12.6-14.6] 11.6 [11.6-11.6] 15.1 [12.6-17.6] 15.4 [13.1-17.6] 
Glomerular LM 
 
      
Crescents (%)  22** [16-52] 0 [0] 56** [0-64] 0 [0-6] 
Mean PAS+  
quadrants (N°) 0.8** [0.4-1.6] 0.1 [0.0-0.3] 0.4* [0.1-0.6] 0.1 [0.0-1.2] 
Mean neutrophils (N
o
) 0.6 [0.3-1.2] 0.3 [0.1-0.5] 0.3* [0.1-0.6] 0.2 [0.0-0.3] 
Glomerular IF     
Mean fibrin+  
quadrants (N°) 1.6* [0.4-2.6] 0.04 [0.0-0.7] n/a n/a 
Mean CD68+ cells (N°) 5.9 [2.2-5.1] 3.6 [2.1-3.3] 5.3 [0.5-8.5] 5.0 [0.8-6.6] 
Mean C3 (AFU) 70.0 [51.6-74.4] 58.7 [42.6-71.4] 73.8 [44.6-99.7] 79.6 [59.6-141.3] 
Mean sheep IgG (AFU) 68.1 [58.1-76.1] 87.8 [59.5-96.1] 50.8 [33.0-85.5] 50.2 [36.3-88.5] 
Mean mouse IgG (AFU) 109.3 [87.0-132.5] 97.6 [81.1-149.3] 70.9 [54.3-95.6 44.5 [27.9-73.1] 
Data expressed as median [range]. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Mann-Whitney test) 
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On day 1 of ANTN2, haematuria was again present exclusively in 4 of the 5 CD11b-/- mice 
(median dipstick CD11b-/- 2+ versus WT 0; p = 0.0476, Fig. 22a) whereas proteinuria was 
no different between groups (median dipstick CD11b-/- 2+ versus WT 1.0+; p = 0.3651, Fig. 
22b). At this point, haematuria was still increased in CD11b-/- mice (median dipstick   
CD11b-/- 3+ versus WT 0.0; p = 0.0079) whereas increased proteinuria from baseline in 
both groups was similar (median dipstick CD11b-/- 3+ versus WT 4+; p = 0.4921). Urinary 
albumin excretion was not assessed in analogous fashion to the spontaneous cohort 
experiment (Chapter 3), as mice were not suitable for placement in metabolic cages. Day 10 
plasma urea levels were increased in CD11b-/- compared to WT mice (median plasma urea 
CD11b-/- 38.8mmol/L versus WT 6.4mmol/L; p = 0.0079, Fig. 22c). Plasma titres of mouse 
IgG against sheep IgG were also increased in CD11b-/- compared to WT mice (median -log2 
titre 13.64 versus WT 11.64; p = 0.0079, Fig. 22d). Plasma C3 levels were no different 
between groups (median CD11b-/- 517.7µg/mL versus WT 407.6µg/mL; p = 0.0952, Fig. 
22e).  
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Figure 22 ANTN2: day 1 urine and day 10 plasma biochemistry  
Dipstick (a) haematuria and (b) proteinuria on day 1 following NTS injection in CD11b-/- and WT 
mice. Plasma (c) urea levels in mmol/L, (d) -log2 IgG titre against sheep IgG and (e) C3 levels in µg/mL 
at sacrifice on day 10. Horizontal bars denote median values. *p < 0.05, **p < 0.01 (Mann-Whitney).   
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4.8 CD11b deficiency is associated with crescentic nephritis in ANTN (ANTN2) 
LM in ANTN2 showed circumferential crescents exclusively in CD11b-/- mice (median 
crescents CD11b-/- 22% of glomeruli versus WT 0% of glomeruli; p = 0.0079, Fig. 23a-c). 
Increased PAS-positive material was present in glomerular capilllary loops in CD11b-/- 
compared to WT mice (median PAS-positive quadrants CD11b-/- 0.8 versus WT 0.1; p = 
0.0079, Fig. 23d). A non-significant trend was seen towards increased glomerular 
neutrophils in CD11b-/- mice (median neutrophils 0.62 versus WT 0.26, p = 0.0873, Fig. 
23e).  
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Figure 23 ANTN2: day 10 renal PAS staining 
Representative LM images (400×) of glomeruli in (a) CD11b-/- mice, showing a circumferential 
crescent, and (b) WT mice. (c) Glomeruli with crescents as a percentage of total glomeruli, and mean 
number of (d) glomerular quadrants containing PAS-positive material and (e) glomerular 
neutrophils. Horizontal bars denote median values. **p < 0.01 (Mann-Whitney).   
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4.9 CD11b deficiency does not influence glomerular staining for sheep IgG or 
mouse IgG or C3 in ANTN (ANTN2) 
Renal immunostaining showed increased glomerular fibrin/fibrinogen deposition in CD11b-/- 
compared to WT mice (median fibrin-positive quadrants CD11b-/- 1.6 versus WT 0.0; p = 
0.0317). Fibrin and PAS scores were correlated (r = 0.77; p = 0.0125). A linear pattern of 
sheep IgG deposition was seen in both groups (i.e. 10 days after NTS administration), with a 
non-significant trend towards reduced intensity in CD11b-/- compared to WT mice (median 
MFI CD11b-/- 68.1 AFU versus WT 87.8 AFU; p = 0.0952, Fig. 24a-c), By contrast, intensity 
of linear glomerular mouse IgG staining showed a non-significant increase in CD11b-/- 
compared to WT mice (median MFI CD11b-/- 70.9 AFU versus WT 44.5 AFU; p = 0.0952, 
Fig. 24d-f). A granular mesangial pattern of C3 staining was of similar intensity in groups 
(median MFI CD11b-/- 70.0 AFU versus WT 58.7 AFU; p = 0.3095, Fig. 24g-i).  
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Figure 24 ANTN2: day 10 glomerular sheep IgG, mouse IgG and C3 staining  
Representative images (400×) of glomeruli in CD11b-/- and WT mice showing direct IF staining in and 
MFI in AFU of (a-c) linear sheep IgG and (d-f) linear.mouse IgG and (g-i) granular C3. Horizontal bars 
denote median values.  
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4.10 CD11b deficiency is associated with a non-significant increase in glomerular 
CD68+ macrophages in ANTN (ANTN2) 
Glomerular CD68+ macrophages were prominent in the glomeruli and, especially, the 
tubulointerstitium of some CD11b-/- mice. However, no difference in glomerular CD68+ 
macrophages was seen between groups overall (median score CD11b-/- 5.9 versus WT 3.6; 
p = 0.1667, Fig. 25a-c). This compares to a previous study of day 10 ANTN in C57BL/6 mice 
showing a CD68+ glomerular cell count of 7 [Masaki et al. 2003]. 
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Figure 25 ANTN2: day 10 renal CD68 staining  
Representative images (400×) of glomeruli in (a) CD11b-/- and (b) WT mice showing direct IF staining 
of CD68+ cells (green), with indirect IF staining of PNA (red). (c) Mean number of glomerular CD68+ 
cells. Horizontal bars denote median values.  
 
  
 
  
c.                
a. CD68 (FITC), PNA (AF555): CD11b-/-            b. CD68 (FITC), PNA (AF555): WT 
             r.  
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4.11 CD11b deficiency exacerbates ANTN in FH-sufficient mice (ANTN3) 
In order to validate the findings in CD11b-/- mice, I performed a repeat ANTN experiment in 
22-week old female CD11b-/- (n=8) and WT (n=10) mice (Table 9, ANTN3). Baseline 
weights were no different between groups (median weight 22.1g; p = 0.8108). On day 2, 
haematuria developed exclusively in 7 out of 8 CD11b-/- mice (median dipstick CD11b-/- 2+ 
versus WT 0.0; p = 0.0003, Fig. 26a) and proteinuria was also increased in CD11b-/- mice 
(median dipstick CD11b-/- 3+ versus WT 1.5+; p = 0.0178, Fig. 26b). The experiment was 
terminated on day 10 with 100% survival in both groups. At this point haematuria was still 
increased in CD11b-/- mice despite its appearance in 4 out of 10 WT mice (median dipstick 
CD11b-/- 2.5+ versus WT 0.0; p = 0.0062), whereas no difference was seen in proteinuria 
between groups (median CD11b-/- 2+ versus WT 3+; p = 0.6589). Haematocrit was 
reduced, with no difference between groups (median haematocrit CD11b-/- 23% versus WT 
28.5%; p = 0.6486). Renal failure was present exclusively in 7 out of 8 CD11b-/- mice 
(median plasma urea CD11b-/- 43.2mmol/L versus WT 10.6mmol/L; p<0.0001, Fig. 26c). 
High plasma titres of mouse IgG against sheep IgG were no different between groups 
(median -log2 titre CD11b-/- 15.14 versus WT 15.39; p = 0.9541, Fig. 26d). Plasma C3 levels 
were increased in CD11b-/- compared to WT mice (median CD11b-/- 450.7µg/mL versus 
WT 298.1µg/mL; p = 0.0494, Fig. 26e). 
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Figure 26 ANTN3: day 2 urine and day 10 plasma biochemistry  
(a) Dipstick haematuria and (b) dipstick proteinuria on day 2 following NTS injection in CD11b-/- and 
WT mice. (c) Plasma urea levels in mmol/L, (d) -log2 plasma IgG titres against sheep IgG and             
(e) plasma C3 levels in µg/mL on day 10. Horizontal bars denote median values. *p < 0.05,            
****p < 0.0001 (Mann-Whitney).   
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4.12 CD11b deficiency is associated with crescentic nephritis in ANTN (ANTN3) 
LM in ANTN3 revealed the presence of circumferential crescents exclusively in 7 out of 8 
CD11b-/- mice, more extensive than in ANTN2 (median crescents CD11b-/- 56% of 
glomeruli versus WT 0% of glomeruli; p = 0.0017, Fig. 27a-c). PAS-positive material in 
glomerular capillary loops was very minor compared to ANTN2, albeit with a slight increase 
in CD11b-/- compared to WT mice (median PAS-positive score CD11b-/- 0.38 versus WT 
0.08; p = 0.0264, Fig. 27d). Glomerular neutrophils were very rare, although slightly 
increased in CD11b-/- compared to WT mice (median CD11b-/- 0.34 versus WT 0.17; p = 
0.0308, Fig. 27e).  
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Figure 27 ANTN3: day 10 renal PAS staining  
Representative LM images (400×) of glomeruli in (a) CD11b-/- mice, showing a circumferential 
crescent and (b) WT mice, with a normal glomerular appearance. (c) Glomeruli with crescents as a 
percentage of total glomeruli, and mean number of (d) glomerular quadrants containing PAS-
positive material and (e) glomerular neutrophils. Horizontal bars denote median values. *p < 0.05,         
**p < 0.01 (Mann-Whitney). 
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4.13 CD11b deficiency does not influence renal immunostaining for sheep or mouse 
IgG in ANTN (ANTN3) 
Renal immunostaining showed a linear pattern of glomerular sheep IgG with similar IF 
intensity in both groups (median MFI CD11b-/- 50.8 AFU versus WT 50.2 AFU; p = 0.5557, 
Fig. 28a-c). Linear mouse IgG was also no different between groups (median CD11b-/- 
109.3 AFU versus WT 97.6; p = 0.3564, Fig. 28d-f).  
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Figure 28 ANTN3: day 10 renal immunostaining for sheep and mouse IgG  
Representative images (400×) of glomeruli in CD11b-/- and WT mice and MFI in AFU for (a-c) sheep 
IgG and (d-f) mouse IgG. Horizontal bars denote median values.  
 
  
C D
1 1
b -/
-
W
T
0
2 0
4 0
6 0
8 0
1 0 0
M
e
a
n
 g
lo
m
e
ru
la
r
s
h
e
e
p
 I
g
G
 (
A
F
U
)
C D
1 1
b -/
-
W
T
0
4 0
8 0
1 2 0
1 6 0
M
e
a
n
 g
lo
m
e
ru
la
r
m
o
u
s
e
 I
g
G
 (
A
F
U
)
   d. Mouse IgG: CD11b-/-              e. Mouse IgG: WT              f.                             
   a. Sheep IgG: CD11b-/-           b. Sheep IgG: WT            c.    
  
 134 
4.14 Circumferential C3 staining is observed in CD11b-/- mice following induction of 
NTN (ANTN3) 
C3 staining in ANTN3 revealed a striking circumferential glomerular C3 staining pattern 
exclusively in CD11b-/- mice (median glomeruli CD11b-/- 94% versus WT 0%; p = 0.0002, 
Fig. 29a-c). Excluding circumferential C3, scanty intraglomerular C3 was seen in a granular 
pattern in both groups, with no difference in IF intensity (median CD11b-/- 73.8 versus WT 
79.6 AFU; p = 0.5557, Fig. 29d).  
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Figure 29 ANTN3: day 10 renal immunostaining for C3 
Representative images (200×) show circumferential glomerular C3 in (a) CD11b-/- but not (b) WT 
mice. (c) Number (%) of glomeruli with circumferential C3 and (d) MFI of intraglomerular C3 (i.e. 
excluding circumferential C3 staining). Horizontal bars denote median values. ***p < 0.001 (Mann-
Whitney). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C D
1 1
b -/
-
W
T
0
2 0
4 0
6 0
8 0
1 0 0
N
u
m
b
e
r 
o
f 
g
lo
m
e
ru
li
 w
it
h
c
ir
c
u
m
fe
re
n
ti
a
l 
C
3
 (
%
)
* * *
a. C3: CD11b-/-                              b. C3: WT 
                        
c.         d. 
 136 
 
4.15 CD11b deficiency does not influence the number of glomerular CD68+ 
macrophages in ANTN (ANTN3) 
Glomerular CD68+ macrophages were no different in number between CD11b-/- and WT 
mice (median score CD11b-/- 5.3 versus WT 5.0; p = 0.5576, Fig. 30a-c). 
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Figure 30 ANTN3: day 10 renal CD68 staining  
Representative images (200×) show glomerular CD68+ cells (in green, with staining of PNA in red) in 
(a) CD11b-/- and (b) WT mice. (c) Number of glomerular CD68+ cells. Horizontal bars denote median 
values.  
 
  
a. CD68 (FITC) and PNA (AF555): CD11b-/-                         b. CD68 (FITC) and PNA (AF555): WT                       
   c.     
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4.16 CD11b deficiency does not enhance the plasma IgG immune response in 
heterologous NTN 
At the conclusion of ANTN2, plasma IgG titres against sheep IgG were higher in CD11b-/- 
mice compared to WT mice (with increased glomerular mouse IgG seen at day 2 in 
ANTN1b). In order to assess whether NTS induces a greater IgG immune response in 
CD11b-/- compared to WT mice, I performed heterologous NTN. Weight-matched, 13-week 
old male CD11b-/- (n=8) and WT (n=8) mice received a single i.v. tail vein injection of an 
identical dose of sheep NTS to that used in the ANTN experiments.  
Haematuria remained absent and proteinuria did not exceed 1+ over an 8-week observation 
period, at the end of which 100% survival was observed in both groups. Plasma urea was no 
different between groups (median plasma urea CD11b-/- 9.3mmol/L versus WT 9.2mmol/L; 
p = 0.6606, Fig. 31a). Plasma C3 levels were also no different between groups (median 
plasma C3 CD11b-/- 157.2µg/mL versus WT 147.0µg/mL; p = 0.4245, Fig. 31b). Mouse IgG 
against sheep IgG rose from baseline titres in both groups, but with no difference between 
CD11b-/- and WT mice at any assessed time-point (p > 0.05, Fig. 31c).  
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Figure 31 Heterologous NTN: plasma biochemistry  
(a) Plasma urea levels in mmol/L and (b) plasma C3 levels in µg/mL at week 8. Horizontal bars 
denote median values. (c) -log2 plasma IgG titres against sheep IgG prior to NTS injection (PRE) and 
over an 8-week evaluation period. Points represent median values with bars showing range.  
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4.17 Renal histological injury is absent in heterologous NTN 
On LM, features of glomerular injury/inflammation were absent (Fig. 32a,b). PAS-positive 
material was absent in glomerular capillary loops (median PAS-positive score 0.0 in both 
groups; p = 0.2308, Fig. 32c) and glomerular neutrophils were also virtually absent (median 
CD11b-/- 0.1 versus WT 0.0; p = 0.0, Fig. 32d).  
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Figure 32 Heterologous NTN: renal PAS staining 
Representative LM images (400×) of glomeruli in (a) CD11b-/- mice and (b) WT mice. (c) PAS staining 
of intracapillary material in glomerular quadrants and (d) glomerular neutrophils. Horizontal bars 
denote median values. 
  
 
  
a.               b.     
  
c.               d.     
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4.18 CD11b does not influence glomerular deposition of mouse IgG in heterologous 
NTN 
On renal immunostaining, linear-pattern glomerular sheep IgG was of similar intensity in 
both groups (median MFI CD11b-/- 56.74 AFU versus WT 52.82 AFU; p = 0.9319, Fig. 33a). 
Intensity of granular C3 staining in the glomerulus was also similar in both groups (median 
MFI C3 CD11b-/- 76.0 AFU versus WT 63.4 AFU; p = 0.3231, Fig. 33b). Intensity of linear 
mouse IgG staining was also no different between groups (median MFI CD11b-/- 102.04 
AFU versus 92.83; p = 0.8541, Fig. 33c). This was correlated with week 8 plasma IgG titres 
(r = 0.79; p = 0.0006, Fig. 33d), with no separation of the CD11b-/- and WT groups.  
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Figure 33 Heterologous NTN: glomerular scoring based on immunostaining  
MFI in AFU of (a) linear sheep IgG, (b) granular C3 and (c) linear mouse IgG. Horizontal bars denote 
median values. (d) Correlation of MFI of glomerular mouse IgG with plasma IgG titres against sheep 
IgG (Spearman, ***p < 0.001). 
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4.19 Enhanced IgG response in CD11b-/- mice correlates with antigen persistence 
In order to examine whether the IgG immune response to antigen/CFA was influenced by 
CD11b deficiency, I performed an alternative immunization protocol. This involved s.c. base-
of-tail injection of female CD11b-/- (n=6) and  WT (n=6) mice with NP4-haptenated chicken 
gammaglobulin (CGG) in CFA. CD11b-/- mice were older than WT mice (22.4 weeks versus 
13.7 weeks) and weighed more (median weight CD11b-/- 24.8g versus WT 17.3g; p = 
0.0022, Fig. 34c). 10 days after injection, ulcerating lesions were noted at the injection site in 
4 out of 6 CD11b-/- mice, whereas WT mice were unaffected (Fig. 34a,b). The injected 
material was present in the wounds, which received daily topical antibiotic treatment with 2% 
fusidic acid cream (Fusiderm, Eva Pharma, Egypt) before healing completely at around 
weeks 4-5. The clinical course correlated with the anti-hapten IgG response in CD11b-/- 
mice. Titres of low and high affinity IgG against haptenated CGG were significantly 
increased in CD11b-/- compared to WT mice at week 2 (median titre CD11b-/- 14.3 versus 
WT 6.8; p = 0.0312, Fig. 34d), peaking at week 4 (median titre CD11b-/- 17.2 versus WT 
4.6; p<0.0001). At week 6, titres had fallen in 5 out of 6 CD11b-/- mice to levels similar to 
WT (median titre CD11b-/- 7.5 versus WT 5.8; p = 0.2656). At sacrifice, plasma C3 levels 
were also no different between groups (median plasma C3 CD11b-/- 295.3 versus WT 
321.6, p = 0.8550). 
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Figure 34 S.c. injection of NP4-haptenated chicken gammaglobulin in CFA 
Representative images obtained 3 weeks after s.c. base-of-tail injection with CGG/CFA showing an 
ulcerating lesion at the injection site in (a) CD11b-/- but not in (b) WT mice. (c) Baseline weights.         
(d) Anti-hapten IgG titres in both groups prior to CGG/CFA injection (PRE) and over a 6-week 
evaluation period (points represent median values with bars showing range). **p < 0.01 (Mann-
Whitney) 
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4.20 Discussion 
In this chapter, deficiency of CD11b was shown to enhance the susceptibility of FH deficient 
mice to ANTN. In ANTN1, dipstick proteinuria at day 1 and plasma urea and glomerular 
thrombosis at day 2 were increased in Cfh-/-.CD11b-/- compared to Cfh-/- mice, with a non-
significant trend towards increased day 2 mortality in the Cfh-/-.CD11b-/- group. Due to early 
termination of the experiment on day 2, the severity of renal injury was only mild to moderate 
in surviving Cfh-/-.CD11b-/- mice. Nevertheless, these data are consistent with the increased 
severity of experimental C3 glomerulopathy in the absence of CD11b demonstrated in 
chapter 3. Hence they provide additional evidence that CD11b deficiency exacerbates 
experimental renal disease in Cfh-/- mice.  
An unexpected finding in ANTN1 was that CD11b deficiency was associated with day 1 
haematuria irrespective of the FH genotype. This implies that CD11b may mediate 
protection against ANTN outside the setting of FH deficiency, and was therefore investigated 
in two additional ANTN experiments that compared CD11b-/- and WT mice only. Early 
haematuria was again observed exclusively in CD11b-/- mice, and was associated with the 
development of crescentic nephritis at day 10. Crescents were more extensive in ANTN3 
than ANTN2, possibly related to the use of female mice in ANTN3 [Park et al. 1998]. This 
protective effect of CD11b in ANTN could again be dependent on ligation of CD11b on 
glomerular macrophages, as important immune effector cells in the ANTN model. Moreover 
CD11b ligation spefically due to iC3b appears likely on the basis of (1) generation of 
abundant C3 activation products using the ANTN model; (2) previous demonstration of 
increased severity of ANTN in C3-/- mice [Sheerin et al. 2001]; and (3) the finding that 
deficiency of other CD11b ligands including ICAM-1 [Janssen et al. 1998] and fibrinogen 
[Drew et al. 2001] is associated with reduced severity of ANTN.  
An additional explanation for renal protection due to CD11b involves the role of T cell 
stimulation in ANTN, which in C57BL/6 mice is conventionally viewed as a model of TH-1 
CD4+ T cell-directed DTH (and more recently recently of TH-17 immune differentiation). An 
important role for CD11b in suppressing both DTH and TH-17-mediated immunity has 
previously been demonstrated using a model of low-dose oral antigen (ovalbumin) exposure 
followed by high-dose immunization with antigen in CFA [Ehirchiou et al. 2007]. Whereas 
ovalbumin-specific DTH following the high-dose immunization was no different in CD11b-/- 
and WT PBS-fed mice, it was increased in CD11b-/- compared to WT antigen-fed mice. 
Passive transfer of naïve WT splenic APCs in CD11b-/- mice prior to antigen feeding was 
effective in re-establishing orally induced peripheral immune tolerance (i.e. strongly reducing 
antigen-specific DTH). After completion of the experiment, single cell suspensions from 
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draining lymph nodes (LNs) were restimulated in vitro with ovalbumin, revealing enhanced 
production of IL-2, IL-6 and IL-17 in LNs from CD11b-/- compared to WT mice (only under 
antigen feeding conditions). The CD11b-/- LN CD4+ T cell population was also shown to be 
enriched for the TH-17 subset. IL-17 administration in WT mice was shown to abrogate 
ovalbumin-specific oral tolerance. On this basis, the authors attributed enhanced DTH in 
CD11b-/- mice to the suppressive effects of CD11b on TH-17 immune differentiation. Hence 
susceptibility of CD11b-/- mice to crescentic ANTN in the present study may also be 
attributable to enhanced DTH and TH-17-mediated immunity.  
Secondly, absence of renal injury 8 weeks after induction of heterologous NTN in 
unsensitized CD11b-/- mice suggests a critical role of the sensitization using CFA in the 
ANTN model. One possible explanation for this is the crosstalk between CD11b and CFA-
induced proinflammatory signalling. CFA is a recognised TLR agonist [Billiau & Matthys 
2001, Lim 2003] and has also been shown to induce a CD11b+ splenic cell population with 
(controversial) immunosuppressive effects on T-cell-mediated immunity [Matthys et al. 2001, 
Wang Z. et al. 2010]. Deficiency of CD11b could therefore result in a more severe 
nephritogenic immune response in CFA-sensitized mice via either of these mechanisms. In 
particular, ANTN is one of several experimental models that have highlighted the deleterious 
role of TLRs in GN [Couser 2012]. The importance of TLR stimulation at sensitization was 
demonstrated in an adapted ANTN protocol in which aluminium hydroxide was substituted 
for CFA as the immune adjuvant. A synthetic TLR2 ligand [Brown et al. 2006] or LPS 
[Giorgini et al. 2010] was co-administered with sheep IgG/adjuvant at sensitization. 
Following NTS injection, severe crescentic nephritis developed, from which mice with 
genetic deficiency of the corresponding TLRs were protected.  
The antigen-specific IgG immune response was not different between CD11b-/- and WT 
mice in the heterologous NTN model, which does not use immune adjuvant. I investigated 
the effects of CFA using a CFA-based protocol in which sheep IgG was substituted as the T-
dependent antigen by haptenated CGG. Following s.c. base-of-tail injection of CGG/CFA, 
local inflammation and ulceration developed exclusively in CD11b-/- mice, with injected 
material persistently present in the wounds. This was reminiscent of the retained 
intraperitoneal sheep IgG/CFA observed exclusively in CD11b-deficient mice in ANTN1. 
Inflammation at local injection sites is a recognised complication of CFA administration 
[Billiau & Matthys 2001]. Infiltration of s.c. CFA injection sites by CD11b+ leukocytes has 
also previously been described [Wang Z. et al. 2010], with possible implications for 
antigen/CFA clearance in CD11b-/- mice. Here, persistent s.c. CGG/CFA and local 
inflammation were temporally associated with increased anti-hapten IgG titres in affected 
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CD11b-/- mice at 2-4 weeks. Hence loss of CD11b-dependent clearance of antigen/CFA, 
potentiating the nephritogenic immune response, may be an additional mechanism leading 
to increased severity in ANTN in CD11b-/- mice. This impaired antigen clearance in the 
setting of CD11b deficiency could further exacerbate TLR-mediated inflammation. In 
addition, generation of complement activation products by APCs and T cells during antigen 
presentation within the peritoneum may become deranged in the setting of impaired antigen 
clearance, effectively priming a proinflammatory immune response that is then targeted to 
the GBM following the administration of NTS. This mechanism is compatible with recent 
evidence showing a role for immune cell-derived complement in directing the differentiation 
of T helper 1 (TH-1) and TH-17 cells, and potentiating TLR-driven APC maturation and the 
secretion of pro-inflammatory cytokines [Kolev et al. 2014]. 
4.21 Conclusions 
4.21.1  CD11b deficiency exacerbates ANTN in FH-deficient mice. This corroborates the 
findings of Chapter 3 that CD11b is protective in experimental renal disease in FH-deficient 
mice (thus negating hypothesis 1). 
4.21.2  CD11b deficiency exacerbates ANTN. This is consistent with CD11b-mediated 
suppression of potentially important mechanisms in GN including DTH, Th-17-mediated 
immunity and TLR-mediated proinflammatory signalling. 
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5. CHAPTER FIVE: EFFECT OF AN ENGINEERED 
NOVEL MINI-FH PROTEIN ON THE 
SPONTANEOUS PHENOTYPE OF 
FACTOR H-DEFICIENT MICE  
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5.1 Introduction 
Cfh-/- mice demonstrate low plasma C3 levels and a linear pattern of C3 staining in the 
glomerulus [Pickering 02]. Murine experimental C3 glomerulopathy thus provides a useful 
model for studying the pathogenetic mechanisms and response to therapeutics in DDD. 
Previously, i.p. injection of 0.5mg of plasma-derived human FH in Cfh-/- mice was shown to 
increase plasma C3 levels at 2h, reaching WT plasma C3 levels at 24h [Fakhouri et al. 
2010]. This was accompanied by reduced intensity and extent of linear C3 staining, similar to 
the effect reported following administration of murine FH in Cfh-/- mice [Paixão-Cavalcante 
et al. 2009]. Accordingly, human recombinant FH has been proposed as a logical treatment 
for establishing physiological AP control and halting disease progression in patients with C3 
glomerulopathy. However, due to the size and complexity of the FH protein, production of 
therapeutic quantities represents a significant challenge [Sharma & Pangburn 1994, 
Sanchez-Corral et al. 2002, Buttner-Mainik et al. 2011]. For this reason a number of smaller 
human recombinant FH proteins expressing only key functional domains are now entering 
preclinical evaluation. Two human recombinant proteins comprising N-terminal complement 
regulatory SCR domains 1-4 and the C-terminal surface recognition SCR domains 19-20 
have been studied in vitro [Hebecker et al. 2013, Schmidt et al. 2013]. It was proposed that 
C-terminal binding to surface-bound iC3b and C3dg was in fact superior to that of full-length 
FH, effectively targeting the novel reagent to ‘sites of high opsonic turnover’ [Schmidt et al. 
2013]. A putative advantage of this class of recombinant proteins may therefore be surface 
targeting, whereby some of the systemic effects (specifically, increased risk of infection) 
associated with therapeutic complement inhibition are circumvented [Thurman et al. 2013]. 
Administration of murine and human FH in Cfh-/- mice was also associated previously with 
the appearance at 24h of tubulointerstitial C3. The presence of tubulointerstitial C3 in WT 
mice [Park et al. 2001, Thurman et al. 2003] and C4-deficient mice [Quigg et al. 1998], but 
not Cfb-/- mice [Lenderink et al. 2007], indicates a requirement for an intact AP. As 
discussed in Chapter 1, in vitro studies indicate that the apical surface of proximal renal 
tubular cells provides an AP-activating surface (section 1.2.8.2). It has also been suggested 
based on studies in sub-total nephrectomized rats that tubulointerstitial C3 deposition occurs 
due to accumulation of ammonia in the renal tubules, providing an AP-activating surface 
[Nath et al. 1985]. Studies in mice with deficiency of Crry indicate that this rodent-specific 
regulatory protein normally provides partial protection against C3 activation via the AP on the 
PTEC surface. IF microscopy of WT murine renal tissue [Thurman et al. 2006a, Miao et al. 
2014] indicates that Crry is the only membrane-bound complement regulatory protein 
expressed on PTEC, where it is localized to the basolateral surface (with a similar finding for 
MCP on human PTEC [Ichida et al. 1994]). Reconstitution of Cfb-/- mice with purified murine 
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FB led to increased deposition of C3 along the proximal tubule in those with accompanying 
Crry deficiency compared to those without [Renner et al. 2010]. PTEC-specific deficiency of 
Crry was also associated with increased C3 on the basolateral PTEC surface in 
unmanipulated mice [Miao et al. 2014]. Finally, in the ischaemia/reperfusion (I/R) model, 
enhanced C3 deposition on the basolateral surface of PTEC and associated tubular injury 
are AP-dependent [Thurman et al. 2003, Thurman et al. 2006b, Miwa et al. 2013]. A study in 
WT mice concluded that loss of Crry from the basolateral tubular surface as a result of I/R 
injury ‘permits uncontrolled activation of the alternative pathway on the surface of tubular 
epithelial cells’ [Thurman et al. 2006a]. Mice with PTEC-specific Crry deficiency also show 
increased severity of tubular injury using the I/R model [Miao et al. 2014]. 
Paradoxically, given uncontrolled C3 activation via the AP, Cfh-/- mice lack tubulointerstitial 
C3. The appearance of tubulointerstitial C3 24h after murine FH administration in Cfh-/- mice 
has thus been attributed to a requirement for ‘the presence of intact circulating C3’ [Paixão-
Cavalcante et al. 2009]. Similarly, transplantation of kidneys from Cfh-/- mice into WT 
recipients resulted in the appearance of discontinuous tubular C3 staining within 30 minutes, 
and more prominent tubular and Bowman’s capsule staining at 5 weeks [Alexander et al. 
2007]. The authors concluded that ‘activation of C3 onto the basolateral aspects of tubules 
requires an intact systemic alternative pathway, including its main regulator, Cfh’ [Alexander 
et al. 2007]. The authors of a study in which tubulointerstitial C3 was absent in Cfh-/- mice 
even after induction of I/R injury concluded that ‘uncontrolled fluid phase activation of C3 in 
these mice does not leave sufficient intact C3 to support complement activation on the TEC 
surface after I/R’ [Renner et al. 2011]. The interaction of FH with PTEC was assessed in WT 
mice through administration prior to I/R induction of a recombinant murine FH protein 
fragment comprising SCR domains 19-20 as a ‘dominant negative inhibitor of the native 
protein’ [Coleman et al. 2008]. Although this led to increased tubular injury, indicating that 
‘factor H is important for limiting injury after renal I/R’, C3 staining was not reported 
[Coleman et al. 2008]. 
In this chapter, I describe the administration in Cfh-/- mice of a novel engineered protein 
comprising SCR domains 1-5 and 18-20 of human FH, hereafter referred to as ‘mini-FH’. My 
experimental aim was to assess whether the C-terminal surface recognition domains of FH 
are necessary for therapeutic effect in experimental C3 glomerulopathy. Hence these 
experiments address hypothesis 2, that FH protects the GBM from surface phase C3 
activation via the AP. I show that mini-FH reduces glomerular C3 reactivity in Cfh-/- mice 
similar to full-length, serum-derived human FH (hFH), with partial restoration of plasma C3 
levels. This effect was not reproduced using a recombinant human FH protein comprising 
only SCR domain 1-5 (FH1-5). These results indicate a plausible therapeutic role for mini-FH 
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in patients with DDD and other disorders of AP regulation. A second observation was that, 
unlike plasma-derived FH, administration of mini-FH did not lead to the appearance of 
tubulointerstitial C3 staining at 24h. As the presence of tubulointerstitial C3 is potentially 
informative regarding surface phase C3 activation via the AP, an additional in vivo 
experiment was performed to address its relationship to C3 accumulation along the GBM in 
experimental C3 glomerulopathy. Here, my experimental aim was to assess whether 
glomerular and tubulointerstitial C3 staining could be triggered concurrently in FH-deficient 
mice. I injected FI-containing mouse serum in Cfh-/-.Cfi-/- mice, which has previously been 
shown to result in the appearance of linear C3 staining in the glomerulus [Rose et al. 2008]. 
As this was not associated with the appearance of tubulointerstitial C3 staining at any of the 
assessed time-points, it appears that C3 accumulation occurs via distinct mechanisms along 
the GBM and on the renal tubular surface. 
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5.2 Overview of the mini-FH experiments 
Mini-FH was assessed for therapeutic effect following i.p. injection in Cfh-/- mice. In the first 
experiment (Mini-FH Exp. 1, Table 10), comparison was made with a 3nmol (0.50mg) dose 
of hFH, as this was the dose used to positive effect in the previous study in Cfh-/- mice 
[Fakhouri et al. 2010]. A 6nmol dose (0.35mg) of mini-FH was assessed, double the molar 
dose of hFH, in order to allow for potentially increased clearance of the smaller, recombinant 
protein from plasma. Plasma C3 levels were assessed at 2h, 6h and 24h and glomerular C3 
staining at 24h, as in the earlier study.  
In the second experiment (Mini-FH Exp. 2), the effect of mini-FH on renal C3 staining in    
Cfh-/- was assessed 6h after administration (timed to coincide with the maximal effect of 
mini-FH on plasma C3 in the first experiment). In order to assess whether mini-FH produces 
a dose-dependent effect on plasma C3 levels and renal C3 staining, two doses of mini-FH 
were assessed, a 6nmol dose identical to that used for the first experiment, and a double 
(12nmol) dose. As in the first experiment, 3nmol hFH was used as a positive control. A 
negative control group comprising PBS-injected mice was also included in this experiment. 
Additional mice were injected with 12nmol FH1-5. As this protein lacks the surface 
recognition SCR domains 18-20 present on both mini-FH and hFH, my experimental aim 
was to assess the role of these domains specifically on glomerular C3 staining.  
In the third experiment (Mini-FH Exp. 3), the effect of split doses of mini-FH at 6-hourly 
intervals was assessed over a 24-hour period. Limited availability of the mini-FH reagent 
meant that only 3nmol mini-FH could be used per injection. Mice received four 6-hourly 
injections of 3nmol mini-FH, equimolar (3nmol) FH1-5 or PBS. Additional mice received a 
single injection of 3nmol hFH, used as in the previous experiments as a positive control, or a 
single equimolar (3nmol) dose of mini-FH or FH1-5, or PBS. In the four-injections groups, 
the last dose was administered at the 18h time-point, with termination of the experiment in all 
mice at 24h. 
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Table 10 Doses of human FH reagents used in mini-FH experiments 1-3 
 
  
 Reagent 
Protein 
concentration 
(mg/mL) 
MW (kDa) 
Molarity 
(μM) 
Total protein 
injected (μg) 
Moles per 
injection         
( x10
-9
) 
Total volume     
in sterile PBS      
(μL) 
Exp. 1 (24h)  
hFH 11.00 155 71 500 3 1000 
mini-FH         0.65 59 11 350 6 1000 
Exp. 2 (6h) 
hFH 2.88 155 18.6 465 or 930 3 900 
mini-FH          0.88 59 14.9 355 or 710 6 or 12 900 
FH1-5 1.00 36 28.2 430 12 900 
Exp. 3 (24h) 
hFH 1.60 155 10.3 465  
3 
 
340 (×1 dose) or 
200 (×4 doses) 
mini-FH         1.00 59 17.0 170 
FH1-5 1.75 36 48.6 110 
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5.3 6nmol mini-FH transiently increases plasma C3 levels in Cfh-/- mice (Mini-FH 
Exp. 1) 
Mini-FH Exp. 1 was terminated 24h after administration of 6nmol mini-FH (n=4, 2M/2F) or 
3nmol hFH (n=4, 2M/2F) in weight-matched, 8-12-week old mice. Plasma C3 levels rose in 
mice injected with mini-FH, peaking at 6h (median plasma C3 59.2 μg/mL, Fig. 35). 
However, a much greater rise was observed in hFH-injected mice, peaking at 24h (median 
plasma C3 254.5µg/mL versus 42.3 μg/mL for mini-FH; p = 0.0020).  
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Figure 35 Mini-FH Exp.1: 24h plasma C3 levels  
Plasma C3 levels in μg/mL before (PRE) and after (at 2h, 6h and 24h) injection of 6nmol mini-FH or 
3nmol hFH in Cfh-/- mice. Horizontal bars represent median values. **p < 0.01 (t-test).  
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5.4 6nmol mini-FH alters the glomerular C3 pattern at 24h (Mini-FH Exp. 1) 
In the glomerulus, a mixed granular mesangial and linear C3 staining pattern was seen at 
24h in mice injected with 6nmol mini-FH (Fig. 36a), whereas the pattern in 3nmol hFH-
injected mice was predominantly mesangial (Fig. 36b). In the tubulointerstitium, prominent 
C3 staining was observed within the renal cortex and outer medulla in 3nmol hFH-injected 
mice, whereas minimal tubulointerstitial C3 was seen in mice injected with 6nmol mini-FH. 
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Figure 36 Mini-FH Exp.1: 24h glomerular C3 staining  
Representative images (400×) following direct IF staining for C3 24h after administration in Cfh-/- 
mice of (a) 6nmol mini-FH, with a mixed linear and mesangial C3, and (b) 3nmol hFH, showing a 
granular mesangial C3 staining pattern with some tubulointerstitial C3. (c) A pure linear C3 pattern is 
shown from a naïve Cfh-/- mouse for comparison.  
 
  
  
   a. C3: mini-FH 6nmol                    b. C3: hFH 3nmol              c. Naïve   
 159 
 
5.5 Mini-FH is rapidly cleared from plasma after 2h (Mini-FH Exp. 2) 
Mini-FH Exp. 2 was terminated 6h after administration of 6nmol mini-FH (n=3; 2M/1F) or 
12nmol mini-FH (n=3; 2M/1F), 3nmol hFH (n=3; 2M/1F), 12nmol FH1-5 (n=3, 2M/1F) or PBS 
(n=3; 2M/1F) in weight-matched, 9-10-week old Cfh-/- mice. An ELISA was developed by Dr 
Kevin Marchbank to detect the injected proteins in plasma. This assay did not give a signal 
in the PBS-injected animals indicating that it was not detecting mouse FHR proteins, which 
are still present in Cfh-/- mice. Using this assay, mini-FH was detectable 2h after injection 
(Fig. 37). After a single 12nmol dose of mini-FH, the 2h median plasma level was 
203.1µg/mL. After a single 12nmol dose of FH1-5, the 2h median plasma level was 
189.1µg/mL. At 6h, plasma levels had fallen for the recombinant proteins, with only hFH 
detectable. 
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Figure 37 Plasma levels of injected proteins 
FH ELISA performed by Dr K. Marchbank using OX24 antibody shows plasma levels of injected 
proteins in μg/mL 2h and 6h after injection of 6nmol or 12nmol mini-FH, 3nmol hFH, 12nmol FH1-5 
or PBS in Cfh-/- mice. Horizontal bars denote median values. *p < 0.05, **p < 0.01, ****p < 0.0001 
versus PBS (one-way ANOVA/Bonferroni). 
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5.6 6-12nmol mini-FH increases plasma C3 levels at 2-6h (Mini-FH Exp. 2) 
Compared to PBS, mini-FH produced a significant rise in plasma C3 levels at 2h at both the 
6nmol dose (median plasma C3 mini-FH 41.2µg/mL versus PBS 9.9µg/mL; p = 0.0360,      
Fig. 38) and the 12nmol dose (median plasma C3 mini-FH 41.5µg/mL; p = 0.0369 versus 
PBS). This effect at 2h was comparable to that of 3nmol hFH (median plasma C3 
47.8µg/mL; p = 0.0128 versus PBS). By contrast, 12nmol FH1-5-treated animals did not 
have significantly elevated plasma C3 levels at the 2h time-point (median plasma C3 
29.6µg/mL; p = 0.2044 versus PBS). At 6h, plasma C3 levels were significantly increased 
compared to PBS for the 12nmol dose of mini-FH (median plasma C3 mini-FH 88.5µg/mL 
versus PBS 33.4; p = 0.0268) and 3nmol hFH (median plasma C3 139.3µg/mL; p = 0.0005 
versus PBS) only.  
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Figure 38 Mini-FH Exp.2: plasma C3 levels 
Plasma C3 levels in μg/mL before and after injection of 6nmol or 12nmol mini-FH, 3nmol hFH, 
12nmol FH1-5 or PBS in Cfh-/- mice. Horizontal bars denote median values. *p < 0.05, ***p < 0.001 
versus PBS (one-way ANOVA/Bonferroni). 
  
  
 163 
5.7 6-12nmol mini-FH reduces glomerular C3 staining at 6h (Mini-FH Exp. 2) 
Compared to PBS, mini-FH reduced the intensity of linear C3 staining in the glomerulus at 
both the 6nmol dose (median MFI of mini-FH 62.4 AFU versus PBS 110.3 AFU; p = 0.0174) 
and 12nmol dose (median MFI 58.1 AFU versus PBS 110.3 AFU; p = 0.0098, Fig. 39a,d,e). 
Intensity of glomerular C3 staining was also reduced in mice injected with 3nmol hFH 
(median MFI 73.5 AFU versus PBS 110.3 AFU; p = 0.0974, Fig. 39b). That this did not reach 
statistical significance in comparison to PBS is attributable to the presence of some 
mesangial C3 staining only in mice injected with hFH, increasing the total glomerular C3 
intensity in comparison to the mini-FH-injected mice. Slightly increased glomerular C3 
intensity was observed for PBS and especially 12nmol FH1-5 (Fig. 39c) compared to a naïve 
Cfh-/- mouse. This likely reflects glomerular accumulation of increased plasma C3 due to 
acute phase response. Tubulointerstitial C3 was absent at 6h in all mice. 
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Figure 39 Mini-FH Exp.2: 24h renal cortical C3 staining 
Representative images (400×) of direct IF staining for C3 in Cfh-/- mice 6h after administration of        
(a) 12nmol mini-FH, (b) 3nmol hFH, (c) 12nmol FH1-5, (d) PBS. (e) MFI in AFU for glomerular C3 in 
Cfh-/- mice at 6h. Horizontal bars denote median values. *p < 0.05, **p < 0.01 versus PBS (one-way 
ANOVA/Bonferroni). 
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5.8 hFH and mini-FH are detected in the glomerulus at 6h in Cfh-/- mice (Mini-FH 
Exp. 2) 
Glomerular deposition of injected human FH reagents was assessed. In a previous study in 
Cfh-/- mice injected with full-length human FH, goat anti-human FH antisera (Quidel) used to 
detect the injected human FH protein were found to cross-react with murine FHR proteins in 
a linear staining pattern [Paixão-Cavalcante et al. 2009]. Accordingly, I developed an 
alternative FH staining protocol using OX24, a mouse monoclonal IgG1 anti-human FH 
antibody that recognises an epitope within human FH SCR 5 [Sim et al. 1983, Jokiranta et 
al. 1996]. Dr Marchbank has demonstrated that OX24 recognises both the mini-FH and FH1-
5 proteins in vitro (capture antibody for FH ELISA, Fig. 37, and also western blot). 
6h after administration of 12nmol mini-FH, this reagent was faintly detected in a linear 
staining pattern in the glomerulus using biotinylated OX24 followed by phycoerythrin (PE)-
labelled streptavidin (Fig. 40a). A much brighter linear pattern was seen following injection of 
3nmol hFH (Fig. 40b), with absence of linear staining using the PE-labelled streptavidin 
alone (Fig. 40d). Linear staining was also absent in mice injected with 12nmol FH1-5 (Fig. 
40c).  
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Figure 40 Mini-FH Exp.2: OX24 staining with PE secondary  
Representative images (400×) of direct IF staining using biotinylated OX24 and PE-conjugated 
streptavidin 6h after injection of human proteins. Shown are (a) 12nmol mini-FH, (b) 3nmol hFH, and 
(c) 12nmol FH1-5. (d) PE-labelled streptavidin without primary antibody in a 3nmol hFH-injected 
mouse. 
 
 
 
  
a. OX24/PE: 12nmol mini-FH           b. OX24/PE: 3nmol hFH                     c. OX24/PE: 12nmol FH1-5 
  
   d. PE secondary only: 3nmol hFH 
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A similar profile of glomerular staining was obtained using OX24 with a different secondary 
antibody (AF555-labelled streptavidin). This showed a faint linear appearance for 12nmol 
mini-FH, bright linear staining for 3nmol hFH, and absent glomerular staining for 12nmol 
FH1-5 (Fig. 41a-c). By contrast, when OX24 was used with a third secondary antibody 
(AF488-labelled avidin), faint linear staining only was observed for 3nmol hFH, with absent 
glomerular staining for 12nmol mini-FH (Fig. 42a,b).  
These data are consistent with accumulation of mini-FH along the GBM and its persistence 
6h after administration in Cfh-/- mice. However, the binding of OX24 to the glomeruli is 
reduced after mini-FH administration in comparison to hFH despite a fourfold higher molar 
dose of mini-FH. This suggests that binding of mini-FH to the GBM and/or GBM-bound C3 
fragments may be less efficient than that of hFH. Glomerular staining was absent for mini-FH 
using OX24 with the AF488-labelled secondary antibody. This is likely to be due to the 
AF488-labelled secondary antibody, which also produced comparatively faint linear staining 
for hFH compared to the other secondary antibodies tested. As OX24 was unable to detect 
12nmol FH1-5 using the PE-labelled or AF555-labelled secondary antibodies, both of which 
detected 12nmol mini-FH and 3nmol hFH, this is attributed to absence of FH1-5 within the 
glomerulus 6h after injection. 
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Figure 41 Mini-FH Exp.2: OX24 staining with AF555 secondary  
Representative images (400×) of direct IF staining using biotinylated OX24 and AF555-conjugated 
streptavidin 6h after injection of human proteins. Shown are (a) 12nmol mini-FH, (b) 3nmol hFH, and 
(c) 12nmol FH1-5.  
a. OX24/AF555: 12nmol mini-FH        b. OX24/AF555: 3nmol hFH             c. OX24/AF555: 12nmol FH1-5 
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Figure 42 Mini-FH Exp.2: OX24 staining with AF488 secondary  
Representative images (400×) of direct IF staining using biotinylated OX24 and AF488-conjugated 
streptavidin (green) 6h after injection of human proteins. Shown are (a) 12nmol mini-FH and            
(b) 3nmol hFH. 
a. OX24/AF488: 12nmol mini-FH        b. OX24/AF488: 3nmol hFH                
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5.9 3nmol mini-FH is detectable in plasma 2-6h after administration in Cfh-/- mice 
(Mini-FH Exp. 3) 
Mini-FH Exp. 3 was terminated at 24h, following four 6-hourly injections 3nmol mini-FH 
(n=4), 3nmol FH1-5 (n=4) or PBS (n=4) in 8-week old female mice. In the single injection 
group, 13-week old female mice received 3nmol mini-FH (n=4), 3nmol hFH (n=1), 3nmol 
FH1-5 (n=4) or PBS (n=4). An FH western blot of mouse plasma using polyclonal anti-FH 
antibody (Quidel) reveals the presence of the injected proteins in plasma 2h after a single 
injection (Fig. 43a). 24h after a single injection of 3nmol hFH, this protein was still detectable 
in plasma (Fig. 43b). The recombinant proteins mini-FH and FH1-5 were detectable in 
plasma at the 24h time-point in mice that had received four 6-hourly 3nmol doses (i.e. six 
hours after the last of the four doses, which was administered at the 18 time-point). 
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Figure 43 Mini-FH Exp.3: detection of injected human FH reagents in mouse plasma 
FH western blot using 1μL Cfh-/- mouse plasma under non-reducing conditions, with detection of 
injected reagents using primary anti-human FH antisera (Quidel). Predicted MWs are 155kDa (hFH), 
59kDa (mini-FH) and 36kDa (FH1-5). (a) 2h after a single 3nmol dose of hFH (n=1), mini-FH (n=4) or 
FH1-5 (n=4). (b) 24h after a single 3nmol dose of hFH (n=1) or four 6-hourly 3nmol doses of mini-FH 
(n=4) or FH1-5 (n=4), with longer exposure of the film than for (a).  
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  25 – 
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5.10 3nmol mini-FH has little or no effect on plasma C3 at 2-6h (Mini-FH Exp. 3) 
Notwithstanding a rise in plasma C3 levels from baseline in all mice injected with mini-FH, 
FH1-5 and PBS, no difference was seen between these proteins at any of the assessed 
time-points (with the analysis at 24h time-point divided between one and four injection 
groups, Fig. 44). This is likely attributable to the lower dose of mini-FH (3nmol) used for this 
experiment. A marked rise was seen in plasma C3 levels in mice injected with 3nmol hFH, 
peaking at 24h as in Mini-FH Exp. 1. 
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Figure 44 Mini-FH Exp. 3: plasma C3 levels 
Plasma C3 levels in μg/mL before and at 2 h and 6h after a single injection of 3nmol mini-FH, 3nmol 
hFH, 3nmol FH1-5 or PBS in Cfh-/- mice, and at 24h after a single injection or four 6-hourly injections 
of 3nmol mini-FH, 3nmol FH1-5 or PBS. Horizontal bars denote median values. Arrows indicate 
injections. 
 
 
  
m
in
i-
FH
FH
1 -
5
P B
S
m
in
i-
FH
FH
1 -
5
P B
S
m
in
i-
FH
FH
1 -
5
P B
S
m
in
i-
FH
FH
1 -
5
P B
S
m
in
i-
FH
 (4

)
F H
1 -
5  
(4

)
P B
S  
(4

)
N
a i
v e
h F
H
 a
t  
2 4
h
W
T  
c o
n t
ro
l
0
1 0
2 0
3 0
4 0
5 0
1 5 0
3 0 0
P
la
s
m
a
 C
3
 (

g
/
m
L
)
P R E 6 h2 h 2 4 h2 4 h
 174 
5.11 Four 6-hourly injections of 3nmol mini-FH reduce glomerular C3 staining at 24h 
(Mini-FH Exp. 3) 
In the glomerulus, the intensity of linear C3 staining was reduced in mice that received four 
injections of 3nmol mini-FH compared to four doses of PBS (median MFI mini-FH 65.5 AFU 
versus PBS 138.9 AFU; p < 0.0001; Fig. 45a,d,e). Some mesangial C3 staining was also 
evident in the mini-FH-injected mice, with a similar glomerular appearance in mice that 
received a single injection of 3nmol hFH (Fig. 45b). Four injections of 3nmol FH1-5 produced 
no effect, with a bright linear C3 pattern identical to four injections of PBS (Fig. 45c). Neither 
3nmol mini-FH nor 3nmol FH1-5 administered as a single dose produced any effect on linear 
C3 staining at 24h in comparison to PBS.  
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Figure 45 Mini-FH Exp.3: 24h glomerular  C3 staining  
Representative images (400×) of direct IF staining for C3 24h after (a) four 6-hourly injections of 
3nmol mini-FH, (b) a single injection of 3nmol hFH, or four 6-hourly injections of (c) 3nmol FH1-5 or 
(d) PBS. (e) MFI of glomerular C3 staining is reduced following four 6-hourly injections of 3nmol 
mini-FH, but not 3nmol FH1-5, compared to PBS. Horizontal bars denote median values.               
****p < 0.0001 versus PBS (one-way ANOVA/Bonferroni).  
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5.12 Mini-FH does not affect glomerular C3d staining at 24h in Cfh-/- mice (Mini-FH 
Exp. 3) 
The linear staining pattern for C3d was no different following four injections of 3nmol mini-
FH, 3nmol FH1-5 or PBS (Fig. 46a-c). This indicates that the reduction in linear C3 staining 
and appearance of mesangial staining following four injections of mini-FH may be due to 
cleavage of GBM-bound iC3b. This could release C3c to the mesangium (detected using the 
anti-C3 antibody but not the anti-C3d antibody), leaving C3d attached to the GBM, as 
surmised previously at 24h using human FH [Fakhouri et al. 2010].  
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Figure 46 Mini-FH Exp.3: 24h glomerular C3d staining  
Representative images (400×) at 24h of indirect IF staining of the glomerulus using biotinylated anti-
C3d antibody and PE-labelled streptavidin after four 6-hourly injections in Cfh-/- mice of (a) 3nmol 
mini-FH, (b) 3nmol FH1-5, or (c) PBS. 
 
 
  
 a. C3d: mini-FH (4× injections)          b. C3d: FH1-5 (4× injections)        c. C3d: PBS (4× injections) 
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5.13 24h plasma C3 levels are correlated with tubulointerstitial C3 scores (Mini-FH 
Exp. 3)  
As noted in Mini-FH experiment 1, prominent 24h tubulointerstitial C3 staining was seen only 
in the 3nmol hFH-injected mouse. Tubulointerstitial C3 staining in all mice was assigned a 
score between 0 (negative C3 staining) and 3 (maximal C3 staining, Fig. 47). In contrast to 
the mouse injected with a single dose of 3nmol hFH (24h tubulointerstitial C3 score of 3), 
mice receiving a single injection of 3nmol mini-FH, 3nmol FH1-5 or PBS all had 24h 
tubulointerstitial C3 scores of 0. Mice receiving four 6-hourly injections of 3nmol mini-FH, 
3nmol FH1-5 or PBS had 24h tubulointerstitial C3 scores of 0 or 1. Correlation of 24h 
plasma C3 levels and tubulointerstitial C3 scores shows the distinct effect of a single 3nmol 
dose of hFH on both these parameters compared to four doses of 3nmol mini-FH, 3nmol 
FH1-5 or PBS (r = 0.84, p = 0.0004, Fig. 48). 
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Figure 47 Mini-FH Exp.3: scoring system used for 24h tubulointerstitial C3 staining 
Tubulointerstitial C3 scoring (0-3) is based on direct IF staining for C3, as represented by low original 
magnification (200×) images. 
  
       score 2                score 3                       
   
      score 0                score 1                       
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Figure 48 Mini-FH Exp. 3: Correlation of 24h plasma C3 levels and tubulointerstitial C3 scores 
Correlation of 24h plasma C3 levels and tubulointerstitial C3 scores enables separation of the 3nmol 
hFH-injected mouse from mice injected four times with 3nmol doses of either of the recombinant FH 
reagents, or PBS (Pearson, ***p < 0.001) 
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5.14 FI is detected in plasma of Cfh-/-.Cfi-/- mice injected with Cfh-/-.C3-/- serum 
In Mini-FH Exp. 1 and Mini-FH Exp. 3, administration of hFH produced opposite effects at 
24h on glomerular C3 staining (reduced) and plasma C3 levels/tubulointerstitial C3 staining 
(increased). The apparent dissociation of glomerular and tubulointerstitial C3 staining raises 
the possibility that C3 accumulation along the GBM and in the tubulointerstitium arise via 
distinct mechanisms. In order to assess whether in fact they could be triggered concurrently 
in FH-deficient mice, an alternative in vivo approach was adopted. In Cfh-/-.Cfi-/- mice, 
excessive C3 activation via the AP is characterized by low plasma levels of C3, circulating in 
the form of C3b, and by mesangial C3 accumulation [Rose et al. 2008]. Previously FI 
reconstitution of Cfh-/-.Cfi-/- mice led to the appearance of florid linear C3/C3d staining from 
24h in association with rapid cleavage of plasma C3b [Rose et al. 2008, Paixão-Cavalcante 
et al. 2009]. In the present study, a single injection of pooled Cfh-/-.C3-/- serum was 
performed, with assessment of plasma and renal histology at serial time-points. 2h after 
injection, FI was detected in plasma of Cfh-/-.Cfi-/- mice by western blot, falling below the 
detection limit after 8h (Fig. 49).  
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Figure 49 FI western blot of Cfh-/-.Cfi-/- mouse plasma before and after FI reconstitution  
Western blot under non-reducing conditions of plasma from Cfh-/-.Cfi-/- mice before (PRE) and after 
injection of Cfh-/-.C3-/- serum (denoted as FI), with detection of mouse FI (88kDa) using primary 
anti-human FI antisera.  
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5.15 FI reconstitution of Cfh-/-.Cfi-/- mice is associated with rapid cleavage of plasma 
C3b 
Prior to FI reconstitution of Cfh-/-.Cfi-/- mice, C3b and high MW C3b complexes were 
detected in plasma. 2h after administration of Cfh-/-.C3-/- serum, cleavage of total plasma 
C3b had occurred (Fig. 50). This was associated with the appearance of abundant C3b 
cleavage products, which gradually diminished before the reappearance of C3b after 96h.  
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Figure 50 C3 western blot of Cfh-/-.Cfi-/- mouse plasma 
Western blot under reducing conditions of plasma from Cfh-/-.Cfi-/- mice before and after injection 
of Cfh-/-.C3-/- serum (FI), with C3 detection using a polyclonal anti-mouse C3 antibody. Prior to 
injection, the α’-chain of C3b is seen together with high MW C3b aggregates. 2h after FI 
administration, the α’-chain is absent and α’-chain fragments are seen. 8 days after injection, the C3 
profile has returned to baseline. WT serum shows the slightly higher, uncleaved α-chain of intact C3. 
C3 is not detected in Cfh-/-.C3-/- serum.  
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5.16 FI reconstitution of Cfh-/-.Cfi-/- mice leads to C3/C3d accumulation along the 
GBM but not renal tubules 
C3 staining in Cfh-/-.Cfi-/- mice prior to injection showed a mesangial C3 pattern without 
linear or tubulointerstitial C3 [Rose et al. 2008] (Fig. 51a). 8h after injection of Cfh-/-.C3-/- 
serum, mesangial C3 was less prominent, with the appearance of linear C3 staining (Fig. 
51b). At 24-48h, linear C3 was more prominent (Fig. 51c,d). Thereafter the intensity of linear 
C3 staining gradually reduced, and at 192h some mesangial C3 staining had reappeared 
(Fig. 51e). Glomerular C3d staining was absent in naïve Cfh-/-.Cfi-/- mice, as previously 
shown [Paixão-Cavalcante et al. 2009] (Fig. 51f). Following administration of Cfh-/-.C3-/- 
serum, glomerular C3d staining was seen in a linear pattern at 8h, intensifying at 24h 
(Fig.51g-i). Thereafter it became less prominent although it was still faintly visible at 192h 
(Fig. 51j). Tubulointerstitial C3 staining was not apparent in Cfh-/-.Cfi-/- mice at any of the 
assessed time-points after FI reconstitution. As a positive control, a Cfh-/- mouse received 
an i.p. injection of 3nmol hFH, which was associated with reduction in linear C3 and the 
appearance of mesangial and prominent tubulointerstitial C3 at 24h (Fig. 51k,l). I.p. injection 
of hFH in Cfh-/-.Cfi-/- mice did not alter the C3 staining pattern at 24h (Fig. 51m). This is 
consistent with an identical renal phenotype in FI-deficient mice independent of the presence 
or absence of FH [Rose et al. 2008]. 
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Figure 51 Renal immunostaining in Cfh-/-.Cfi-/- mice  
(a-e) Direct IF for C3 and (f-j) indirect IF for C3d (red) in Cfh-/-.Cfi-/- mice before (PRE) and after i.v. injection of Cfh-/-.C3-/- (denoted as FI). (k,l) C3 staining 
in a Cfh-/- mouse before and after i.p. injection of hFH, and (m) in a Cfh-/-.Cfi-/- mice after i.p. injection of hFH. All images at magnification 400×. 
f. C3d: Cfh-/-.Cfi-/- PRE                     g. C3d: Cfh-/-.Cfi-/- + FI 8h             h. C3d: Cfh-/-.Cfi-/- + FI 24h          i. C3d: Cfh-/-.Cfi-/- + FI 48h        j. C3d: Cfh-/-.Cfi-/- + FI 192h 
 
 k. C3: Cfh-/- PRE                          l. C3: Cfh-/- + hFH 24h                     m. C3: Cfh-/-.Cfi-/- + hFH 24h         
 
a. C3: Cfh-/-.Cfi-/- PRE                       b. C3: Cfh-/-.Cfi-/- + FI 8h             c. C3: Cfh-/-.Cfi-/- + FI 24h          d. C3: Cfh-/-.Cfi-/- + FI 48h        e. C3: Cfh-/-.Cfi-/- + FI 192h 
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5.17 Discussion 
Accumulation of C3 along the GBM is the earliest pathological renal abnormality observed in 
Cfh-/- mice [Pickering et al. 2002]. Accordingly, reduction in glomerular C3 staining at 24h 
has previously been used as a surrogate marker for therapeutic effect in experimental C3 
glomerulopathy following administration of plasma-derived murine or human FH [Paixão-
Cavalcante et al. 2009, Fakhouri et al. 2010]. Here, in collaboration with colleagues at the 
Institute of Cellular & Genetic Medicine, Newcastle University, I have demonstrated that 
administration in Cfh-/- mice of a novel engineered mini-FH protein comprising SCR domains 
1-5 and 18-20 leads to reduced linear C3 staining in the glomerulus at 24h (Mini-FH Exp. 1 
and Exp. 3) and at 6h (Mini-FH Exp. 2). This effect was comparable to that of full-length, 
serum-derived hFH, used at lower molar doses as a positive control. One implication of 
these data is that the ‘middle’ SCR domains 6-17, which include the GAG-binding site in 
SCR 7, are not essential to the therapeutic effect of FH reagents.  
The therapeutic effect of both mini-FH and hFH was associated with the detection of these 
human reagents in a linear staining pattern within the glomerulus 6h after injection (Mini-FH 
experiment 2). This glomerular staining pattern is consistent with binding to the GBM and/or 
to GBM surface-attached iC3b ± C3d(g). The demonstration of FH surface-binding on the 
GBM and/or GBM-attached C3 fragments in association with therapeutic effect in Cfh-/- mice 
is a novel one. In the previous studies, neither murine nor human FH could be detected in 
the glomerulus 24h after injection of Cfh-/- mice [Paixão-Cavalcante et al. 2009, Fakhouri et 
al. 2010]. Daily administration of human FH for 10 days led to the development of 
proliferative GN, in association with glomerular deposition of C3, IgG and human FH in a 
non-linear staining pattern. This was attributed to formation of immune complexes containing 
human FH and murine anti-human FH antibodies, which were demonstrated in the 
circulation in conjunction with rapid clearance of human FH. In another study, murine FH 
was detected only within the mesangium of Cfh-/- kidneys that had been transplanted into 
WT recipients [Alexander et al. 2007].  
One interpretation of these data is that the mini-FH and FH must bind to the surface in order 
to reduce glomerular C3. This is ostensibly supported by the observation that FH1-5, which 
lacks the C-terminal SCR domains 18-20 present on both mini-FH and hFH, could not be 
detected in the glomerulus and also did not reduce linear C3 staining. Hence these data 
provide evidence in support of hypothesis 2, that FH protects the GBM from surface phase 
C3 activation via the AP.  
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However, an alternative explanation for the lack of therapeutic effect of FH1-5 is its 
inefficiency at restoring fluid phase AP control. For example, in mini-FH experiment 2, 
plasma C3 levels were significantly increased for 6nmol or 12nmol mini-FH, but not 12nmol 
FH1-5, compared to PBS. As the presence of C-terminal domains 18-20 would not be 
expected to confer increased FH complement regulatory activity in the fluid phase, these 
data could be explained by more rapid clearance of FH1-5 compared to mini-FH from the 
circulation. Factors that might favour more rapid clearance of FH1-5 include its lower MW 
and the absence of SCR 18 as the only natural N-glycosylation site present on mini-FH. Both 
mini-FH and FH1-5 were more rapidly cleared from plasma than hFH based on Dr 
Marchbank’s ELISA. However, a difference in half-life between mini-FH and FH1-5 was not 
demonstrated, and more detailed pharmacokinetic studies would be required to answer this 
question. In summary, restoration of fluid phase AP control was insufficient at the doses of 
FH1-5 assessed in these experiments for this to be discounted as the principle mechanism 
by which hFH and mini-FH reduced glomerular C3. Accordingly, hypothesis 2, that FH 
protects the GBM from surface phase C3 activation via the AP, is not excluded on the basis 
of Mini-FH Experiments 1-3. 
Mini-FH merits further evaluation for therapeutic use in DDD and potentially other AP-
mediated conditions. Although the reduction in glomerular C3 achieved using mini-FH was 
comparable to that of hFH, mini-FH has a lesser effect than hFH on plasma C3 levels. This 
may indicate superior targeting of the therapeutic effects of mini-FH to the glomerular site of 
C3 activation. As it lacks SCR domains 6 and 7, which are important binding sites for 
microorganisms as part of complement evasion [Blom et al. 2009, Caesar et al. 2014], mini-
FH may also confer a favourable infection risk profile. However, a clear role for therapeutic 
FH administration in AP-mediated conditions associated with normal plasma FH levels has 
yet to be defined.  
The dissociation of linear C3 staining and tubulointerstitial C3 staining 24h after 
administration of hFH in Cfh-/- mice prompted an additional experiment in Cfh-/-.Cfi-/- mice. 
FI reconstitution led to accumulation of C3/C3d in a linear staining pattern in the glomerulus, 
in conjunction with cleavage of circulating C3b, as previously reported [Rose et al. 2008, 
Paixão-Cavalcante et al. 2009]. This was not associated with the appearance of 
tubulointerstitial C3 at any of the assessed time-points up to 192h, at which point the plasma 
C3 profile had returned to baseline. These data suggest that C3 accumulates along the GBM 
via a distinct mechanism from that of tubulointerstitial C3, for which strong evidence exists in 
vitro and in vivo implicating surface phase C3 activation via the AP. Nevertheless these 
observations in vivo provide insufficient grounds for rejecting hypothesis 2. 
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5.18 Conclusions 
5.20.1 Mini-FH reduces glomerular C3 staining in Cfh-/- mice at 6h and 24h, indicating a 
plausible therapeutic role in patients with DDD. 
5.20.2 A modest effect on plasma C3 levels, and detection of mini-FH in a linear staining 
pattern in the glomerulus, indicate that its therapeutic effect may be related to binding to the 
GBM and/or GBM-bound C3 activation products. 
5.20.3 The inability of FH1-5, at the doses assessed here, to be detected deposit along the 
GBM or reduce glomerular C3 staining further suggest that surface recognition C-terminal 
SCR domains 18-20 may be critical to the therapeutic effect of mini-FH. 
5.20.4 Nevertheless the minor effects of mini-FH on plasma C3 levels cannot be ruled out as 
a critical determinant of its therapeutic effect; hence hypothesis 2 is not excluded.  
5.20.5 Absence of tubulointerstitial C3 in Cfh-/- mice and in FI-reconstituted Cfh-/-.Cfi-/- mice 
provides circumstantial evidence in vivo that C3 accumulation along the GBM is not due to 
surface phase C3 activation. Nevertheless, this is insufficient to exclude hypothesis 2. 
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6. CHAPTER SIX: THE RELATIONSHIP BETWEEN 
COMPLEMENT FACTOR H AND 
SUSCEPTIBILITY TO C3 ACCUMULATION 
ALONG THE GLOMERULAR BASEMENT 
MEMBRANE  
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6.1 Introduction 
The strong association of DDD with FH deficiency/dysfunction implies that the FH protein 
normally protects against pathogenic C3 accumulation along the GBM. An unresolved 
question is whether FH-mediated protection is due to prevention of C3 activation in the 
circulation or on the GBM surface [Barbour et al. 2015]. This distinction has implications for 
therapeutic drug design, for example systemically acting versus surface-targeted C3 
inhibitors. The fluid phase hypothesis states that C3b cleavage products generated in the 
circulation become associated with the GBM in patients with DDD. This is consistent with 
several clinical observations: (1) abundant circulating C3b cleavage products in patients with 
DDD [Schwertz et al. 2001, Appel et al. 2005, Zhang et al. 2014]; (2) proteomic studies 
showing C3 fragments in the glomerular tissue of patients with DDD, without detection of FB 
(required for AP C3 convertase formation) [Sethi et al. 2010]; (3) low serum C3 serum in a 
case of C3NeF-associated MPGN persisting weeks after bilateral nephrectomy [Vallota et al. 
1971], indicating that ‘hypocomplementemia could be the result almost entirely of a 
complement reaction occurring in the circulation rather than…in the kidneys’ [West et al. 
1973]; (4) a human DDD renal biopsy study suggesting that deposition of ‘circulating iC3b’ 
mediated renal pathology [West et al. 2001]; and (5) the demonstration that excessive C3 
activation via the AP due to FH-resistant C3 in a family study of DDD was restricted to the 
fluid phase in vitro [Martinez-Barricarte et al. 2010]. In addition, the appearance of linear C3 
staining in Cfh-/-.Cfi-/- mice following administration of murine FI-containing serum provides 
experimental evidence that C3 accumulation in DDD is critically dependent on FI-mediated 
cleavage of circulating C3b [Rose et al. 2008]. However, the tropism of systemically 
generated C3 fragments for the GBM has not been adequately explained for the fluid phase 
hypothesis [West & McAdams 1995]. 
The surface phase hypothesis states that covalent binding of C3b to the GBM results in C3b 
amplification on the GBM surface, with subsequent conversion to surface-bound C3b 
cleavage products. In this case, protection due to FH would be attributable to the ability of 
the FH to bind surface-attached C3b, abrogating surface phase C3b amplification. A key 
argument in support of this hypothesis has been that the GBM, which lacks intrinsic 
membrane-bound AP regulators, is highly susceptible to surface phase C3 activation via the 
AP in the setting of FH deficiency/dysfunction [Jansen et al. 1998, Zipfel 2006]. Thus in the 
original family study of ‘atypical’ DDD associated with homozygous FH deficiency, disease 
causation was explained in terms of ‘locally uncontrolled alternative pathway activation’. 
There, low plasma C5 levels in the affected brothers were attributed to the presence of ‘an 
alternative pathway activating surface (possibly in the glomerulus) allowing the formation on 
its surface of a C3/C5 convertase, which is unusually stable in the absence of [F]H’ [Levy et 
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al. 1986]. The demonstration in vitro of enhanced FH deregulation using serum fractions 
containing abnormal FHR proteins from patients with familial C3GN also provides 
experimental evidence that FH normally protects the GBM from surface phase C3 activation 
[Tortajada et al. 2013, Goicoechea de Jorge et al. 2013].  
In this chapter, I address hypothesis 2, that FH protects the GBM from surface phase C3 
activation via the AP. My approach was to assess the ability of normal human serum (NHS) 
and FH-depleted human serum (FHdplHS) to trigger C3 activation and/or deposition on 
purified GBM components. These components were collagen type IV, fibronectin and 
laminin. As a positive control for C3 activation in my assays, I used zymosan as the 
canonical AP activating surface [Pillemer et al. 1953, Lay et al. 2014]. I also examined the 
ability of murine renal cryosections to activate C3. Notably, a number of studies have shown 
that human GBM preparations [Lambert et al. 1974, Williams et al. 1984] or purified GBM-
like proteins [Hindmarsh & Marks 1998] provide an AP activating surface (i.e. in the 
presence of FH). However, strict AP dependence has not generally been demonstrated, nor 
in some cases appropriate experimental controls used (as discussed below). Additional 
studies have suggested that the binding affinity of intact C3 or its activation products is 
increased for some of these purified GBM components, without proposing surface phase C3 
activation per se [Hautanen & Keski-Oja 1983, Leivo & Engvall 1986].  
  
  
 193 
6.2 Development of a plate assay to assess surface phase C3 activation via the 
alternative pathway 
Purified GBM proteins were assessed for their ability to activate C3 via the AP in vitro. I used 
a zymosan-coated surface as a positive control in this assay, and detected surface C3 
deposition using a polyclonal anti-human C3 antibody.  
A standard curve for surface phase C3 activation via the AP was developed by incubating 
zymosan-coated wells in 5% v/v NHS in EGTA/Mg2+-containing incubation buffer at 37C for 
45 minutes. As expected, detection of surface-bound C3 using the polyclonal anti-human C3 
antibody was increased for zymosan-coated wells compared to wells incubated with coating 
buffer (CB) alone in a dose-dependent manner (maximal mean OD 1.54 for zymosan 
12.5µg/mL versus mean OD 0.28 for CB, Fig. 52a). The zymosan-dependent C3 activation 
was inhibited when EDTA was added to incubation buffer (maximal mean OD 0.14 for 
zymosan 25µg/mL versus mean OD 0.10 for CB alone). C3 western blot using buffer from 
the wells showed evidence of C3 α´-chain fragments in zymosan 6.25µg/mL-coated wells 
(Fig. 52c). The appearance of these fragments was EDTA-inhibitable. Hence, in my assay, 
zymosan-coated wells triggered the appearance of surface C3 and fluid-phase C3 fragments 
both of which were inhibited by EDTA. Slightly increased C3 detection in CB-coated wells 
following incubation with NHS compared to NHS in the presence of EDTA (NHSEDTA) 
indicates minor C3 activation via the AP not specifically due to zymosan. Based on my dose-
response data (Fig. 52a,b), zymosan 6.25µg/mL was used as the upper limit for surface 
phase C3 activation via the AP in this assay.  
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Figure 52 Zymosan plate assay to detect surface phase C3 activation via the alternative pathway 
using NHS 
Wells coated with zymosan up to 25µg/mL in coating buffer (CB) were incubated using NHS in 
Mg2+/EGTA-containing incubation buffer with or without 10mM EDTA for 45 minutes at 37°C.           
(a) Surface-bound C3 was detected using HRP-labelled anti-human C3 antibody, and (b) the OD  
plotted against zymosan concentration on a logarithmic scale, yielding a sigmoid curve. (c) The 
corresponding C3 western blot reveals C3 activation in the presence of zymosan 6.25 µg/mL (with 
EDTA inhibition). Data are shown as mean values with vertical bars representing the standard error 
of the mean (SEM). 
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6.3 Assessment of GBM proteins for C3 activation in normal human serum 
I next examined whether purified collagen type IV, fibronectin and laminin could trigger 
surface phase C3 activation. Using NHS, there was no evidence that purified collagen type 
IV, fibronectin or laminin could activate C3 in my plate assay (Fig. 53a-c). In addition, there 
was no evidence of activation of C3 within the well buffer with the exception (as previously 
seen, Fig. 52c) of the wells containing zymosan (Fig. 54). To ensure that each of these 
proteins was bound to the well following coating, I performed an ELISA assay using 
antibodies specific for each protein. This confirmed dose-dependent binding of the purified 
proteins to the wells (Fig. 55). I next examined the effect of using sera that did not contain 
FH in these assays First, I characterized the FH-depleted serum that I would use in the 
assays.  
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Figure 53 Plate assay to assess the ability of fibronectin, laminin and collagen type IV to activate 
C3 through the alternative pathway using NHS 
Wells were coated with each of the purified GBM components up to a concentration of 25µg/mL, or 
CB alone. Zymosan-coated wells were used as a positive control. C3 detection due to (a) collagen 
type IV, (b) fibronectin and (c) laminin. Data are shown as mean with horizontal bars representing 
the SEM. 
  
c.  
a.             
b.            
      
 197 
 
 
 
 
 
 
 
 
 
 
 
                                      
Figure 54 Assessment of C3 activation in NHS due to purified GBM components: collagen type IV, 
fibronectin and laminin 
C3 western blot using buffer from wells incubated with 6.25µg/mL zymosan (Zym), collagen type IV 
(Coll), fibronectin (Fibro) and laminin (Lam) in the presence of NHS.  
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Figure 55 Detection of plated-protein used in C3 plate assay 
ELISA was used to detect collagen type IV, fibronectin and laminin after coating at increasing 
concentrations. 
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6.4 Rapid activation of C3 in the fluid phase in FH-depleted serum 
In order to study the ability of FH to protect surfaces from C3 activation and to control C3 
activation in the fluid phase, I utilized FHdplHS, which I purchased from CompTech. I wanted 
to ensure that this FHdplHS contained intact C3, since it has long been appreciated that 
removal of FH in sera results in rapid and complete C3 activation via the AP. In other words, 
there is a difference between FH-deficient sera (in which there is complete consumption of 
C3 and the AP activation protein, FB and variable consumption of terminal pathway 
components) and experimentally generated FH-depleted serum (in which the only missing 
serum component is FH). To prevent C3 activation, the FHdplHS is supplied in the absence 
of cations. I expected to see intact C3 at the time cations were restored, followed by rapid 
C3 activation after incubation in EGTA/Mg2+-containing buffer at 37°C. Serum C3 was 
assessed by western blot using the polyclonal anti-human C3 antibody. C3 -chain and β-
chain were seen in both NHS and FHdplHS before incubation (Fig. 56a). The presence of a 
faint lower band corresponding to -chain fragments is consistent with minor C3 activation 
during handling prior to incubation. After incubation of NHS for 60 minutes, the intact C3 -
chain was still evident, with a minor increase in -chain fragments. As expected, the intact 
C3 -chain was absent from FHdplHS after only 10 minutes, with the concomitant 
appearance of the -chain of C3b and prominent -chain fragment bands. After 60 
minutes, the -chain of C3b had also disappeared from FHdplHS, with a 38kDa -chain 
fragment band being prominent. Rapid activation of total intact C3 and C3b thus occurred 
spontaneously during incubation of FHdplHS, generating C3b (transiently) and C3b cleavage 
products. Purified hC3 in incubation buffer had an unchanged appearance after incubation 
for 60 minutes. However, addition of hC31.0mg/mL to FHdplHS prior to a second incubation 
assay again resulted in activation of the exogenous C3 after 60 minutes (Fig. 56b).  
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Figure 56 Western blots of C3 using normal serum, FH-depleted serum and purified C3 during 
incubation in Mg2+/EGTA-containing buffer at 37°C  
Samples taken before (PRE) and 10 and 60 minutes after incubation of (a) NHS, FHdplHS, hC31.0mg/mL 
and (b) FHdplHS reconstituted with hC31.0mg/mL in Mg2+/EGTA-containing buffer at 37°C. Western blot 
was performed under reducing conditions using 0.5µL serum, with C3 detection using primary 
polyclonal anti-human C3 antibody. This reveals the -chain of intact C3 (MW 110kDa), -chain (MW 
75kDa), -chain of C3b (MW 108kDa) and ~38kDa/42kDa -chain fragments (C3b cleavage 
products). High MW bands (>230kDa) likely represent aggregates.  
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C3 activation in FHdplHS was prevented through reconstitution of FHdplHS with either 
hFH0.05mg/mL (Fig. 57a) or hFH0.5mg/mL (Fig. 57b) prior to adding EGTA/Mg2+-containing buffer. 
Addition of EDTA to incubation buffer prevented C3 activation in FHdplHS, confirming 
dependency on Mg2+-dependent formation of the AP C3 convertase (Fig. 57b).  
Despite rapid activation of C3 in FHdplHS, only intact C5 was demonstrable after 60 minutes 
using both NHS and FHdplHS (Fig. 57c). This is consistent with the comparatively slow 
physiological rate of C5 activation compared to C3 activation [Rawal & Pangburn 1998] and 
could be further explained in FHdplHS by the rapid conversion of C3b to fragments, 
preventing the formation of a fluid-phase C5 convertase.  
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Figure 57 Western blots of C3 using FH-depleted serum with and without purified FH or C3 during 
incubation in Mg2+/EGTA-containing buffer at 37°C  
Human serum samples taken before and 10 and 60 minutes after incubation in Mg2+/EGTA-
containing buffer at 37°C. (a) Incubation of FHdplHS with or without hFH0.05mg/mL reconstitution, and 
reducing C3 western blot using 0.5µL serum. (b) Standardized incubation (see Materials and 
Methods 2.17) of FHdplHS with or without hFH0.5mg/mL reconstitution and/or addition of 10mM EDTA, 
and reducing C3 western blot using 0.28µL serum. (c) Standardized incubation method and C5 
western blot with C5 detection using anti-human C5 antisera. Comparison is with purified human C5 
(hC5, MW 190kDa). 
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6.5 Characterization of commercially sourced FH-depleted serum 
It might be expected that cleavage of C3b would not occur in FH-depleted serum since FH is 
considered to be an essential cofactor for the factor I-mediated cleavage of C3b to iC3b in 
plasma [Pangburn et al. 1977, Harrison & Lachmann 1980]. Clearly in my assays C3b 
cleavage did occur in the FHdplHS and I considered that this might be due to residual FH, 
FHR or FHL-1 proteins or possibly to cofactor activity of C4BP [Nagasawa & Stroud 1977, 
Fujita & Nussenzweig 1979, Blom et al. 2003] or CR1 [Lachmann 2010].  
In NHS used for these assays I could detect both of the glycosylated forms of FHR-1 with or 
without FHL-1 using the primary anti-human FH antibody (Fig. 58a). None of these proteins 
was seen in the FHdplHS. Western blot using secondary antibody only was negative (Fig. 
58b). Importantly I could not detect any FH in the FHdplHS using this assay. FH was clearly 
detectable, as expected, following reconstitution of FHdplHS with hFH0.5mg/mL. FHR-1/FHL-1 
was not detected in FHdplHS reconstituted with hFH0.5mg/mL, indicating that the FH preparation 
did not contain FHR-1/FHL-1.  
FHR-5 was detected in NHS, with FHR-1 also detected using this anti-human FHR-5 
antibody (Fig. 58c). None of these proteins were detected in FHdplHS or FHdplHS 
reconstituted with hFH0.5mg/mL.  
I concluded that (1) neither the FHdplHS nor the purified FH contained FHR-1, FHL-1 or FHR-
5; and (2) the FHdplHS did not contain residual FH. 
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Figure 58 FH and FHR western blots using FHdplHS  
Western blot under non-reducing conditions using 1μL (or 0.01μL, denoted as 1%) of NHS, and 
FHdplHS with or without FH0.5mg/mL reconstitution. (a) Detection of FH (MW 155kDa) using primary 
anti-human FH antisera. A double band at ~35 and 37kDa is slightly below the predicted MW of the 
two isoforms for FHR-1 (37kDa and 43kDa) with or without FHL-1 (43kDa). A large amount of protein 
was loaded to ensure that the FHR proteins (present at lower concentrations than FH) could be 
detected. (b) FH western blot with secondary antibody only. (c) Detection of FHR-5 (MW 55kDa) and 
FHR-1 using polyclonal anti-human FHR-5 antibody. (d) FHR-5 western blot with secondary antibody 
only.  
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6.6 Surface deposition of C3 on GBM proteins using FH-depleted serum 
Using the plate assay for C3 activation, increased C3 deposition was detected in 6.25 
zymosan-coated wells following incubation of FHdplHS compared to FHdplHSEDTA (Fig. 59a). 
However, there was also significant C3 detected (based on similar OD readings) in wells that 
did not contain zymosan (referred to as CB only, Fig. 59b). This was consistent with rapid 
activation of C3 in the FHdplHS on restoration of cations, with non-specific deposition of C3 
within the well. This C3 activation in FHdplHS was, as previously, EDTA-inhibitable (Fig. 59a). 
When I coated the purified GBM components (at a concentration of 6.25µg/mL) and 
incubated with FHdplHS I again noted significant OD readings that were comparable to those 
for uncoated wells (Fig. 59a).  
C3 western blot showed an identical pattern of C3 activation in FHdplHS after the ELISA 
irrespective of surface coating with zymosan, the GBM components, or CB alone (Fig. 60). 
This was characterized by the disappearance of the α-chain of intact C3 and appearance of 
the α´-chain and α´-chain fragment bands. Based on the presence of the α´-chain, C3b 
cleavage appeared to be less efficient in the ELISA compared to water bath incubation. 
Nevertheless, activation of total intact C3 using FHdplHS for the ELISA contrasts with the 
findings using NHS (Fig. 54).  
These results created a difficulty in answering my original question, which was ‘do 
components of the GBM (fibronectin, laminin, collagen type IV) activate C3 in the absence of 
FH?’. In the complete absence of FH, but in the presence of intact C3 (the situation that 
exists in the FHdplHS), allowing the AP to proceed (through the restoration of cations i.e. the 
Mg2+/EDTA buffer) resulted in rapid C3 activation beyond C3b in the fluid phase together 
with ‘indiscriminate’ C3 deposition on surfaces. This suggests that, if there is sufficient C3 in 
proximity to a surface, then the absence of FH will result in indiscriminate surface 
opsonization.  
I next performed a functional assay to determine the effect of FH depletion of human serum 
on both C3 opsonization and surface phase C3 activation via the AP. I chose to utilize the 
erythrocyte surface, as haemolysis provides a functional readout of surface phase C3 
activation (in the presence of C5). 
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Figure 59 C3 activation in plate assay is EDTA-inhibitable but indiscriminate when using FHdplHS 
C3 activation ELISA shows (a) reduced C3 deposition on 6.25μg zymosan-coated wells using FHdplHS 
compared to either NHS or FHdplHS reconstituted with hFH0.5mg/mL. C3 activation was similar using 
FHdplHS for zymosan and the purified GBM components at a concentration of 6.25μg/mL or (b) CB 
only. C3 deposition on zymosan-coated wells was EDTA-inhibitable using NHS or FHdplHS (a). 
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Figure 60 Assessment of GBM-like proteins using C3 activation ELISA in FHdplHS 
C3 western blot before and after 45 minute incubation of FHdplHS in wells coated with 6.25µg/mL 
zymosan (Zym), collagen type IV (Coll), fibronectin (Fibro) and laminin (Lam) or CB alone.  
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6.7 Assessment of FH-depleted serum for lysis of erythrocytes 
In my haemolysis assay, 0.6% rabbit erythrocytes (ER) were incubated with human 
sera/proteins in EGTA/Mg2+-containing lysis buffer for 1h at 37°. Serum concentration-
dependent haemolysis was observed after a single incubation of ER in NHS but not FHdplHS 
(Fig. 61a). At the maximal NHS concentration tested (20%), mean haemolysis was 104.3% 
of that due to the positive control (water), compared to 8.5% due to lysis buffer alone 
(negative control). Mean haemolysis in 10% and 5% NHS also exceeded that in lysis buffer 
alone. By contrast, FHdplHS even at the maximal 20% concentration produced only 6.9% 
mean haemolysis. However, following reconstitution of 20% FHdplHS with hFH, haemolysis 
was observed proportional to hFH concentration (Fig. 61b). Addition of EDTA to lysis buffer 
prevented haemolysis using either 20% NHS or 20% FHdplHS reconstituted with hFH0.5mg/mL, 
confirming AP dependence of ER lysis in this assay (Fig. 61a). C3 western blot of pre-assay 
(sera/proteins) and post-assay (supernatant) specimens revealed complete loss of the -
chain of intact C3 in FHdplHS, but not NHS or FHdplHS reconstituted with hFH0.5mg/mL (Fig. 
61c).  
In summary, FH depletion of human serum abrogated AP-dependent ER lysis during a single 
serum incubation. This was associated with rapid activation of total intact C3/C3b in 
FHdplHS. I hypothesized that some C3 was nevertheless deposited on the ER surface, and 
that this would render ER susceptible to lysis during a second incubation with FHdplHS. 
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Figure 61 Rabbit haemolysis assay using human sera  
ER lysis following incubation in human sera/proteins in in Mg2+/EGTA-containing lysis buffer for 1h at 
37°C, with results expressed as percent haemolysis due to water. (a) Haemolysis due to 2.5-20% 
NHS, and FHdplHS with or without hFH0.125mg/mL reconstitution. (b) hFH concentration-dependent 
haemolysis in reconsituted 20% FHdplHS, with EDTA inhibition. Dotted lines show haemolysis in 20% 
NHS and NHSEDTA (c) C3 western blot of human sera before, and supernatant after, incubation with 
ER. Data are shown as mean values with vertical bars representing the SEM. 
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6.8 Erythrocyte lysis during sequential incubation in FH-depleted serum  
Following an initial incubation in FHdplHS, which I had shown did not result in lysis, ER were 
gently washed before undergoing a second incubation in one of NHS, FHdplHS, FHdplHSEDTA 
or C3-depleted human sera (C3dplHS). Serum concentration-dependent haemolysis was 
observed following the second incubation of ER in either NHS or FHdplHS (Fig. 62a). 
Haemolysis using two sequential incubations of 20% FHdplHS was equivalent to sequential 
incubation in 20% FHdplHS followed by 20% NHS. Mean haemolysis was 92.6% and 90.2%, 
respectively, of that due to water (substituted for the second incubation). 
As a single incubation of ER in FHdplHS is associated with activation of total intact C3/C3b, 
the effect of C3 replenishment was assessed. Substitution of 20% FHdplHSEDTA for the 
second incubation produced only 18.0% mean haemolysis (compared to 11.9% for lysis 
buffer alone), confirming AP-dependence (Fig. 62a). Substitution of 20% C3dplHS for the 
second incubation also produced 18.8% haemolysis, indicating that replenishment of intact 
C3 (and possibly additional AP factors) during the second incubation with FHdplHS is critical 
to haemolysis. 
Next, the functional importance of surface C3 accumulation during the initial incubation of ER 
in FHdplHS was assessed. Compared to 85.8% mean haemolysis following two incubations 
in FHdplHS, substitution of 20% C3dplHS for the first incubation produced only 18.7% mean 
haemolysis (compared to 11.1% haemolysis using 20% C3dplHS for both incubations, Fig. 
63a). In a separate assay, an initial incubation of ER in either 20% FHdplHS or 20% C3dplHS 
was followed by a second incubation using 20% C3dplHS with hC3 reconstitution. 
Approximately four times the hC3 concentration was required for equivalent ER lysis during 
the second incubation if the initial incubation was performed using C3dplHS compared to 
FHdplHS (Fig. 63b). 
Dependence of ER lysis on the availability of intact C3 was confirmed by demonstrating that 
the inability of C3dplHS to mediate lysis was restored after the addition of hC3 up to 
1.0mg/mL serum (Fig. 62b)  
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Figure 62 Rabbit haemolysis assay on repeated incubation with FHdplHS 
(a) Following an initial incubation of ER in FHdplHS where lysis does not occur, cells were incubated a 
second time in (1) NHS, (2) FHdplHS, (3) FHdplHS containing EDTA and (4) C3-depleted human sera and 
then haemolysis assessed. (b) C3-dependent haemolysis in reconstituted 20% C3dplHS, with EDTA 
inhibition. Data are shown as mean values with vertical bars representing the SEM. 
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Figure 63 Rabbit haemolysis assay: effect of initial incubation in FHdplHS 
(a) Haemolysis due to 2.5-20% FHdplHS following an initial incubation in FHdplHS is compared to that 
following an initial incubation in 20% C3dplHS. NHS is used as a positive control for lysis of ER 
following an initial incubation in C3dplHS. (b) Haemolysis following a second incubation in 
reconstituted C3dplHS has ~fourfold greater hC3 requirement if the first incubation is performed in 
C3dplHS compared to FHdplHS. Data are shown as mean values with vertical bars representing the 
SEM. 
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6.9 C3 deposition on the erythrocyte surface following exposure to FH-depleted 
serum  
That ER lysis in FHdplHS occurred only with two sequential incubations in FHdplHS suggested 
that the initial incubation resulted in sub-lytic deposition of C3 on the ER surface. Thus during 
the first incubation of FHdplHS, rapid activation of C3 and cleavage of C3b in the fluid phase 
produced a C3 deficiency state in which surface phase C3 activation could not proceed. On 
re-incubation with FHdplHS, which contains intact C3 initially, I hypothesized that C3b 
deposited on the ER surface as a result of the first incubation would, in the presence of 
additional C3, facilitate surface phase C3 activation sufficient to trigger lysis. I next examined 
C3 deposition on ER exposed to FHdplHS using FACS. ER were incubated in 2.5% human 
sera followed by C3 detection using the poyclonal anti-human C3 antibody. As control sera I 
used C5-depleted human sera (C5dplHS), in which I expected normal C3 deposition but 
absent lysis due to the lack of C5, enabling me to analyse intact cells. Surface C3 was 
detected on ER after incubation with FHdplHS: MFI 338 AFU (Fig. 64a). This was much lower 
than that seen after incubation with the C5-depleted control sera: MFI 1739 AFU. Hence 
these data are consistent with ‘inefficient’ surface opsonization in FHdplHS: surface C3 
positivity was 81% lower using FHdplHS compared to C5dplHS. Increased C3 detection using 
C3dplHS compared to buffer only was attributed to detection of non-specific human antigens 
in serum, similar to detection of the negative control protein (mouse IgG) following incubation 
in 10% human sera (Fig. 64b).  
 
 
In summary, my sequential haemolysis and flow cytometry data show that FH depletion of 
human serum is associated with inefficient opsonization and surface phase C3 activation via 
the AP. Nevertheless, C3 deposited on the ER surface as a result of the first incubation in 
FHdplHS was sufficient to mediate ER lysis during a second incubation with FHdplHS (provided 
C3 was also replenished). This implies that some of the surface C3 deposited on the ER 
surface during the first FHdplHS incubation must be in the form of C3b. This is because only 
C3b is functionally capable of forming the AP C3 convertase on the ER surface leading to 
surface phase C3 activation via the AP, and to ER lysis during the second FHdplHS 
incubation.  
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Figure 64 Surface C3 detection on ER following incubation in FHdplHS sera using flow cytometric 
analysis  
(a) Detection of C3 following a single incubation in human sera. C3 due to FHdplHS is intermediate 
between that due to C3dplHS (negative control serum) and C5dplHS (positive control serum).               
(b) Corresponding assay with detection of mouse IgG (negative control protein).  
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6.10 C3 deposition on renal tissue ex vivo  
I next examined the ability of renal tissue to activate C3 in NHS or FHdplHS. In my 
experimental approach, C3 activation was assessed by incubation of C3-deficient mouse 
renal sections ex vivo with human sera/protein in EGTA/Mg2+-containing incubation buffer for 
45 minutes at 37°C. C3 deposition on the PTEC apical surface following serum incubation 
ex vivo of renal cryosections is generally attributed to surface phase C3 activation via the AP 
(Chapter 1.2.8.2). The use of C3-deficient mouse tissue avoided the concern that any 
detected C3 could be endogenous murine C3 rather than derived from the human sera.  
Following incubation in 10% NHS, C3 detection using the polyclonal anti-human C3 antibody 
was most prominent in the corticomedullary junction (Fig. 65a). At higher magnification of 
this area, intense, granular C3 staining followed the pattern of proximal tubular cells. This is 
most clearly visualized using 5% NHS (Fig. 65c). Negative staining using the equivalent 
concentrations of NHSEDTA confirmed AP dependence (Fig. 65b,d). Glomerular C3 staining 
was less bright than proximal tubular staining using 5-10% NHS, and at a lower 1.25% 
concentration of NHS was almost absent from the cortical areas that contain numerous 
glomeruli (Fig. 66a). 
C3 staining following incubation of FHdplHS was much fainter than for NHS, and was no 
different on proximal tubules from other anatomical structures (Fig. 65e,g). That some AP-
dependent C3 activation had nevertheless occurred using FHdplHS is indicated by 
comparison with absent C3 staining using FHdplHSEDTA (Fig. 65f,h). In contrast to sparse 
glomerular staining with NHS, 1.25% FHdplHS produced intense C3 staining of glomeruli 
(Fig. 66b). High magnification of glomeruli revealed sparse C3 using NHS, with EDTA 
inhibition (Fig. 66c,d), and bright granular C3 with some staining of capillary loops using 
FHdplHS. with EDTA inactivation (Fig. 66e,f).  
Reconstitution of FHdplHS with hFH0.5mg/mL restored the scanty glomerular C3 pattern 
observed using NHS (Fig. 66g). Glomerular C3 staining was absent using 1.25% FHdplHS 
that had undergone prior water bath incubation for 1h at 37°C thereby resulting in complete 
C3 activation before incubation on the renal tissue (Fig. 66h). The glomerular pattern of C3 
staining due to FHdplHS is unchanged following incubation on a section from a C3-deficient 
mouse injected with sheep NTS (Fig. 66i). Glomerular C3 staining is absent using purified 
hC31.0mg/mL (at the equivalent 1.25% serum concentration, Fig. 66j). 
In summary, these data show that FH depletion of human serum reduces the degree and 
specificity of C3 activation on mouse cryosections. This is consistent with my other assays 
showing that surface opsonization using the FHdplHS was both inefficient and indiscriminate.  
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Figure 65 C3 staining following incubation of C3-deficient mouse renal sections with human sera  
5-10% human sera were incubated on cryosections in Mg2+/EGTA-containing buffer for 45 minutes at 37°C, followed by C3 detection using polyclonal anti-
human C3 antibody. (a) Using 10% NHS, bright C3 staining is seen along the inner cortex/outer medulla at low magnification (20×), with (b) EDTA inhibition. (c) 
At higher magnification of this area (200×), bright C3 staining follows the pattern of proximal tubular cells, and is most intense on their internal (luminal) 
aspect, with (d) EDTA inhibition. (e) In the corresponding low power image using FHdplHS, C3 staining is not visualized, being no different to (f) incubation in 
the presence of EDTA. (g) At higher power, FHdplHS produces some C3 staining in the corticomedullary junction. This is less bright than for NHS, and is similar 
for non-tubular as well as tubular structures, with (h) EDTA inhibition. 
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Figure 66 Glomerular C3 staining following incubation of C3-deficient mouse renal sections with human 
sera.   
Representative images (200×) of C3 staining of renal cortex following incubation of C3-deficient renal 
cryosections with 1.25% (a) NHS and (b) FHdplHS. High power images (400×) of glomeruli following 
incubation with (c) NHS with (d) EDTA inhibition, and (e) FHdplHS with (e) EDTA inhibition. Glomerular C3 
staining is also shown using (g) FHdplHS reconstituted with hFH0.125mg/mL or (h) preincubated FHdplHS. (i) The 
glomerular C3 pattern following incubation of FHdplHS on a cryosection from a C3-/- mouse injected with 
sheep NTS (anti-GBM Ig). (j) Glomerular C3 staining using hC31.0mg/mL in buffer only.  
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6.11 Discussion 
In this chapter, GBM components (collagen type IV, fibronectin and laminin) were assessed 
for their ability to activate C3 via the AP in human sera. Compared to zymosan, none of 
these proteins produced significant C3 activation in the presence of FH. Hence these 
components do not confer the properties of an AP-activating surface on the GBM. When I 
assessed the ability of the GBM components to activate C3 in the absence of FH, my results 
were notable in two respects: (1) rapid activation of total intact C3/C3b occurred in the fluid 
phase; and (2) surface deposition of C3 was similar for each of the proteins, zymosan, and 
CB alone. This suggested that FH depletion of human serum produces indiscriminate C3 
opsonization. However, a limitation of this assay using the purified GBM components was 
that the specific contribution of surface phase C3 activation to the total signal for C3 surface 
deposition could not be accurately assessed. To determine whether surface phase C3 
activation could still occur in this setting of FH depletion, I moved to an alternative assay in 
which ER were used as the AP-activating surface in human sera. 
The sequential haemolysis and flow cytometry assays show that, whereas C3 activation in 
the fluid phase occurs rapidly in FHdplHS, opsonization and surface phase C3 activation via 
the AP are reduced in comparison to FH-replete serum. AP-dependent ER lysis was absent 
during a single incubation of FHdplHS despite levels of intact C3 sufficient to mediate lysis if 
FHdplHS was instead reconstituted with hFH protein prior to incubation. Flow cytometry 
confirmed that C3 deposition was reduced on the ER surface following incubation in FHdplHS 
compared to C5dplHS. These flow cytometry data recapitulate the original findings of Fearon 
& Austen that surface deposition of C3 is inefficient in the absence of FH [Fearon & Austen 
1977b]. These authors further showed that C3 opsonization occurred indiscriminately, being 
similar on both AP-activating and non-activating surfaces in the absence of FH (0.14% and 
0.16% C3 uptake for ER and ES, respectively). However, they did not address the 
implications of this finding for surface phase C3b amplification, whereas I used haemolysis 
as a functional readout. In my assays, AP-dependent ER lysis could be effectively restored 
via a second incubation using fresh FHdplHS. C3 deposited on the ER surface as a result of 
the first incubation in FHdplHS was a critical requirement of haemolysis, as was the provision 
of intact C3, during the second FHdplHS incubation. Hence these data show that (1) surface 
accumulation of C3b does occur despite rapid C3 activation in the fluid phase using FHdplHS; 
and (2) this facilitates unequivocal surface phase C3 activation via the AP, albeit insufficient 
for ER lysis during a single incubation. My data showing attenuation, but not abrogation, of 
surface phase C3 activation via the AP thus challenge the view that ‘the presence of a 
regulated fluid phase reaction is essential for fixation of C3b on the activating principle’ 
[Fearon & Austen 1977b].  
 219 
Finally, FH depletion of human serum was shown to attenuate renal tubular C3 deposition 
following ex vivo incubation of murine kidney sections. This finding recapitulates the 
observation in vivo in Chapter 5 of absent tubulointerstitial C3 staining in Cfh-/- mice, 
restored only through administration of hFH. As intact C3 is present in both FHdplHS and 
NHS prior to incubation on mouse renal sections, these data suggest that failure to deposit 
C3 on renal tubules (as an AP activating surface) is due to a functional defect in surface 
phase C3 activation using FHdplHS, consistent with the in vitro assays presented in this 
chapter. Hence absence of tubulointerstitial C3 in the setting of FH deficiency in vivo may 
equally be due to a functional defect in surface phase C3 activation via the AP (rather than 
being merely the result of chronic serum depletion of C3). Notably, at lower serum 
concentrations, FH depletion had the opposite effect on AP-dependent glomerular C3 
staining ex vivo, which was enhanced. These data are reminiscent of the dissociation in vivo 
of glomerular and tubulointerstitial C3 staining in Cfh-/- mice discussed in Chapter 5. 
The mechanism underlying preferential glomerular (as opposed to tubular) C3 staining 
following ex vivo incubation of mouse renal sections using low concentration FHdplHS 
remains unclear. Notably, the C3 staining pattern was not strictly a linear one even in the 
presence of GBM-bound IgG as a putative AP-activating surface in NTS-injected mice 
[Reiter & Fishelson 1989]. Nevertheless some C3 detected on glomerular structures may 
have accumulated preferentially along the GBM. On one hand, surface phase C3 activation 
on the GBM and/or other glomerular structures using FHdplHS appears unlikely given (1) the 
absence of C3 staining on tubular structures (as an established AP-activating surface); and 
(2) the demonstration in vitro using the haemolysis assay that FH depletion of human serum 
attenuates surface phase C3 activation via the AP on a classic AP activating surface (ER). 
Moreover, surface phase C3 activation specifically on the GBM appears unlikely since 
purified proteins similar to those found in the GBM did not provide an AP activating surface 
in vitro. However, these data do not exclude some other property of the GBM favouring 
surface phase C3 activation in the absence of FH. In theory, this could be assessed though 
incubation with FHdplHS of purified human or murine GBM and comparison with basement 
membranes obtained from other tissues. In practice, difficulties would probably arise 
regarding accurate assessment of surface phase C3 activation, similar to those encountered 
due to indiscriminate and nonspecific C3 activation in FHdplHS using the ELISA presented in 
this chapter.  
An alternative explanation for preferential glomerular C3 staining following ex vivo incubation 
of murine sections using FHdplHS is that abundant C3b cleavage products generated in the 
fluid phase during serum incubation accumulate preferentially on the GBM and/or other 
glomerular structures. It is possible that binding of FH to the GBM and/or GBM-bound C3 
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fragments normally prevents ongoing deposition of serum C3b metabolites along the GBM 
(irrespective of whether FH is also preventing surface phase C3 activation). Limitations to 
those studies purportedly showing detection of FH along the GBM in human kidney sections 
were discussed in Chapter 1.3. However, the detection of hFH along the GBM following 
administration in Cfh-/- mice could be consistent with a role in preventing deposition. 
Additional assays to assess binding of FH to the GBM, with comparison to other basement 
membranes, are clearly warranted. Of note, however, glomerular C3 staining was not 
observed following incubation of murine sections using FHdplHS that had undergone prior 
water bath incubation. As this serum contains abundant C3b metabolites, it might have been 
expected to produce a similar C3 staining pattern in the glomerulus to fresh FHdplHS if 
accumulation of C3b metabolites alone was required.  Finally, as glomerular C3 
accumulation occurred following incubation of murine sections in FHdplHS, this might suggest 
that physiological filtration across the GBM, which does not occur using the ex vivo staining 
method, is not required for glomerular C3 accumulation in vivo. However, as noted above, 
the C3 staining pattern was not strictly a linear one, and further assessment of C3 
accumulation specifically along the GBM would be required.  
In summary, these data indicate that ongoing deposition of minor amounts of C3b and 
consequent surface C3b amplification could plausibly account for C3 accumulation along the 
GBM in patients with DDD. Hence hypothesis 2, that FH protects the GBM from surface 
phase C3 activation, is not excluded. At the same time, my experiments demonstrate that, in 
human plasma depleted of FH, C3 activation in vitro occurs predominantly in the fluid phase. 
This suggests that accumulation of iC3b ± C3d fragments along the GBM as a consequence 
of their generation in the fluid phase, is a more likely explanation in DDD. A third possibility, 
that C3 accumulation occurs via both these mechanisms in the setting of FH deficiency, is 
also not excluded. For example, whereas fluid phase C3 activation may be the predominant 
cause of C3 accumulation in DDD, surface phase C3 activation may play a minor role. This 
pattern would be reversed in those cases of C3 glomerulopathy (e.g. CFHR5 nephropathy) 
in which abnormal FHR proteins mediate FH deregulation. 
6.12 Conclusions 
6.12.1  FH depletion of human serum in vitro is associated with inefficient and indiscriminate 
C3 opsonization of surfaces. This could also explain surface accumulation of C3 activation 
products in vivo, including along the GBM, in individuals with FH deficiency/dysfunction.  
6.12.2 FH depletion of serum attenuates (but does not abrogate) surface phase C3 
activation via the AP, in association with rapid fluid phase C3 activation in the fluid phase. 
Hence hypothesis 2 cannot be excluded.  
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7. CHAPTER SEVEN: FINAL DISCUSSION 
In Chapter 3,  I demonstrated increased severity of the spontaneous renal phenotype due to 
accompanying CD11b deficiency in 8-month-old Cfh-/- mice. This was characterized by 
increased albuminuria and glomerular hypercellularity, with a nonsignificant trend towards 
increased mesangial expansion. A minor increase in glomerular neutrophils was observed in 
Cfh-/-.CD11b-/- compared to Cfh-/- mice, together with a nonsignificant trend towards 
increased glomerular CD68+ macrophages. The finding that CD11b ameliorates 
experimental C3 glomerulopathy is a novel and unexpected one. It is especially intriguing 
since progressive renal disease in Cfh-/- mice is attributable to accumulation of iC3b, a 
major CD11b ligand, along the GBM. Hence one possible explanation for my results is that 
CD11b ligation by abundant glomerular iC3b in Cfh-/- mice mediates partial protection. This 
would reconcile the observation in a previous study of spontaneous GN in SLE-prone 
MRL/MpJ-FASlpr mice of no difference in severity between those with and without CD11b 
deficiency [Kevil et al. 2004]. iC3b is not implicated in the lupus model, in which severe GN 
in older mice was characterized by crescents, hypercellularity, mesangial expansion and 
neutrophil accumulation. In Cfh-/- mice, I have suggested that CD11b+ macrophages are 
likely to play a key role in glomerular protection. This is based on a body of previous work 
showing that ligation of CD11b on macrophages by iC3b and other molecules suppresses 
proinflammatory immune responses, including via negative regulation of TLR signalling.  
In Chapter 4, further evidence in support of a protective effect due to CD11b was provided 
using the ANTN model of immune complex GN. Cfh-/-.CD11b-/- mice showed enhanced 
susceptibility to glomerular thrombosis at day 2 compared to their Cfh-/- counterparts. 
Following the completion of the experimental work presented in this thesis, a different model 
of immune complex GN was reported that showed increased severity in Cfh-/- mice that 
received a CD11b-/- bone marrow (BM) transplant compared to a Cfh-/- or WT BM 
transplant [Alexander et al. 2015]. The chronic serum sickness (CSS) model used in that 
study involves repeated daily i.p. administration of horse spleen apoferritin for 5 weeks. This 
leads to the appearance of anti-horse apoferritin IgG and immune complexes in plasma and 
mouse IgG within the glomerulus. Cfh-/- mice (on a C57BL/6 background) had previously 
been shown to be susceptible to proliferative GN using this model, as characterized by 
diffuse glomerular hypercelullarity and crescents in ~6% of glomeruli [Alexander et al. 2005]. 
BM transplantation studies were also suggestive of protection against glomerular immune 
complex deposition, but not proliferative GN, due to FH expressed on platelets [Alexander et 
al. 2006]. This was attributed to the role of platelet FH as the immune adherence receptor, 
analogous to human erythrocyte-expressed CR1.  
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Induction of CSS in Cfh-/- mice 4 weeks after BM transplant led to increased plasma anti-
apoferritin IgG titres, circulating immune complexes and extension of mesangial immune 
complexes in CD11b-/- chimaeras compared to Cfh-/- or WT chimaeras [Alexander et al. 
2015]. This was associated with increased albuminuria, plasma urea and glomerular 
hypercellularity in the CD11b-/- chimaeric mice. Hence these results were broadly consistent 
with my data showing exacerbation of experimental GN due to CD11b deficiency in Cfh-/- 
mice. Glomerular macrophages were not specifically assessed in the CSS model, but 
immunophenotyping of tubulointerstitial macrophages revealed an increase in classic, pro-
inflammatory (M1) macrophages in the CD11b-/- chimaeras.  
An unexpected finding in my first ANTN experiment was that CD11b deficiency was 
signiificantly associated with day 1 haematuria irrespective of the FH genotype of the mice. I 
therefore switched the focus of my study away from experimental C3 glomerulopathy, to 
study the phenotype of CD11b deficiency in ANTN. I showed that ANTN in CD11b-/- mice is 
characterized by severe crescentic nephritis at day 10. I concluded that CD11b could 
mediate a protective effect in ANTN not only via its interaction with iC3b on macrophages, 
but also via its reported role in suppression of DTH and TH-17 immune activation. It is 
perhaps surprising, therefore, that glomerular macrophages, as major effector cells of DTH-
like immune responses, were not significantly increased in CD11b-/- mice. However 
previous ANTN studies (in C57BL/6 mice) have also shown no difference in CD68+ 
glomerular macrophage recruitment in Fas-ligand-deficient mice [Tarzi et al. 2012] and 
leukocyte specific FcR-/- mice (both of which were protected from crescentic GN induced in 
WT mice). In the latter study, the authors concluded that ‘without FCR stimulation, the 
infiltrating macrophages were not activated to induce glomerular injury’ [Tarzi et al. 2002].  
Similarly, my results do not exclude the possibility that, in the absence of CD11b ligation, 
macrophages recruited to the glomerulus following induction of NTN are unable to mediate 
important protective effects. It is recognised that macrophages are a heterogeneous cell 
population. That their deleterious effects in experimental models of GN including ANTN are 
more familiar may be partly explained by methods of immune induction that favour distinct 
macrophages subsets/functions. This is exemplified by a study in transgenic mice that 
express the human diphtheria toxin receptor under the control of the CD11b promoter. 
Macrophage ablation through administration of diphtheria toxin on day 15 after ANTN 
induction was associated with a subsequent reduction in crescents and renal failure [Duffield 
et al. 2005]. As glomerular macrophages appeared to comprise both proinflammatory and 
reparative subtypes, the authors concluded that the effects of macrophage depletion were 
dependent on its timing in relation to initiation and recovery of glomerular injury.  
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I proposed one additional mechanism by which CD11b may prevent severe glomerular injury 
in ANTN, namely suppression of CFA-mediated proinflammatory signalling, including that 
due to TLR stimulation. One other CFA-based protocol showed increased severity of 
immune complex GN due to CD11b deficiency in lupus-prone transgenic mice using the 
lupus passive transfer model [Rosetti et al. 2012]. Of note, increased day 14 albuminuria 
was also observed in 2 out of 7 sensitized CD11b-/- mice compared to none out of 3 WT 
mice (or a total of 16 CD11b-sufficient mice) [Rosetti et al. 2012]. This difference was not 
statistically significant, whilst other parameters of glomerular injury were not reported.  
In my ANTN and heterologous NTN experiments, I did not find any difference in the antigen-
specific IgG immune response between CD11b-deficient and CD11b-sufficient mice. A 
recent study has suggested that CD11b plays a role in negative regulation of B-cell receptor 
(BCR) signalling [Ding et al. 2013]. CD11b deficiency was associated with increased B cell 
proliferation and survival following BCR ligation in vitro using B cells from anti-snRNP Ig 
transgenic mice. In vivo, weekly i.v. administration of apoptotic thymocytes for 9 weeks was 
associated with increased serum IgG antinuclear antibody (ANA) and anti-snRNP antibody 
levels, and increased glomerular mouse IgG deposition, in the transgenic mice with CD11b 
deficiency compared to those without. In the CSS model, increased severity of proliferative 
GN in Cfh-/- mice receiving a CD11b-/- BM transplant correlated with increased anti-
apoferritin IgG titres [Alexander et al. 2015]. Both the thymocyte and CSS studies utilized 
repeated antigen administration (without adjuvant) and a longer course (5-13 weeks) than 
the ANTN experiments, and hence may be more sensitive models for assessing IgG 
immune responses. Notably, however, CSS (without BM transplantation) did not produce 
proliferative GN in CD11b-/- mice (notwithstanding significantly increased albuminuria 
compared to WT mice), nor were differences observed in the anti-apoferritin IgG immune 
response between CD11b-/- and WT mice. 
In summary, the results of these ANTN experiments are in agreement with several previous 
studies showing protection due to CD11b in severe, immune complex GN [Rosetti et al. 
2012, Shi et al. 2013, Alexander et al. 2015]. By contrast, earlier hNTN studies indicated that 
CD11b plays a proinflammatory role in acute GN [Tang et al. 1997, Hirahashi et al. 2009]. 
However, those studies specifically addressed early, neutrophil-dependent glomerular injury, 
which was either mild [Tang et al. 1997] or mimicked features of HUS, in the setting of LPS 
co-administration with NTS [Hirahashi et al. 2009]. Hence the protective effects of CD11b in 
my ANTN experiments occurred within the specific immune context of DTH and TH-17 
immune differentiation, which are of undoubted importance in GN, and of CFA-mediated 
proinflammatory responses. 
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In Chapter 5, I showed for the first time that a mini-FH protein is able to regulate the AP in 
vivo, effectively reversing glomerular C3 accumulation and transiently increasing plasma C3 
levels in Cfh-/- mice. Given the robust association of FH deficiency/dysfunction with severe, 
progressive renal disease, therapeutic evaluation of full-length recombinant FH has long 
seemed merited. However this has been technically challenging due to the size and 
complexity of the FH protein. By contrast, production of recombinant mini-FH is technically 
feasible and may offer therapeutic advantages over full-length FH. For example, targeting of 
the therapeutic effects of mini-FH to the glomerular site of C3 activation may be superior. As 
mini-FH lacks SCR domains 6 and 7, which are important binding sites for microorganisms, 
particularly meningococcal strains, as part of complement evasion [Blom et al. 2009, Caesar 
et al. 2014], it may also confer a favourable infection risk profile.  
A novel finding in my mini-FH experiments is that the reduction in glomerular C3 staining 
was associated with detection of administered FH or mini-FH in a linear staining pattern 
within the glomerulus. This could be consistent with a requirement for surface recognition 
domains, as an FH1-5 protein lacking these domains had no effect on glomerular C3. 
However, mini-FH was also shown to have a modest effect on fluid phase AP control, which 
therefore cannot be excluded in glomerular protection. That FH1-5 demonstrated neither 
significant plasma nor glomerular C3 effects may thus have been simply a matter of 
insufficient doses. Importantly, both mini-FH and FH1-5 were rapidly cleared in vivo, which 
could potentially limit their clinical utility. 
In chapter 6, I showed that the purified GBM components (collagen type IV, fibronectin and 
laminin) do not provide an AP-activating surface in vitro. Several previous studies have 
suggested that GBM constituents may induce C3 activation. One early study used a purified 
human GBM preparation to assess ‘the possibility of a local activation of complement by 
components of renal glomeruli…in vitro with glomerular basement membranes’ [Lambert et 
al. 1974]. C3 activation was demonstrated in NHS only if the GBM preparation first 
underwent partial proteolytic digestion with pronase. After collagen type IV-like soluble 
glycoproteins had been isolated from the GBM preparation, protein concentration-dependent 
C3 activation was also demonstrated, with dependency on both the AP and CP. The authors 
concluded that ‘GBM altered in vivo by some proteolytic processes or solubilized GBM 
fragments may act as local activators of the complement system, proceeding through both 
the classical or alternate pathways of the complement system’. In a later study, incubation of 
a human GBM preparation in NHS or C2-depleted human serum was associated with a 
~threefold increase in AP-dependent C3 deposition compared to FD-depleted human serum 
[Williams et al. 1984]. This could be inhibited in C2-depleted serum through the addition of 
supraphysiological purified human FH and FI. Immuno-EM revealed C3 on the epithelial, but 
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not endothelial, aspect of the GBM. The authors concluded that ‘isolated and intact human 
GBM serves as a surface activator of the human alternative C [complement] pathway, as 
assessed by the deposition of C3b…compatible with an endogenous activating capacity of 
the native surface’. However, C3 deposition was not compared using any other surface, and 
C3 activation attributed to the GBM was modest (‘2.2% of the activating activity of Er [ER] 
and 0.09% of the activating activity of zymosan’ [Williams et al. 1984]). Hence, the possibility 
that C3 tickover was solely responsible for C3 deposition was not excluded. By contrast, one 
other study showed that incubation of a rat renal tubular fraction in either rat serum or NHS 
resulted in C3 activation via the AP, whereas this was absent using a glomerular fraction 
[Camussi et al. 1982]. 
In a widely cited study, AP-dependent C3 deposition following incubation of NHS was 
demonstrated on subendothelial ECM from which the HUVEC monolayer had been removed 
[Hindmarsh & Marks 1998]. C3 deposition on the ECM surface co-localized with the ECM 
components fibronectin and collagen type IV. NHS was then incubated in culture wells 
coated with HUVEC, cell-free subendothelial ECM, Matrigel (a soluble matrix preparation 
containing collagen type IV, laminin, entactin and heparan sulfate proteoglycan) or purified 
human ECM components. ELISA-based detection of surface-bound C3 was increased for 
ECM compared to either HUVEC or gelatin (negative control). C3 detection was also 
increased for Matrigel or vitronectin, with a slight increase for fibronectin, but not for laminin 
or collagen type IV. Finally, C3 detection was increased for ECM but not HUVEC following 
incubation with purified hC3 if a prior incubation was performed using purified hC3 and AP 
components rather than NHS. This was attributed to formation of a stable C3 convertase in 
the absence of serum-derived regulatory proteins. Nevertheless, two incubations using NHS 
led to increased C3 detection for ECM (but not HUVEC) compared to a single NHS 
incubation. An important weakness of the study is that gelatin was not also assessed using 
the purified AP components. For example, had this shown similar C3 activation to ECM, then 
the increased C3 activation due to ECM in comparison to both HUVEC and gelatin using 
NHS would not have been replicated. The authors’ conclusion that ‘spontaneous activation 
of complement on ECM suggested that the alternative pathway was responsible, and this 
interpretation was supported by the finding that purified alternative pathway components 
could reproduce the complement activation observed with whole serum’ [Hindmarsh & 
Marks 1998] is therefore unsatisfactory.  
I further showed in chapter 6 that FH depletion of human serum attenuates, but does not 
abolish, surface phase C3 activation via the AP. The implication in patients with DDD is that 
C3 accumulation could plausibly be due to chronic, low-level opsonization and C3b 
amplification along the GBM. However, the finding that C3 activation in the absence of FH 
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predominantly occurs in the fluid phase suggests that this may also be the source of 
glomerular C3 fragments including iC3b. If surface phase C3 activation is indeed attenuated 
in the in vivo setting of FH deficiency/dysfunction, this could provide an additional 
explanation for those surface-based assays (classically, rabbit haemolysis) showing AP 
dysfunction in patients with DDD. It may also account for the absence of tubulointerstitial C3 
in Cfh-/- mice, resolving the paradox wherein ‘activation of C3 onto the basolateral aspects 
of tubules requires an intact systemic alternative pathway, including its main regulator, Cfh’ 
[Alexander et al. 2007]. A similar solution concerns the Cfh-/-.FH16-20 mouse model, which 
provides evidence that ‘FH mutations specifically impairing surface recognition can result in 
spontaneous aHUS’ [Pickering et al. 2007]. The absence of spontaneous renal TMA in both 
Cfh-/-.FHΔ16-20low mice, in which plasma FHΔ16-20 levels were only 2% of WT FH levels, 
and Cfh-/- mice was attributed to a requirement for ‘effective plasma C3 regulation’ if 
spontaneous renal TMA was to occur [Pickering et al. 2007]. Absence of a renal lesion 
(TMA) that is dependent on surface phase C3 activation via the AP could thus be 
attributable to a relative surface phase defect in these strains. 
The presence of a surface phase defect sufficient to prevent tubulointerstitial C3 deposition 
and renal TMA in Cfh-/- mice would suggest that C3 accumulation along the GBM is equally 
unlikely to be due to surface phase C3 activation. In my in vivo experiments in Chapter 5, I 
initially noted this dissociation of glomerular and tubulointerstitial C3 following hFH 
administration in Cfh-/- mice. I further demonstrated that tubulointerstitial C3 staining was 
not apparent at any stage during the evolution of experimentally triggered C3 accumulation 
along the GBM in FI-reconstituted Cfh-/-.Cfi-/- mice. I then assessed the dissociation of 
glomerular and tubulointerstitial C3 deposition ex vivo through serum incubation of murine 
cryosections. Here again, FH depletion of human serum markedly attenuated tubular C3 
deposition, as a marker of surface phase C3 activation. At the same time, it enhanced 
glomerular C3 accumulation, although the mechanism by which this occurred remains 
unexplained. As discussed above, these data do not exclude the contribution of a gradual 
process of surface phase C3 activation to C3 accumulation along the GBM in patients with 
DDD. 
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8. CHAPTER EIGHT: FUTURE WORK 
No treatment is proven to be effective in DDD. My experimental results in Cfh-/- mice 
indicate that pharmacological potentiation of CD11b could be an effective strategy in 
patients with DDD. Preclinical evaluation of small-molecule, synthetic CD11b agonists (so-
called leukadherins) has shown promising results in a number of animal models of 
glomerular disease [Kanagavelu et al. 2013, Khan et al. 2014]. This includes murine 
heterologous NTN where, paradoxically, leukadherin administration was more effective than 
an inhibitory anti-CD11b antibody in reducing peak glomerular neutrophil influx at 3 days in 
C57BL/6 mice [Maiguel et al. 2011]. This may have been related to the ability of 
leukadherins to trap neutrophils in a ligand-binding conformation during adhesion, 
preventing de-adhesion and migration. In my future work I would aim to assess the 
therapeutic effect of leukadherins in the FH-deficient mouse model of C3 glomerulopathy. 
Administration of leukadherins prior to induction of ANTN in Cfh-/- mice would be one valid 
experimental approach. 
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